<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003530" GROUP_ID="AIRWAYS" ID="327299111421035057" MERGED_FROM="" MODIFIED="2014-12-08 13:28:44 +0000" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Technical Editing by CJC 2/10/2001&lt;br&gt;References checked and look fine.&lt;br&gt;Tables of included studies carry extensive data.&lt;br&gt;DATA TABLES AND GRAPH LABELS HAVE BEEN REVERSED FOR ALL COMPARISONS&lt;br&gt;Use of SMD and WMD looks sensible.&lt;br&gt;The text has been spell checked and the caution over delivery devices included in the abstract and reviewer's conclusions.&lt;/p&gt;&lt;p&gt;Paul,&lt;br&gt;I am now happy for this to go out to peer review.&lt;/p&gt;&lt;p&gt;&lt;br&gt;____________________________________&lt;/p&gt;&lt;p&gt;++++++++++++++++++++++++++++++++++++&lt;br&gt;____________________________________&lt;/p&gt;&lt;p&gt;&lt;br&gt;Revisions made by NPA 27/11/01&lt;/p&gt;&lt;p&gt;1. Synopsis added&lt;br&gt;2. Likely relevant studies from the update search included under 'Studies awaiting assessment' with explanatory paragraph under 'Description of Studies'&lt;br&gt;3. I have checked the revisons made my Paul to Conclusions and Implications for practice and agree&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2014-12-08 13:26:02 +0000" NOTES_MODIFIED_BY="Emma J Welsh" REVIEW_NO="IBE3-AST" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-12-08 13:26:02 +0000" MODIFIED_BY="Emma J Welsh">
<TITLE>Beclomethasone versus budesonide for chronic asthma</TITLE>
<CONTACT>
<PERSON ID="12372" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Nick</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Adams</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Physician</POSITION>
<EMAIL_1>Nick.Adams@wash.nhs.uk</EMAIL_1>
<EMAIL_2>nadams2002@btinternet.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Respiratory Medicine</DEPARTMENT>
<ORGANISATION>Worthing &amp; Southlands NHS Trust</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Worthing</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01903 205111</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-12-08 13:20:42 +0000" MODIFIED_BY="Emma Welsh">
<PERSON ID="12372" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Nick</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Adams</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Physician</POSITION>
<EMAIL_1>Nick.Adams@wash.nhs.uk</EMAIL_1>
<EMAIL_2>nadams2002@btinternet.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Respiratory Medicine</DEPARTMENT>
<ORGANISATION>Worthing &amp; Southlands NHS Trust</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Worthing</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01903 205111</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19138" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Janine</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Bestall</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Senior Research Fellow</POSITION>
<EMAIL_1>j.bestall@leeds.ac.uk</EMAIL_1>
<EMAIL_2>janinecb@hotmail.co.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Academic Unit of Psychiatry and Behavioural Sciences</DEPARTMENT>
<ORGANISATION>Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds</ORGANISATION>
<ADDRESS_1>Charles Thackrah Building</ADDRESS_1>
<ADDRESS_2>101 Clarendon Road</ADDRESS_2>
<CITY>Leeds</CITY>
<ZIP>LS2 9LJ</ZIP>
<REGION>West Yorkshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>0113 343 5114</PHONE_1>
<PHONE_2>07403 322 486</PHONE_2>
<FAX_1>0113 343 30862</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7702" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jones</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>pjones@sgul.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Medicine</DEPARTMENT>
<ORGANISATION>St George's Hospital Medical School</ORGANISATION>
<ADDRESS_1>Cranmer Terrace</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>SW17 0RE</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 8725 5371</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 8725 5955</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-07-21 14:07:45 +0100" MODIFIED_BY="Toby Lasserson" NOTES="&lt;p&gt;Minor update: 16/11/01&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 14:07:45 +0100" NOTES_MODIFIED_BY="Toby Lasserson">
<UP_TO_DATE>
<DATE DAY="14" MONTH="11" YEAR="1999"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="11" YEAR="1999"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2014-12-08 13:26:02 +0000" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2014-12-08 13:26:02 +0000" MODIFIED_BY="Emma J Welsh">
<DATE DAY="8" MONTH="12" YEAR="2014"/>
<DESCRIPTION>
<P>Feedback added and typos corrected.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-12-08 13:25:40 +0000" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-12-08 13:25:40 +0000" MODIFIED_BY="Emma J Welsh">
<DATE DAY="21" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="1999"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Garfield Weston Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-12-08 13:24:58 +0000" MODIFIED_BY="Emma J Welsh">
<SUMMARY MODIFIED="2008-07-21 13:56:35 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-21 13:56:35 +0100" MODIFIED_BY="Toby J Lasserson">The effects of beclomethasone or budesonide for chronic asthma</TITLE>
<SUMMARY_BODY>
<P>Beclomethasone and budesonide are commonly used to treat people with asthma in the long-term. Despite the large amount of research which has been conducted with these two steroids, very little can be concluded as to how effective they are, because the quality of the research to date has not been strong enough. The available research does not therefore provide a clear answer as to whether beclomethasone or budesonide are better for treating asthma. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-07-21 14:05:18 +0100" MODIFIED_BY="Toby J Lasserson">
<ABS_BACKGROUND>
<P>Beclomethasone dipropionate (BDP) and budesonide (BUD) are used widely in the treatment of chronic asthma. The two drugs have different in vitro pharmacokinetic characteristics. It is unclear whether this translates into clinically significant differences in efficacy or safety when treating children and adults with chronic asthma.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess clinical outcomes in studies which have compared inhaled BDP and BUD in the treatment of chronic asthma.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Airways Group Trial Register (1999) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Prospective, randomised trials comparing BDP to BUD in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>One reviewer extracted data; authors were contacted to clarify missing information. Quantitative analyses where undertaken using Review Manager 4.0.3 with MetaView 3.1.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-07-21 14:05:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>24 studies met the criteria for inclusion (1174 participants). Methodological quality was variable. A meta-analysis of crossover studies did not demonstrate a significant difference between BDP and BUD for FEV1, morning PEF, evening PEF, asthma symptoms or rescue beta2 agonist use, over a dose range of 400 to 1000 mcg/d. The majority of crossover trials had significant design flaws related to a lack of washout and/or failure to exclude carryover effects so the results must be viewed with caution. A single crossover study with adequate washout showed that BUD 400 mcg/d delivered via Turbohaler dry powder inhaler (DPI) may be more effective than BDP 400 mcg/d delivered via Rotahaler DPI in reducing histamine bronchial hyper-responsiveness: Weighted Mean Difference (WMD) 0.43 log10 PC20 FEV1 (95% Confidence Intervals (CI) 0.05, 0.81 log10 PC20 FEV1). A meta-analysis of two parallel group, dose down-titration studies (231 patients) showed that less BUD delivered via a Turbohaler DPI was required to maintain control in adults asthmatics compared to BDP delivered via metered dose inhaler with or without a spacer: WMD 444 mcg/d (95% CI 332, 556 mcg/d).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is limited high quality randomised controlled trial data comparing the relative efficacy of BDP and BUD. Current guidelines (BTS 1997; GINA 1995; NHLBI 1997) assume BDP and BUD to have equal efficacy, such that for each defined level of asthma severity, the recommended doses BDP and BUD are the same. Although there is some data to suggest that BUD via Turbohaler is more effective than BDP via either Rotahaler or MDI (with and without spacer), these comparisons are confounded by use of different delivery devices, and are not sufficient to warrant a change in guideline recommendations.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-12-08 13:24:50 +0000" MODIFIED_BY="Emma J Welsh">
<BACKGROUND>
<P>Beclomethasone dipropionate (BDP) was the first inhaled corticosteroid (ICS) marketed for use in the treatment of chronic asthma in 1972. Budesonide had been available since the early 1980's. Extensive clinical experience has been gained with these compounds in the treatment of chronic asthma, both are regarded as having a highly favourable therapeutic index when compared to oral corticosteroids, i.e. offering large advantages in terms of their efficacy at the cost of few side-effects. </P>
<P>In vitro studies assessing pharmacodynamic properties have shown differences between BDP and BUD. Receptor affinity is a measure of the strength with which an active molecule binds to the glucocorticoid receptor. This is 1.5 fold higher for 17-beclomethasone monopropionate (17-BMP), the bronchially active metabolite of BDP, compared to BUD (<LINK REF="REF-Boobis-1998" TYPE="REFERENCE">Boobis 1998</LINK>). However when assessing drugs in terms of their relative in vitro potency, i.e. the concentration of drug required producing a standard effect, BUD appears more potent than BDP. This has been shown in early experimental studies for the MacKenzie skin-blanching test (<LINK REF="REF-Johansson-1982" TYPE="REFERENCE">Johansson 1982</LINK>), and more recently in terms of several in vitro assays of anti-inflammatory action including eosinophil survival, basophil histamine release and expression of vascular cell adhesion molecule-1 (<LINK REF="REF-Stellato-1999" TYPE="REFERENCE">Stellato 1999</LINK>). It is noteworthy that in these in vitro assays, the maximum effect of BDP and BUD (i.e. their intrinsic activity) was similar, and at very high concentrations (on the 'plateau' of the dose response curve) the quantitative effects of the two drugs were closely matched.</P>
<P>Do differences in the in vitro pharmacodynamic actions of BDP and BUD translate into differences in clinical efficacy? This may depend on dose. At low inhaled dose, more likely to be on the 'steep' portion of the dose response curve for each drug, differences in potency might lead to differences in clinical efficacy. Conversely, at higher inhaled dose (approaching or on the 'plateau' of the dose response curve for each drug) differences in clinical efficacy may not be apparent. A retrospective analysis of prescription records for BDP and BUD in primary care in New Zealand has recently been published (<LINK REF="REF-Pethica-1998" TYPE="REFERENCE">Pethica 1998</LINK>). The investigators concluded that BDP was more 'potent' than BUD because the mean daily-prescribed dose of BDP over a one-year period was 635 mcg/d compared to a mean daily BUD dose 979 mcg/d. This study has a number of limitations however including the fact that drug exposure could not validated and other known and unknown biases may have been operating in this non-randomised, retrospective cross-sectional study. </P>
<P>The purpose of this review is to assess the relative clinical efficacy and safety of BDP and BUD delivered at equal nominal dose in the treatment of chronic asthma by systematically reviewing the prospective randomised trials that have compared these inhaled corticosteroids.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess clinical outcomes in studies which have compared inhaled beclomethasone (BDP) and inhaled budesonide (BUD) in the treatment of chronic asthma.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-12-08 13:24:47 +0000" MODIFIED_BY="Emma J Welsh">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We considered all randomised studies. Double, single and non-blinded studies were considered. Studies could be of either parallel group or crossover design.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies of both children and adults were included, but patients under two years of age were excluded. To be eligible, participants had to have a diagnosis of chronic asthma. Studies conducted in both primary and secondary care settings were considered.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>BDP versus BUD delivered by oral inhalation. Each drug had to be delivered at the same nominal daily dose. Nominal dose was calculated as the valve dose multiplied by the number of actuations per day. Each drug could be delivered by different device including pressurised metered dose aerosol inhaler (MDI), MDI+spacer or dry powder device (DPI). Studies using nebuliser devices were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>All outcomes were considered. Those identified as important a priori were as follows:</P>
<P>Efficacy related<BR/>1. Clinic measured FEV1 and PEF, diary card morning and evening PEF, diurnal variability in PEF<BR/>2. Symptoms<BR/>3. Rescue beta2 agonist use<BR/>4. Histamine and methacholine bronchial hyper-responsiveness (BHR)<BR/>5. Asthma exacerbations: hospital admission, emergency room attendance, unscheduled primary care visits, days off school or work<BR/>6. Health-related quality of life (HRQOL)<BR/> <BR/>Safety related<BR/>1. Hypothalamo-pituitary-adrenal (HPA) axis function reflected in serum and urinary cortisol measures and clinical adrenal insufficiency <BR/>2. Oropharyngeal side effects (hoarseness, sore throat, oral Candidiasis)</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-21 13:57:51 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2008-07-21 13:57:41 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Stage 1: a search was carried out of the Cochrane Airways Group Trials Register (1999). The following search terms were applied:</P>
<P>steroid* OR glucocorticoid* OR corticosteroid* OR beclomethasone OR budesonide OR fluticasone OR triamcinolone OR flunisolide OR Becotide OR Becloforte OR Pulmicort OR Flixotide</P>
<P>Abstracts from this search were imported into a bibliographic database termed the Inhaled Steroid Register. This was hand-searched by two reviewers (NPA and JB). Duplicate publications were removed.</P>
<P>Stage 2: two further registers were created by undertaking searches of the Inhaled Steroid Register using the following terms:</P>
<P>beclomethasone OR Becotide OR Becloforte: the Beclomethasone Register</P>
<P>budesonide OR Pulmicort : the Budesonide Register</P>
<P>Each register was hand-searched for RCTs meeting the inclusion criteria. Citations were excluded based on abstract if it was clear that the study was a) not concerned with the treatment of asthma in humans b) not an RCT c) did not include a treatment arm with inhaled corticosteroid (ICS). Where uncertainty existed, the publication was retrieved in full text form.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-21 13:57:48 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Reference lists of all included trails and relevant narrative reviews were searched for additional RCTs. Authors of identified trials, Glaxo Wellcome (UK) and Astra Zeneca (Sweden) were contacted and were asked about any further published or unpublished trials that may have been conducted. There were no language restrictions. The British Journal of Clinical Research and the European Journal of Clinical Research, which are not electronically indexed on MEDLINE or EMBASE, were hand searched for relevant studies. The proceedings of the British Thoracic Society (1997/1998), European Respiratory Society (1997/1998) and the American Thoracic Society (1997-1999) were searched for relevant trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-12-08 13:24:47 +0000" MODIFIED_BY="Emma J Welsh">
<STUDY_SELECTION MODIFIED="2008-07-21 13:58:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The decision to exclude studies prior to full paper retrieval was made by one reviewer (NPA). Papers retrieved in full text form were assessed independently by two reviewers (NPA and JB); disagreement as to which papers to include was resolved by consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-21 14:01:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>One reviewer (NPA) extracted data for each outcome from the published results of included trials. In the case of continuous outcomes such as FEV1 measures:</P>
<P>1. Where outcomes were evaluated at a number of time points only data from the last evaluable time point was used.<BR/>2. Data were extracted from graphical plots when presented in this form; attempt was made to verify such data by contacting authors.<BR/>3. If an intention-to-treat analysis was not used by the investigators, and it was not explicit in the presentation of results how many subjects (N) were in each group at the time of last evaluation of that outcome, the appropriate N value for each intervention group was calculated by subtracting the number of patients who withdrew in each intervention group from those randomised to each intervention group.</P>
<P>Authors were written to (by mail, fax and/or electronic mail) to clarify details of randomisation and/or request missing outcome data. Attempt was made to send requests to correct current addresses by searching MEDLINE, EMBASE and hospital World Wide Web (WWW) sites for up-to-date contact details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-21 13:58:32 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Two reviewers (NPA and JB) who were blinded to the author's names, institution and funding sources independently assessed each study for methodological quality. The trials were scored using the Cochrane approach:</P>
<P>Grade A: adequate allocation concealment<BR/>Grade B: unclear allocation concealment<BR/>Grade C: clearly inadequate concealment</P>
<P>The methodological quality of included studies was also assessed using a 5 point scoring instrument (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>):</P>
<P>a) Was the study described as randomised? (yes=1 no=0)<BR/>b) Was the study described as double blind? (yes=1 no=0)<BR/>c) Was there a description of withdrawals and dropouts? (yes=1 no=0)<BR/>d) Was the method of randomisation well described and appropriate? (yes=1 no=0)<BR/>e) Was the method of double blinding well described and appropriate? (yes=1 no=0)<BR/>f) deduct 1 point if method of randomisation or blinding inappropriate</P>
<P>Inter-rater agreement was measured using the kappa statistic. Disagreement was resolved by consensus.</P>
</QUALITY_ASSESSMENT>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-12-08 13:24:47 +0000" MODIFIED_BY="Emma J Welsh">
<P>Heterogeneity of effect size across studies pooled was calculated using a chi square test, with P&lt; 0.05 used as the cut-off level for significance. Sensitivity analyses were performed on the basis of methodological quality. Results were re-analysed using studies of only the highest quality scores (Jadad 3 to 5). Subgroup analyses based upon patient age, delivery device and study duration were planned.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-21 14:01:28 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A weighted treatment effect across trials was calculated using the Cochrane statistical package RevMan 4.0.3 with MetaView 3.1. For continuous outcomes, a weighted mean difference (WMD) or standardised mean difference (SMD) was calculated as appropriate. For dichotomous outcomes a relative risk (RR) was calculated. Pooled treatments effects are expressed with their 95% confidence intervals (95% CI). A fixed effect model was used throughout. A number of a priori conditions were established regarding the comparisons made:</P>
<P>1. Studies were distinguished as those in which patients were a) not treated with regular oral corticosteroid (OCS), b) dependent upon regular oral steroid treatment prior to study. Trials involving OCS-dependent patients in which the efficacy of inhaled corticosteroid (ICS) is being assessed may have an 'OCS down-titration' design using reduction in the use of oral steroid as an outcome measure, whilst maintaining a given level of asthma control. However, studies in which patients were not treated with regular OCS are more likely to have a design aimed at detecting improvements in asthma control. It is inappropriate to combine trials with these different designs and objectives.</P>
<P>2. The results of parallel and crossover trials were not pooled.</P>
<P>3. It was anticipated that measures of bronchial hyper-responsiveness (PD20 FEV1, PC20 FEV1) would often be reported as geometric means. Presentation of results in this way indicates that data has been logarithmically transformed prior to analysis by investigators to take account of a skewed distribution. Data for such outcomes was only pooled across studies where the mean and standard deviation of logged values (from which geometric means are derived) could be calculated.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-12-08 13:24:50 +0000" MODIFIED_BY="Emma J Welsh">
<STUDY_DESCRIPTION MODIFIED="2008-07-21 14:02:48 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2008-07-21 14:02:22 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Stage 1 electronic search: 6494 citations retrieved, 2162 original citations</P>
<P>Stage 2 electronic search:</P>
<P>BDP register BUD register</P>
<P>Electronic citations 1149 1036</P>
<P>Citations excluded from abstract description:<BR/>Not RCT 379 331<BR/>Not chronic asthma in humans 190 195<BR/>Not concerned with ICS treatment 177 129<BR/>Clearly not concerned with BDP v BUD 113 40</P>
<P>Papers retrieved in full text 290 341</P>
<P>Excluded after full paper retrieval:<BR/>Not RCT 94 46<BR/>Not involving BDP v BUD comparison at 176 275<BR/>equal nominal daily dose</P>
<P>Included studies 20<BR/>(same studies identified from both registers)</P>
<P>One study (<LINK REF="STD-Greefhorst-1992" TYPE="STUDY">Greefhorst 1992</LINK>) was identified after searching the bibliographies of included studies, three studies (<LINK REF="STD-Dal-Negro-1997" TYPE="STUDY">Dal Negro 1997</LINK>, <LINK REF="STD-Hamalainen-1998" TYPE="STUDY">Hamalainen 1998</LINK>, <LINK REF="STD-Micheletto-1997" TYPE="STUDY">Micheletto 1997</LINK>) were identified by searching the proceedings of respiratory society meetings.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-07-21 14:02:48 +0100" MODIFIED_BY="Toby J Lasserson">
<P>24 publications were identified met the inclusion criteria for the review representing 24 studies. Publication dates ranged from 1982 to 1998. Details of the trials are in the table of Characteristics of Included Studies. Four studies were identified that were published in abstract form only (<LINK REF="STD-Dal-Negro-1997" TYPE="STUDY">Dal Negro 1997</LINK>, <LINK REF="STD-Greefhorst-1992" TYPE="STUDY">Greefhorst 1992</LINK>, <LINK REF="STD-Hamalainen-1998" TYPE="STUDY">Hamalainen 1998</LINK>, <LINK REF="STD-Micheletto-1997" TYPE="STUDY">Micheletto 1997</LINK>). No outcome data for these studies is available. The studies have been included as further information may be available at a future date when the review is updated. Two further publications (<LINK REF="STD-Hernandez-1995" TYPE="STUDY">Hernandez 1995</LINK>, <LINK REF="STD-Lee-1995" TYPE="STUDY">Lee 1995</LINK>) require translation and are awaiting assessment. We would also like to draw the reader's attention to the six further citations (<LINK REF="STD-Baxter_x002d_Jones-2000" TYPE="STUDY">Baxter-Jones 2000</LINK>, <LINK REF="STD-Brand-2001" TYPE="STUDY">Brand 2001</LINK>, <LINK REF="STD-Dal-Negro-1999b" TYPE="STUDY">Dal Negro 1999b</LINK>, <LINK REF="STD-Jager-2000" TYPE="STUDY">Jager 2000</LINK>, <LINK REF="STD-Kraszko-1999" TYPE="STUDY">Kraszko 1999</LINK>, <LINK REF="STD-Reichel-2001" TYPE="STUDY">Reichel 2001</LINK>) listed under Studies awaiting assessment. Due to unforeseen delays in the publication of this review, a number of potentially relevant trials have been identified after an up dated search of the electronic sources from April 1999 - August 2001. These studies will be fully evaluated and included as appropriate in a future update at the earliest possible opportunity.</P>
<P>Study Populations</P>
<P>The majority of studies were conducted in Europe (Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Sweden, The Netherlands, UK). One study (<LINK REF="STD-Springer-1987" TYPE="STUDY">Springer 1987</LINK>) was conducted in Israel. One study (<LINK REF="STD-Baran-1987" TYPE="STUDY">Baran 1987</LINK>) was conducted in a residential centre for asthmatic children; in one study (<LINK REF="STD-Greefhorst-1992" TYPE="STUDY">Greefhorst 1992</LINK>) the setting was unclear. All other studies were conducted in a hospital outpatient clinic setting. Six studies were in children, 18 in adults.</P>
<P>Diagnosis of asthma</P>
<P>In 17 studies (71%) there was no clear indication of the criteria upon which a diagnosis of asthma was made and appears to have been at the discretion of the investigators. In one study (<LINK REF="STD-Boe-1989" TYPE="STUDY">Boe 1989</LINK>) diagnosis was based upon ATS 1962 criteria. In three studies (<LINK REF="STD-Bisgaard-1988" TYPE="STUDY">Bisgaard 1988</LINK>, <LINK REF="STD-Ebden-1986" TYPE="STUDY">Ebden 1986</LINK>, <LINK REF="STD-Petrie-1990" TYPE="STUDY">Petrie 1990</LINK>) diagnosis was supported by demonstrable reversibility of clinic PEF or FEV1 following inhaled beta2 agonist; in three studies (<LINK REF="STD-Brambilla-1994" TYPE="STUDY">Brambilla 1994</LINK>, <LINK REF="STD-Svendsen-1992" TYPE="STUDY">Svendsen 1992</LINK>, <LINK REF="STD-Tjwa-1995" TYPE="STUDY">Tjwa 1995</LINK>) diagnosis was supported by demonstration of a 15% or greater reversibility in FEV1 following inhaled beta2 agonist or variability in FEV1 in combination with bronchial hyper-responsiveness (BHR) to methacholine or histamine.</P>
<P>Treatment with oral corticosteroids</P>
<P>In three early studies (<LINK REF="STD-Rafferty-1985" TYPE="STUDY">Rafferty 1985</LINK>, <LINK REF="STD-Stiksa-1982a" TYPE="STUDY">Stiksa 1982a</LINK>, <LINK REF="STD-Stiksa-1982b" TYPE="STUDY">Stiksa 1982b</LINK>) requirement for oral corticosteroid (OCS) for asthma control in the form of prednisolone was an inclusion criterion. In one study (<LINK REF="STD-Stiksa-1985" TYPE="STUDY">Stiksa 1985</LINK>) a proportion of enrolled patients were OCS-treated, although this was not a specific inclusion criterion. In 20 studies regular OCS treatment was either a specific exclusion criterion or it was clear from baseline demographic characteristics that patients were not receiving regular OCS prior to the study.</P>
<P>Asthma severity and asthma control</P>
<P>Asthma severity may be defined in terms of the amount of medication required to achieve a certain level of asthma control, or in terms of the frequency of symptoms experienced and/or the degree to which FEV1 (% predicted) is depressed before commencing regular prophylactic therapy. Asthma control is best considered the degree to which patients symptoms are uncontrolled and/or the degree to which their FEV (% predicted) is depressed, irrespective of the amount/type of prophylactic medication prescribed. The characteristics of the included studies in terms of these factors have been listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> and <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. Baseline FEV1 (% predicted) and symptom frequency were reported infrequently, so, in the majority of studies, it was not possible to determine the level of asthma control at randomisation.</P>
<P>Study design</P>
<P>Five studies (<LINK REF="STD-Bisgaard-1988" TYPE="STUDY">Bisgaard 1988</LINK>, <LINK REF="STD-Brambilla-1994" TYPE="STUDY">Brambilla 1994</LINK>, <LINK REF="STD-Dal-Negro-1997" TYPE="STUDY">Dal Negro 1997</LINK>, <LINK REF="STD-Micheletto-1997" TYPE="STUDY">Micheletto 1997</LINK>, <LINK REF="STD-Selroos-1994" TYPE="STUDY">Selroos 1994</LINK>) were parallel group studies. Nineteen studies (79%) were of crossover design.</P>
<P>Only two crossover design studies (<LINK REF="STD-Bjorkander-1982a" TYPE="STUDY">Bjorkander 1982a</LINK>, <LINK REF="STD-Tjwa-1995" TYPE="STUDY">Tjwa 1995</LINK>) incorporated a washout (one week or four weeks respectively) between treatment periods. No other crossover studies had a washout period between active treatments. In only two of these (<LINK REF="STD-Pedersen-1988" TYPE="STUDY">Pedersen 1988</LINK>, <LINK REF="STD-Petrie-1990" TYPE="STUDY">Petrie 1990</LINK>) was it stated if carryover/sequence effects were tested for and excluded. In all the remaining crossover studies without washout, no comment was made regarding this possible confounding factor.</P>
<P>The length of treatment period varied. Twelve studies (50%) had treatment periods of between two and four weeks, 10 studies (42%) had treatment periods of between six and 12 weeks. The longest study (<LINK REF="STD-Selroos-1994" TYPE="STUDY">Selroos 1994</LINK>) had an effective treatment period of two years. The only study enrolling OCS-dependent patients (<LINK REF="STD-Rafferty-1985" TYPE="STUDY">Rafferty 1985</LINK>) had a complex and unique trial design with treatment periods of variable length and is discussed separately below.</P>
<P>As an inclusion criterion for the review, all studies had to assess equal nominal daily doses of BDP and BUD. Ten studies (42%) assessed 400 mcg/d, seven studies (29%) assessed 800 mcg/d. Two studies (<LINK REF="STD-Ebden-1986" TYPE="STUDY">Ebden 1986</LINK>, <LINK REF="STD-Svendsen-1992" TYPE="STUDY">Svendsen 1992</LINK>) assessed higher daily doses i.e. BDP 1500 mcg/d v BUD 1600 mcg/d. Only one study (<LINK REF="STD-Baran-1987" TYPE="STUDY">Baran 1987</LINK>) assessed 200 mcg/d. Two parallel group studies (<LINK REF="STD-Brambilla-1994" TYPE="STUDY">Brambilla 1994</LINK>, <LINK REF="STD-Selroos-1994" TYPE="STUDY">Selroos 1994</LINK>) used a 'dose down- titration' design in which ICS dose reduction was attempted at regular intervals during the randomised treatment phase to the minimal effective dose. Conversely, one study (<LINK REF="STD-Bisgaard-1988" TYPE="STUDY">Bisgaard 1988</LINK>) used a 'dose-escalation' design whereby patients were randomised to receive BDP or BUD 200 mcg/d, 400 mcg/d then 800 mcg/d each for 4 weeks in succession. Only one study of crossover design (<LINK REF="STD-Boe-1989" TYPE="STUDY">Boe 1989</LINK>) incorporated more than two treatment periods: BDP 400 mcg/d, BUD 400 mcg/d, BDP 1000 mcg/d and BUD 800 mcg/d.</P>
<P>Eight studies (33%) used a MDI to deliver both BDP and BUD. Different types of delivery device were used to deliver each ICS in 16 studies (66%).</P>
<P>Outcomes</P>
<P>A wide range of efficacy and safety outcomes was assessed. A number of reported outcomes have not been considered. These include plasma ACTH and growth hormone levels (<LINK REF="STD-Nicolaizik-1994" TYPE="STUDY">Nicolaizik 1994</LINK>), and 24 hour urinary tetrahydrocortisone glucosiduronate and tetrahydrocortisol glucosiduronate levels (<LINK REF="STD-Springer-1987" TYPE="STUDY">Springer 1987</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Methodological quality of included studies was variable. Only 10 studies (42%) were double blind. 19 studies (79%) provided adequate descriptions of numbers of patients withdrawn and the reasons for withdrawal. As assessed by the Jadad scoring method 15 studies (63%) achieved a score of 3 or 4; no studies achieved a maximum score of 5. In only four studies (17%) was allocation concealment clearly employed. In all other studies allocation concealment was unclear.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-12-08 13:24:50 +0000" MODIFIED_BY="Emma J Welsh">
<P>A significant amount of data for reported outcomes could not be included in the meta-analysis. This included all data for the four studies published in abstract form only, and a number of outcomes reported in crossover studies published as full journal papers. These data are listed in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>. In most cases a narrative description of these results has not been made. This is because the study was either a) low methodological quality (Jadad score 2 or less) and/or b) it was not stated whether carryover effects had been excluded in the case of crossover studies (see Discussion). However, an exception has been made in the case of Pedersen 1990. This was the only fair quality crossover study (Jadad score 3) in which significant carryover effects had been excluded by the investigators. The results are reported in narrative form below.</P>
<SUBSECTION>
<HEADING LEVEL="4">ASTHMA NOT TREATED WITH ORAL STEROIDS</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">CROSSOVER STUDIES</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Spirometry</HEADING>
<P>FEV1 (litres) was reported in six studies (227 subjects). FEV1 (% predicted) was reported in two studies (74 subjects). No significant difference between BDP and BUD was apparent. Studies that reported FEV1 using different measurement scales were pooled in order to increase the power of the analysis (eight studies, 301 subjects). The pooled treatment effect was expressed as a standardised mean difference. No significant difference between BDP and BUD was apparent: SMD -0.15, 95% CI -0.38 to 0.07. A similar result was found for FVC (litres), FVC (% predicted), and FVC (litres, % predicted combined), with no significant difference between BDP and BUD.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Peak expiratory flow rate (PEF)</HEADING>
<P>Six studies (220 subjects) reported diary card recorded morning PEF (L/min). One study (<LINK REF="STD-Field-1982" TYPE="STUDY">Field 1982</LINK>, 54 subjects) reported diary card recorded PEF (% predicted). No significant difference between BDP and BUD was demonstrated, either when outcomes were considered according to the measure used, or when studies were pooled with the treatment effect expressed as a standardised mean difference: SMD -0.04 (95% CI -0.28 to 0.20).</P>
<P>One study (<LINK REF="STD-Springer-1987" TYPE="STUDY">Springer 1987</LINK>, 20 subjects) reported clinic measured PEF (% predicted). No significant difference between treatments was demonstrated. Five studies (111 subjects) reported evening PEF. No significant difference between BDP and BUD was apparent, WMD -5 L/min (95% CI -32 to 21 L/min).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Symptoms</HEADING>
<P>
<BR/>A variety of symptom scores were reported. These included daily, daytime, night-time, morning and evening cough, breathlessness and wheeze scores. No significant difference between treatments was apparent for any of these symptom measures. Those studies reporting daytime breathlessness, morning breathlessness and daily symptom scores were pooled (six studies, 256 subjects). No significant difference between BDP and BUD was apparent: SMD 0.06 (95% CI -0.18 to 0.31). Studies reporting night-time breathlessness and evening breathlessness scores were pooled (three studies, 134 subjects). Again, no significant difference between treatments was apparent: SMD -0.09 (95% CI -0.43 to 0.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Rescue beta-2 agonist use</HEADING>
<P>Numerical data for rescue beta2 agonist use was only reported in two studies. <LINK REF="STD-Tjwa-1995" TYPE="STUDY">Tjwa 1995</LINK> assessed daytime and night-time use; <LINK REF="STD-Willey-1982" TYPE="STUDY">Willey 1982</LINK> assessed morning and evening use. No significant differences between treatments were apparent.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Bronchial hyper-responsiveness (BHR)</HEADING>
<P>Only one study with numerical data (<LINK REF="STD-Tjwa-1995" TYPE="STUDY">Tjwa 1995</LINK>) assessed histamine BHR. This study in adult patients was of fair methodological quality (Jadad score 3), and assessed the effects of BDP and BUD at a nominal daily dose of 400 mcg, with BUD administered via Turbohaler DPI and BDP via a Rotahaler DPI. A significantly lower histamine BHR (expressed as log 10 PC20 FEV1) was apparent after BUD treatment for eight weeks compared to BDP, WMD 0.43 log 10 PC20FEV1 (95% CI 0.05 to 0.81 log10 PC20 FEV1). This translates into a 1.4 fold greater doubling concentration of histamine required to produce a 20% fall in FEV1 compared to BDP (95% CI 0.4 to 2.4 doubling concentrations, investigator's analysis).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Hypothalamo-pituitary adrenal axis (HPA) function</HEADING>
<P>Three studies (118 subjects) reported morning plasma cortisol. Two studies (76 subjects) reported plasma cortisol following a short cosyntropin test. No significant differences between BDP and BUD treatment groups were evident. In a single crossover study (<LINK REF="STD-Pedersen-1988" TYPE="STUDY">Pedersen 1988</LINK>), conducted in children and of fair methodological quality (Jadad score 3) 24 hour urinary free cortisol excretion was assessed. In this study subjects treated with BDP 800-1200 mcg/d had significantly lower 24 hour urinary cortisol levels compared to BUD 800-1200 mcg/d: BDP 7.6 nmol cortisol/mmol creatinine/day v BUD 10.2 nmol cortisol/mmol creatinine/day P&lt;0.01.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Local oral side effects</HEADING>
<P>The incidence of local oral side effects was reported in a number of crossover studies (<LINK REF="STD-Baran-1987" TYPE="STUDY">Baran 1987</LINK>, <LINK REF="STD-Boe-1989" TYPE="STUDY">Boe 1989</LINK>, <LINK REF="STD-Ebden-1986" TYPE="STUDY">Ebden 1986</LINK>, <LINK REF="STD-Petrie-1990" TYPE="STUDY">Petrie 1990</LINK>, <LINK REF="STD-Svendsen-1992" TYPE="STUDY">Svendsen 1992</LINK>). However, interpretation of the results is extremely difficult. In each study, the incidence of side effects was reported by treatment (BDP or BUD), rather than by individual treatment period. It was not stated if, in the case of a patient experiencing an adverse event during the first period of the trial when receiving one ICS, this had resolved by the point of crossover. Because none of the studies incorporated washout periods, this was especially unclear. In summary, the data regarding local oral side effects from the crossover studies comparing BDP to BUD are uninterpretable.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analyses</HEADING>
<P>No heterogeneity in effect size was present when studies were pooled for any outcome. Sensitivity analyses were undertaken by re-analysing outcomes and only including studies with a Jadad score of 3 or greater. This eliminated two studies (<LINK REF="STD-Bjorkander-1982a" TYPE="STUDY">Bjorkander 1982a</LINK>, <LINK REF="STD-Nicolaizik-1994" TYPE="STUDY">Nicolaizik 1994</LINK>). This did not result in a significant change in the size or direction of the treatment effect for any reported outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analyses</HEADING>
<P>Subgroup analyses based upon nominal daily dose, age, study duration, delivery device and asthma control did not identify any groups who appeared to preferentially benefit.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PARALLEL GROUP STUDIES: DOSE-DOWN TITRATION DESIGN</HEADING>
<P>Two parallel group studies adopted a dose down-titration design. Both were non-blinded open studies of variable methodological quality. One study (<LINK REF="STD-Brambilla-1994" TYPE="STUDY">Brambilla 1994</LINK>) had a Jadad score of 2, the other (<LINK REF="STD-Selroos-1994" TYPE="STUDY">Selroos 1994</LINK>) had a Jadad score of 3. Both were undertaken in adult asthmatics treated with BDP 1000 mcg/d or greater. In one study (<LINK REF="STD-Brambilla-1994" TYPE="STUDY">Brambilla 1994</LINK>) patients entered a 4-week run-in phase during which time they were maintained on the same daily dose of BDP that they received before entering the study. In <LINK REF="STD-Selroos-1994" TYPE="STUDY">Selroos 1994</LINK> study patients entered a two-year run-in period during which time the minimal effective dose of BDP was established in order to maintain the 'best possible level' of symptom control, such that patients were free of symptoms. Patients were randomised to either 12 weeks of treatment (<LINK REF="STD-Brambilla-1994" TYPE="STUDY">Brambilla 1994</LINK>) or two years of treatment (<LINK REF="STD-Selroos-1994" TYPE="STUDY">Selroos 1994</LINK>). During this time the daily dose of ICS was down-titrated following pre-defined symptom-based criteria whilst maintaining symptom control. The primary outcome measure in both studies was the end of study daily ICS dose. A significantly lower daily dose of BUD was required to maintain symptom control: WMD 444 mcg/d (95% CI 332 to 556 mcg/d). As would be anticipated given a trial design aimed at maintaining optimal control there were no significant differences in FEV1, PEF, rescue beta2 agonist use or withdrawals due to asthma exacerbation. There were no significant differences between treatments with regard to the incidence of local oral side effects (hoarseness/sore throat or Candidiasis).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PARALLEL GROUP STUDIES: DOSE ESCALATION DESIGN</HEADING>
<P>A single parallel group study of three months duration in children (<LINK REF="STD-Bisgaard-1988" TYPE="STUDY">Bisgaard 1988</LINK>), of high methodological quality (Jadad score 4) had a dose escalation design. Subjects were randomised to treatment with BDP or BUD. Patients in each randomised arm received 200 mcg/d, 400 mcg/d then 800 mcg/d for four week periods in succession with no washout between treatments. Patients were therefore randomised according to ICS, but not by daily dose of ICS. Outcomes reported included 24-hour urinary free cortisol excretion and plasma cortisol 30 min post 250 mcg i.v. tetracosactrin. No statistically significant difference between BDP and BUD were apparent for either outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ASTHMATICS TREATED WITH ORAL STEROIDS</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">CROSSOVER STUDIES: OCS-SPARING STUDY DESIGN</HEADING>
<P>One crossover study (<LINK REF="STD-Rafferty-1985" TYPE="STUDY">Rafferty 1985</LINK>) assessed the relative efficacy of BDP and BUD at a nominal daily dose of 800 mcg/d in adult patients treated with and dependent upon oral prednisolone at dose of 5mg/d or greater. This study was of fair quality (Jadad score 3). The use of a crossover design to assess OCS sparing efficacy is unique to this study. During each treatment period the daily dose of prednisolone was down titrated until asthma symptoms had deteriorated to 'an unacceptable level', although no a priori defined scheme was used to do this, with the decision to down-titrate dose appearing to have been at the discretion of the investigator. The treatment period for each patient concluded at the point of loss of symptom control. Following this, patients entered a 'washout' period during which time their pre-study dose of oral prednisolone was administered for four weeks before entering the second period of the study on the second ICS. Mean reduction in daily dose of oral prednisolone in BDP treated patients was 2.65 mg/d compared to 1.80 mg/d in BUD treated patients, with difference in reduction between groups of 0.85 mg/d in favour of BDP being statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">CROSSOVER STUDIES: NON OCS-SPARING STUDY DESIGN</HEADING>
<P>Three studies enrolled OCS treated patients, but did not assess OCS-sparing effects as part of the study design. In two studies (<LINK REF="STD-Stiksa-1982a" TYPE="STUDY">Stiksa 1982a</LINK>, <LINK REF="STD-Stiksa-1982b" TYPE="STUDY">Stiksa 1982b</LINK>) requirement for OCS therapy was an inclusion criterion. In one study (<LINK REF="STD-Stiksa-1985" TYPE="STUDY">Stiksa 1985</LINK>) OCS treatment was not an inclusion requirement, but 10 out of 27 subjects were being treated with oral prednisolone at the time of enrolment. All studies were of fair methodological quality (Jadad score 3). The outcomes for these studies were pooled (3 studies, 144 subjects). No significant difference between BDP and BUD was apparent for morning PEF, evening PEF, daytime or night-time breathlessness scores, sleep disturbance scores or rescue beta2 agonist use.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-07-21 14:04:47 +0100" MODIFIED_BY="Toby J Lasserson">
<P>This systematic review has assessed the randomised controlled trials that compared BDP and BUD at equal nominal daily dose, with the objective of assessing their relative efficacy and safety. 24 trials with 1174 children and adults were included.</P>
<SUBSECTION>
<HEADING LEVEL="6">RELATIVE EFFICACY</HEADING>
<P>The trials designed to assess the relative efficacy of inhaled BDP and BUD in non oral steroid treated asthmatic patients have been mainly of two period crossover design. Children and adults are represented, with daily doses of ICS ranging from 400 mcg/d or less to 1000 mcg/d or greater. Treatments were compared over a period of up to five weeks. A meta-analysis of the available data from these trials showed no significant difference between BDP and BUD when considering FEV1, morning PEF, or symptoms. Rescue beta2 agonist use was reported infrequently and the two trials that did report it used different scoring systems. Individually, they did not demonstrate a statistically significant difference between treatment groups.</P>
<P>The results of this analysis require cautious interpretation for the following reasons. Particular strengths of a crossover design relate to the fact that subjects recruited to the trial effectively act as their own controls. This results in a) efficiency in design as only half as many subjects are required in order to achieve the same degree of statistical power as an equivalent parallel design study and b) the effect of inter-individual variation in response to treatment is reduced, which may otherwise mask a true treatment effect. Unfortunately this design has some serious limitations when assessing the effects of relatively long acting interventions such as inhaled corticosteroids. Although most of the trials in this group were of fair methodological quality according to recognised grading systems, including that developed by Jadad, only two out of 19 trials had a washout of any length between treatment periods. Inhaled corticosteroids almost certainly exert an action that persists over days if not weeks after they have been discontinued. When the performance of long acting agents are assessed in trials of crossover design, there is also a concern that the effects of treatment administered in the first period of the trial may persist into, and modify the effects of any active agent administered in the second period of the trial. This so called 'carryover' or 'sequence' effect will influence the results of the study and lead to biased judgement concerning the relative efficacy and safety of the agents being assessed. In situations where the control intervention is inactive or a placebo, this effect will tend to produce an under estimate of the efficacy of the active treatment. In trials when two active treatments (such as BDP and BUD) are studied the influence of carryover effects are unpredictable. It is possible that a less effective drug could falsely appear to be the more effective one, if for example the carryover effect was strong and confined to the truly more effective drug. There are well-established statistical methods for assessing the presence or otherwise of carryover effects and excluding them. However a statement as to whether such tests were undertaken was rarely reported.</P>
<P>These considerations somewhat undermine the results of the individual trials and necessitate additional caution in drawing conclusions from any meta-analyses. When considering the crossover trials, bronchial hyper-responsiveness to histamine was the only outcome for which a significant difference between BDP and BUD was reported. This was from a single study (<LINK REF="STD-Tjwa-1995" TYPE="STUDY">Tjwa 1995</LINK>) in which BUD 400 mcg/d was delivered via the Turbohaler DPI and BDP 400 mcg/d was delivered via the Rotahaler DPI. This study incorporated a four-week washout period and the investigators excluded carryover effects, so this study is not subject to the criticisms as discussed above. Caution still needs to taken in interpreting these results because neither physicians nor patients were blinded to treatment allocation. The study was sponsored by Astra, the manufacturers of the Pulmicort Turbohaler, so the possibility of bias in favour of BUD cannot be excluded. It also possible that the observed difference in treatment effect was due to the delivery characteristics of the two dry powder delivery devices, rather than differences in the efficacy of BDP and BUD.</P>
<P>Only two parallel group design studies (<LINK REF="STD-Brambilla-1994" TYPE="STUDY">Brambilla 1994</LINK>, <LINK REF="STD-Selroos-1994" TYPE="STUDY">Selroos 1994</LINK>) assessed the relative efficacy of BDP and BUD in non oral steroid treated subjects and had usable data. These studies had fundamentally different objectives to the studies of crossover design. They used a dose down-titration design to compare the doses of BDP and BUD needed to maintain a good level of asthma control. A significantly lower dose of BUD was required to maintain control compared to BDP: WMD 444 mcg/d (95% CI 332 to 556 mcg/d). No heterogeneity in effect size was apparent between these studies, which differed greatly in duration (12 weeks and two years). It is important to appreciate that the drugs were administered using different delivery devices. In both studies, BUD was delivered by the Turbohaler DPI and BDP was delivered either by an MDI (<LINK REF="STD-Brambilla-1994" TYPE="STUDY">Brambilla 1994</LINK>) or an MDI+Volumatic spacer (<LINK REF="STD-Selroos-1994" TYPE="STUDY">Selroos 1994</LINK>). Unfortunately there were no studies of this type that compared drugs delivered by the same type of delivery device. As with the study by <LINK REF="STD-Tjwa-1995" TYPE="STUDY">Tjwa 1995</LINK>, a weakness common to both of these trials lies in the fact neither physicians nor patients were blinded to treatment allocation. Because both studies were sponsored Astra who manufacture the Pulmicort Turbohaler the possibility of systematic bias in favour of BUD is a possibility that cannot be excluded.</P>
<P>The relative oral steroid sparing efficacy of BDP and BUD was only assessed in one study (<LINK REF="STD-Rafferty-1985" TYPE="STUDY">Rafferty 1985</LINK>). In an approach unique in the inhaled corticosteroid literature, the relative oral prednisolone sparing effect of two interventions was assessed in a trial of crossover design. This study has two significant flaws. Firstly, the minimal effective dose of prednisolone was not established for each patient either at the beginning of the study, or during the 'washout' phase between treatment periods when each patient received 4-6 weeks of treatment with prednisolone. Enrolling subjects who are over treated with oral prednisolone could lead to an overestimate of the absolute prednisolone sparing efficacy of both BDP and BUD and lead to distortion in assessment of their relative effects. The second problem concerns the system used to taper the prednisolone dose. Dose reduction was attempted at regular intervals throughout each treatment period, until the point at which asthma symptoms deteriorated to 'an unacceptable level'. However no a priori definition for unacceptable symptoms was used. This could have led to a large degree of variation in the thresholds used by individual investigators in determining whether or not to continue dose reduction or to stop further dose reduction when assessing patients at clinic visits. The study was double blind and patients were randomised to each treatment sequence so these variations should have affected all patients equally. However in a study of small size (40 subjects) this factor may have had an unpredictable effect on the overall assessment of relative efficacy of the two inhaled steroids.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">RELATIVE SAFETY</HEADING>
<P>24 hour urinary free cortisol and plasma cortisol levels following short tetracosactrin test were assessed in the single high quality parallel group dose, escalation design study (<LINK REF="STD-Bisgaard-1988" TYPE="STUDY">Bisgaard 1988</LINK>) undertaken in children. No significant difference between BDP and BUD delivered by identical delivery device (MDI) were apparent.</P>
<P>No significant difference in post tetracosactrin plasma cortisol levels or basal morning plasma cortisol levels were apparent when BDP and BUD were compared in trials of crossover design. Because of an absence of washout periods and elimination of carryover effects in the trials reporting these outcomes, the same caution in interpretation needs to be taken for the reasons outlined above. Only one crossover study (<LINK REF="STD-Pedersen-1988" TYPE="STUDY">Pedersen 1988</LINK>) reported a sensitive measure of HPA function in the form of 24 urinary cortisol excretion corrected for creatinine. It should be noted that although a range of daily doses of ICS were assessed in this study (800-1200 mcg/d) individual children were randomised to receive identical daily nominal doses of BDP or BUD in each period of the crossover study, via identical delivery devices (MDI). Carryover effects were tested for and excluded in this study, despite the fact that a washout was not used. This study appears to be free of the limitations concerning the majority of crossover design studies. Although these differences are statistically significant, their clinical significance is uncertain. The concern regarding ICS use and HPA function, especially in children, is the long-term risk of adrenal insufficiency/crisis at times of stress. The predictive value of differences in results obtained in any of the available sensitive measures when comparing inhaled steroids and long term risk of adrenal insufficiency is unknown.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">STUDY POWER</HEADING>
<P>The primary purpose of these studies was never clearly defined - i.e. whether their objective was to determine therapeutic superiority or equivalence. This is important since the process of hypothesis testing is different between the two types of study, most noticeably in the use of upper and lower limits of equivalence in equivalence studies. For statistical reasons, equivalence studies usually have to be larger than superiority studies. None of these points were discussed in the trials included here, and all were too small to have been adequate for a test of equivalence.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Current asthma guidelines (<LINK REF="REF-BTS-1997" TYPE="REFERENCE">BTS 1997</LINK>, <LINK REF="REF-GINA-1995" TYPE="REFERENCE">GINA 1995</LINK>, <LINK REF="REF-NHLBI-1997" TYPE="REFERENCE">NHLBI 1997</LINK>) assume beclomethasone and budesonide are equally effective, such that for each defined level of asthma severity, the recommended doses are the same. However, there is little reliable evidence from randomised controlled studies to support this conclusion, and none to refute it. There are some data which suggest that budesonide via a Turbohaler is more effective than BDP delivered by either a Rotahaler or a MDI with or without spacer, but this difference may be due to the delivery device rather than the drug and is not sufficient to warrant any change in guideline recommendations.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a place for a large, parallel group randomised controlled trial to test the equivalence of BDP and BUD. Ideally this would include treatment arms assessing low dose ICS (400 mcg/d or less) and high dose ICS (1000 mcg/d or greater) in asthmatic children and adults. Currently available dry powder delivery devices differ for BDP and BUD. To assess relative drug efficacy without the confounding influence of differences in inhaler performance the newer non-CFC propellant metered dose inhalers could be used as a standardised delivery device if both drugs become available in this form. An intervention period of 6 months or longer would allow assessment of important outcomes such as asthma exacerbation rates, hospital admissions, days lost from work/school and heath status which have not been reported in any studies to date.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Anna Bara for running the initial electronic search and Steve Milan for assistance with statistical methods. We also like to acknowledge the authors who kindly responded to requests for additional information regarding their studies even in cases where information was not available including Dr M Boorsma, Dr C Brambilla, Dr P Ebden, Professor S Godfrey, Dr S Pedersen, Dr S Selroos, Dr G Stiksa, Dr UG Svendsen, Dr MKT Tjwa, Professor JO Warner and Dr RF Willey.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-12-08 13:24:58 +0000" MODIFIED_BY="Emma J Welsh">
<P>Nick Adams retrieved papers identified by electronic search, handsearched additional sources for relevant studies, assessed trials for methodological quality, contacted authors to clarify details of trial design and/or request missing data, extracted data from included trials and wrote the review.</P>
<P>Janine Bestall retrieved papers identified by search, assessed trials for methodological quality, contacted authors for clarification or trial details and/or request missing data.</P>
<P>Paul Jones provided editorial support .</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-12-08 13:24:27 +0000" MODIFIED_BY="Emma J Welsh">
<STUDIES MODIFIED="2014-12-08 13:24:27 +0000" MODIFIED_BY="Emma J Welsh">
<INCLUDED_STUDIES MODIFIED="2014-12-08 13:24:27 +0000" MODIFIED_BY="Emma J Welsh">
<STUDY DATA_SOURCE="PUB" ID="STD-Baran-1987" NAME="Baran 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baran D</AU>
<TI>A comparison of inhaled budesonide and beclomethasone dipropionate in childhood asthma</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1987</YR>
<VL>81</VL>
<NO>2</NO>
<PG>170-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bisgaard-1988" NAME="Bisgaard 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bisgaard H, Damkjaer Nielsen M, Andersen B, Andersen P, Foged N, Fuglsang G, et al</AU>
<TI>Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1988</YR>
<VL>81</VL>
<NO>6</NO>
<PG>1088-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorkander-1982a" NAME="Bjorkander 1982a" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjorkander J, Formgren H, Johansson SA, Millqvist E</AU>
<TI>Methodological aspects on clinical trials with inhaled corticosteroids: results of two comparisons between two steroid aerosols in patients with asthma</TI>
<SO>European Journal of Respiratory Diseases - Supplement</SO>
<YR>1982</YR>
<VL>122</VL>
<PG>108-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boe-1989" NAME="Boe 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boe J, Rosenhall L, Alton M, Carlsson LG, Carlsson U, Hermansson BA, et al</AU>
<TI>Comparison of dose-response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma</TI>
<SO>Allergy: European Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1989</YR>
<VL>44</VL>
<NO>5</NO>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brambilla-1994" NAME="Brambilla 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Using Smart Source Parsing&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brambilla C, Godard P, Lacronique J, Allaert FA, Duroux P, Blaive B, et al</AU>
<TI>A 3-month comparative dose-reduction study with inhaled beclomethasone dipropionate and budesonide in the management of moderate to severe adult asthma</TI>
<SO>Drug Investigation</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>1</NO>
<PG>49-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dal-Negro-1997" NAME="Dal Negro 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dal Negro R, Micheletto C, Ciani F, Muzzi A, Crimi E, Filippa P, et al</AU>
<TI>Efficacy and safety of inhaled beclomethasone dipropionate dry powder in the treatment of chronic asthma: A controlled study vs. budesonide</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<PG>351S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ebden-1986" NAME="Ebden 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ebden P, Jenkins A, Houston G, Davies BH</AU>
<TI>Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 micrograms/day) and budesonide (1600 micrograms/day), for chronic asthma</TI>
<SO>Thorax</SO>
<YR>1986</YR>
<VL>41</VL>
<NO>11</NO>
<PG>869-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Field-1982" NAME="Field 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Field HV, Jenkinson PM, Frame MH, Warner JO</AU>
<TI>Asthma treatment with a new corticosteroid aerosol, budesonide, administered twice daily by spacer inhaler</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1982</YR>
<VL>57</VL>
<NO>11</NO>
<PG>864-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greefhorst-1992" NAME="Greefhorst 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Greefhorst APM</AU>
<TI>Budesonide and terbutaline delivered via Turbuhaler compared to BDP and salbutamol delivered via Rotahaler</TI>
<SO>European Respiratory Journal</SO>
<YR>1992</YR>
<VL>5</VL>
<NO>Suppl 15</NO>
<PG>360S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamalainen-1998" MODIFIED="2014-12-08 13:24:18 +0000" MODIFIED_BY="Emma J Welsh" NAME="Hamalainen 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-12-08 13:24:18 +0000" MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hamalainen KM, Laurikaninen K, Leinonen M, Jager L</AU>
<TI>Comparison of two multidose powder inhalers (MDPI) in the treatment of asthma with inhaled corticosteroids</TI>
<SO>European Respiratory Journal</SO>
<YR>1998</YR>
<PG>61S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keelan-1984" NAME="Keelan 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keelan P, Gray P, Kelly P, Frame M</AU>
<TI>Comparison of a new corticosteroid aerosol, budesonide, with beclomethasone dipropionate in the treatment of chronic asthma</TI>
<SO>Irish Medical Journal</SO>
<YR>1984</YR>
<VL>77</VL>
<NO>8</NO>
<PG>244-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Micheletto-1997" NAME="Micheletto 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Micheletto C, Mauroner L, Burti E, Turco P, Pomari L, Cantini L, Dal Negro R</AU>
<TI>Inhaled beclomethasone dipropionate and budesonide dry powder in chronic asthma: Lung function-serum ECP relationship</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<PG>351S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicolaizik-1994" NAME="Nicolaizik 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicolaizik WH, Marchant JL, Preece MA, Warner JO</AU>
<TI>Endocrine and lung function in asthmatic children on inhaled corticosteroids</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1994</YR>
<VL>150</VL>
<NO>3</NO>
<PG>624-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1988" NAME="Pedersen 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen S, Fuglsang G</AU>
<TI>Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone</TI>
<SO>European Respiratory Journal</SO>
<YR>1988</YR>
<VL>1</VL>
<NO>5</NO>
<PG>433-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrie-1990" MODIFIED="2014-12-08 13:24:27 +0000" MODIFIED_BY="Emma J Welsh" NAME="Petrie 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-12-08 13:24:27 +0000" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;Using Smart Source Parsing&lt;/p&gt;" NOTES_MODIFIED="2014-12-08 13:24:27 +0000" NOTES_MODIFIED_BY="Emma J Welsh" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrie GR, Choo-Kang YFJ, Clark RA, Milledge JSSPR, Whitfield RJ, Higgins AJ</AU>
<TI>An assessment of the acceptability of two breath-actuated corticosteroid inhalers comparison of Turbohaler(TM) with Diskhaler(TM)</TI>
<SO>Drug Investigation</SO>
<YR>1990</YR>
<VL>2</VL>
<NO>2</NO>
<PG>129-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rafferty-1985" NAME="Rafferty 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rafferty P, Tucker LG, Frame MH, Fergusson RJ, Biggs BA, Crompton GK</AU>
<TI>Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: assessment of relative prednisolone-sparing effects</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>3</NO>
<PG>244-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selroos-1994" NAME="Selroos 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selroos O, Backman R, Forsen KO, Lofroos AB, Niemisto M, Pietinalho A, et al</AU>
<TI>Clinical efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI with volumatic spacer. A 2-year randomized study in 102 asthma patients</TI>
<SO>Allergy: European Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>10</NO>
<PG>833-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Springer-1987" NAME="Springer 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Springer C, Avital A, Maayan C, Rosler A, Godfrey S</AU>
<TI>Comparison of budesonide and beclomethasone dipropionate for treatment of asthma</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1987</YR>
<VL>62</VL>
<NO>8</NO>
<PG>815-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiksa-1982a" NAME="Stiksa 1982a" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiksa G, Glennow C, Johannesson N</AU>
<TI>A open cross-over trial with budesonide and beclomethasone dipropionate in patients with bronchial asthma</TI>
<SO>European Journal of Respiratory Diseases - Supplement</SO>
<YR>1982</YR>
<VL>122</VL>
<PG>266-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiksa-1982b" NAME="Stiksa 1982b" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiksa G, Glennow C, Johannesson N</AU>
<TI>A open cross-over trial with budesonide and beclomethasone dipropionate in patients with bronchial asthma</TI>
<SO>European Journal of Respiratory Diseases - Supplement</SO>
<YR>1982</YR>
<VL>122</VL>
<PG>266-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiksa-1985" NAME="Stiksa 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiksa G, Glennow C</AU>
<TI>Once daily inhalation of budesonide in the treatment of chronic asthma: a clinical comparison</TI>
<SO>Annals of Allergy</SO>
<YR>1985</YR>
<VL>55</VL>
<NO>1</NO>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svendsen-1992" NAME="Svendsen 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svendsen UG, Frolund L, Heinig JH, Madsen F, Nielsen NH, Weeke B</AU>
<TI>High-dose inhaled steroids in the management of asthma. A comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial responsiveness and the adrenal function</TI>
<SO>Allergy: European Journal of Allergy and Clinical Immunology</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>2 Pt 2</NO>
<PG>174-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;this study is, I'm 99% sure, the same as the Alergy citation. Need to check with Jane.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svendsen UG, Frolund L, Heinig JH, Madsen F, Nielsen NH, Weeke B</AU>
<TI>[High dose inhaled steroids in the treatment of bronchial asthma. A comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial reactivity and adrenocortical function]</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1993</YR>
<VL>155</VL>
<NO>28</NO>
<PG>2197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tjwa-1995" NAME="Tjwa 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tjwa MK</AU>
<TI>Budesonide inhaled via Turbuhaler: a more effective treatment for asthma than beclomethasone dipropionate via Rotahaler</TI>
<SO>Annals of Allergy, Asthma &amp; Immunology</SO>
<YR>1995</YR>
<VL>75</VL>
<NO>2</NO>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Willey-1982" NAME="Willey 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willey RF, Godden DJ, Carmichael J, Preston P, Frame MH, Crompton GK</AU>
<TI>Twice daily inhalation of a new corticosteroid, budesonide, in the treatment of chronic asthma</TI>
<SO>European Journal of Respiratory Diseases - Supplement</SO>
<YR>1982</YR>
<VL>122</VL>
<PG>138-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Birkebaek-1997" NAME="Birkebaek 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birkebaek NH, Esberg BH, Andersen K, Wolthers OD, Hassager C</AU>
<TI>[Budesonide and beclomethasone dipropionate inhalation powders. The effect on bone and collagen turnover in children]</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1997</YR>
<VL>159</VL>
<NO>17</NO>
<PG>2559-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorkander-1982b" NAME="Bjorkander 1982b" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjorkander J, Formgren H, Johansson SA, Millqvist E</AU>
<TI>Methodological aspects on clinical trials with inhaled corticosteroids: results of two comparisons between two steroid aerosols in patients with asthma</TI>
<SO>European Journal of Respiratory Diseases - Supplement</SO>
<YR>1982</YR>
<VL>122</VL>
<PG>108-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Graaff-1996" NAME="de Graaff 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>de Graaff CS, van der Burgh JHAM, Stallaert RALM, Prins J, van Lier AA</AU>
<TI>A double-blind comparative study of the inhaled corticosteroids budesonide and beclomethasone dipropionate in dry powder inhalers in asthmatic patients</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>Suppl 15</NO>
<PG>S359-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiviranta-1993" NAME="Kiviranta 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiviranta K, Turpeinen M</AU>
<TI>Effect of eight months of inhaled beclomethasone dipropionate and budesonide on carbohydrate metabolism in adults with asthma</TI>
<SO>Thorax</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>10</NO>
<PG>974-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piquet-1996" NAME="Piquet 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Using Smart Source Parsing&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piquet J, Zuck P, Dennewald G, Dugue P, Grivaux M, Brun P, et al</AU>
<TI>Equally efficacious asthma management with budesonide 800 mug administered by Turbuhaler(TM) or with beclomethasone dipropionate &gt;=1500 mug given through a pressurized metered-dose inhaler with spacer</TI>
<SO>Advances in Therapy</SO>
<YR>1996</YR>
<VL>13</VL>
<NO>1</NO>
<PG>38-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenhall-1982" NAME="Rosenhall 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenhall L, Lundqvist G, Adelroth E, Glennow C</AU>
<TI>Comparison between inhaled and oral corticosteroids in patients with chronic asthma</TI>
<SO>European Journal of Respiratory Diseases - Supplement</SO>
<YR>1982</YR>
<VL>122</VL>
<PG>154-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Struijs-1997" NAME="Struijs 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Struijs A, Mulder H</AU>
<TI>The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6</NO>
<PG>233-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Baxter_x002d_Jones-2000" NAME="Baxter-Jones 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baxter-Jones AD, Helms PJ</AU>
<TI>Early introduction of inhaled steroids in wheezing children presenting in primary care. A pilot study</TI>
<SO>Clinical &amp; Experimental Allergy</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>11</NO>
<PG>1618-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brand-2001" NAME="Brand 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brand PL, van der Baan-Slootweg OH, Heynens JW, de Vries TW, Versteegh FG, Vreuls RC, et al</AU>
<TI>Comparison of handling and acceptability of two spacer devices in young children with asthma</TI>
<SO>Acta Paediatrica</SO>
<YR>2001</YR>
<VL>90</VL>
<NO>2</NO>
<PG>133-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dal-Negro-1999b" NAME="Dal Negro 1999b" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dal Negro R, Micheletto C, Tognella S, Mauroner L, Burti E, Turco P, et al</AU>
<TI>Effect of inhaled beclomethasone dipropionate and budesonide dry powder on pulmonary function and serum eosinophil cationic protein in adult asthmatics</TI>
<SO>Journal of Investigational Allergology &amp; Clinical Immunology</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>4</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hernandez-1995" NAME="Hernandez 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez J, Garcia-Selles FJ, Negro JM, Pascual A, Sola J, Miralles JC, et al</AU>
<TI>[Comparative study] of beclomethasone and budesonide, with same posology (400 micrograms every 12 hours), in the control of cortico- dependent intrinsic asthma]</TI>
<SO>Allergologia et Immunopathologia</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>5</NO>
<PG>193-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jager-2000" NAME="Jager 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jager L, Laurikainen K, Leinonen M, Silvasti M</AU>
<TI>Beclomethasone dipropionate Easyhaler is as effective as budesonide Turbohaler in the control of asthma and is preferred by patients</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>6</NO>
<PG>368-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraszko-1999" NAME="Kraszko 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraszko P, Vondra D, Malolepszy J, Svensson M, Baly J, Fiserova J, et al</AU>
<TI>Budesonide via Turbuhaler, 400 mug daily, is as effective as beclomethasone dipropionate via pressurised MDI, 800 mug daily, for control of mild to moderate asthmatic patients</TI>
<SO>Journal of Clinical Research</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>47-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1995" NAME="Lee 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Korean&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee YC, Rhee YK</AU>
<TI>Effect of inhaled steroids on the cortisol concentration by different dosage or delivery method</TI>
<SO>Tuberculosis &amp; Respiratory Diseases</SO>
<YR>1995</YR>
<VL>42</VL>
<NO>6</NO>
<PG>888-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichel-2001" NAME="Reichel 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reichel W, Dahl R, Ringdal N, Zetterstrom O, van den Elshout FJ, Laitinen LA</AU>
<TI>Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2001</YR>
<VL>55</VL>
<NO>2</NO>
<PG>100-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-Boobis-1998" MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Boobis 1998" TYPE="JOURNAL_ARTICLE">
<AU>Boobis AR</AU>
<TI>Comparative physiochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide</TI>
<SO>Respiratory Medicine</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>Suppl B</NO>
<PG>2-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BTS-1997" MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="BTS 1997" TYPE="JOURNAL_ARTICLE">
<AU>British Thoracic Society</AU>
<TI>The British guidelines on asthma management 1995 review and position statement</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>Suppl 1</NO>
<PG>S1-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GINA-1995" MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="GINA 1995" TYPE="OTHER">
<AU>National Asthma Education and Prevention Program</AU>
<TI>Global strategy for asthma management and prevention NHBLI/WHO workshop report</TI>
<SO>Bethesda MD: NIH/National Heart, Lung and Blood Institute</SO>
<YR>1995</YR>
<NO>Publication No. 95-3659</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johansson-1982" MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Johansson 1982" NOTES="&lt;p&gt;in ref list of Szefler JACI 104 4 part 2 S175-183&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 14:02:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Johansson SA, Andersson KE, Brattsand R, Gruvstad E, Hedner P</AU>
<TI>Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1982</YR>
<VL>22</VL>
<PG>523-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHLBI-1997" MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NHLBI 1997" TYPE="OTHER">
<AU>National Asthma Education and Prevention Program</AU>
<TI>Guidelines for the Diagnosis and Managment of Asthma, Expert Panel Report No. 2</TI>
<SO>Bethesda MD: NIH/National Heart, Lung and Blood Institute</SO>
<YR>1997</YR>
<NO>NIH Publication No. 97-4051</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pethica-1998" MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Pethica 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pethica BD, Penrose A, MacKenzie D, Hall J, Beasley R, Tilyard M</AU>
<TI>Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: retrospective study of computerised general practice records</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7164</NO>
<PG>986-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stellato-1999" MODIFIED="2008-07-21 14:02:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Stellato 1999" TYPE="JOURNAL_ARTICLE">
<AU>Stellato C, Atsuta J, Bickel CA, Schleimer RP</AU>
<TI>An in vitro comparison of commonly used topical glucocorticoid preparations</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1999</YR>
<VL>104</VL>
<NO>3 Pt 1</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-12-08 13:25:14 +0000" MODIFIED_BY="Emma J Welsh">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-12-08 13:25:11 +0000" MODIFIED_BY="Emma J Welsh" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-12-08 13:25:00 +0000" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Baran-1987">
<CHAR_METHODS>
<P>Setting: Belgium, residential centre for asthmatic children<BR/>Length of intervention: 3 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, method not stated <BR/>Allocation concealment: unclear<BR/>Masking: double blind<BR/>Excluded: not stated<BR/>Withdrawals: stated (none)<BR/>Baseline characteristics: no tabulated demographic data<BR/>Jadad score: 3 <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-08 13:25:00 +0000" MODIFIED_BY="Emma J Welsh">
<P>21 children: 15M 6F<BR/>Age range: 4-14<BR/>Inclusion criteria:<BR/>Children suffering from chronic asthma and using inhaled corticosteroids to control their disease<BR/>No other criteria given<BR/>Exclusion criteria:<BR/>None stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 50 mcg 2puffs 2xdaily (200 mcg/d) via MDI</P>
<P>BUD: 50 mcg 2puffs 2xdaily (200 mcg/d) via Inhalet spacer <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1<BR/>FVC<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daytime breathlessness score<BR/>Night-time breathlessness score<BR/>Daily cough score<BR/>Sleeping difficulties score<BR/> 8 am plasma cortisol <BR/>Incidence of oropharyngeal Candidiasis<BR/>Both active treatment arms demonstrated significant improvements compared to non-randomised placebo arm for morning PEFR, evening PEFR and symptom scores.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method<BR/>Not stated if carryover effects were tested for.<BR/>Significant improvements in morning PEFR, evening PEFR and symptoms compared to non-randomised placebo treatment period at end of study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bisgaard-1988">
<CHAR_METHODS>
<P>Setting: multicentre Denmark, hospital outpatient clinic<BR/>Length of intervention: 3 months<BR/>Design: parallel group, dose escalation<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Masking: double blind<BR/>Excluded: not stated<BR/>Withdrawals: stated <BR/>Baseline characteristics: comparable<BR/>Jadad score: 4<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>41 children <BR/>Age range: 7-15 years (of those completing trial)<BR/>Inclusion criteria:<BR/>Children with bronchial asthma<BR/>"airway obstruction reversible by &gt; 20%"<BR/>All children recruited were using regular beta2 agonists.<BR/>None of the children recruited had used oral steroids within the previous 6 months, but this was not an explicit exclusion criterion.<BR/>Exclusion criteria: <BR/>None stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: step-wise increased doses (200, 400, 800 mcg daily) via aerosol MDI</P>
<P>BUD: step-wise increased doses (200, 400, 800 mcg daily) via aerosol MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>24 hour urinary free cortisol excretion (corrected for creatinine)<BR/>Plasma cortisol 30 min post 125 mcg iv tetracosactrin (nmol/L)<BR/>Morning PEFR (% predicted)<BR/>Evening PEFR (% predicted)<BR/>Rescue beta2 agonist use<BR/>Withdrawal due to asthma exacerbation (No. of patients)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Dose escalation design: patients were randomised to receive either BDP or BUD. Successive doses (200 mcg/d, 400 mcg/d, 800 mcg/d) were given for 4 week periods in succession, with no washout between each dose. Patients were not randomised to receive each dose.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bjorkander-1982a">
<CHAR_METHODS>
<P>Setting: Sweden, hospital outpatient clinic<BR/>Length of intervention: 2 weeks<BR/>Design: crossover, 1 week washout<BR/>Randomised: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Masking: not stated<BR/>Excluded: not stated<BR/>Withdrawals: none, but 5 patients excluded from analysis due to requirement for oral steroids during washout period<BR/>Baseline characteristics: no details<BR/>Jadad score: 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17 adults randomised, 12 completed the study: 3M 9F<BR/>Age range: 27-66 years<BR/>Inclusion criteria:<BR/>Stable chronic asthma of moderate severity <BR/>Demonstrated requirement for treatment with BDP over last year and were steroid dependent i.e. relapsed if steroid medication was withdrawn<BR/>% predicted FEV1 70 or greater<BR/>Exclusion criteria:<BR/>None stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 100mcg 1 puff 4xdaily (400mcg/day) via MDI</P>
<P>BUD: 100mcg 1 puff 4xdaily (400mcg/day) via MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 <BR/>FVC <BR/>Morning PEFR <BR/>Evening PEFR<BR/>Daily use of beta2 agonists (puffs/day) <BR/>Daily asthma symptom score <BR/>Morning plasma cortisol <BR/>Morning plasma cortisol 30 min post 250mg tetracosactrin <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation method<BR/>Published paper reported two studies. The second study was excluded (see Excluded studies).<BR/>Significantly higher FEV1 and morning PEFR in BDP treated subjects, and higher evening PEFR in BUD treated subjects, compared to placebo washout</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Boe-1989">
<CHAR_METHODS>
<P>Setting: multicentre study Sweden, hospital outpatient clinic<BR/>Length of intervention: 4 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, random number table<BR/>Allocation concealment: unclear<BR/>Masking: double blind<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: no details<BR/>Jadad score: 4<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>128 adults: 67M 61F<BR/>Age range 18-77 years<BR/>Inclusion criteria: <BR/>Asthma as defined by ATS criteria<BR/>Requirement for inhaled steroids in a dose range of 400-800 mcg/d<BR/>Exclusion criteria:<BR/>Cardiovascular disease or diabetes mellitus<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Four treatment allocations:<BR/>1) BDP 200 micrograms 2xdaily (400 mcg/day)<BR/>2) BUD 200 micrograms 2xdaily (400 mcg/day)<BR/>3) BDP 500 micrograms 2xdaily (1000 mcg/day)<BR/>4) BUD 400 micrograms 2xdaily (800 mcg/day)<BR/>All via MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1<BR/>FVC<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daily asthma symptom score<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify if allocation concealment was employed<BR/>Not stated if carryover effects were tested for.<BR/>Significant improvements in morning/evening PEFR, beta2 agonist use, symptoms in BDP and BUD groups compared to non-randomised placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Brambilla-1994">
<CHAR_METHODS>
<P>Setting: multicentre study France, hospital outpatient clinic<BR/>Length of intervention: 12 weeks<BR/>Design: parallel group, dose down-titration<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: stated <BR/>Baseline characteristics: comparable<BR/>Jadad score: 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>146 adults <BR/>Inclusion criteria:<BR/>Recurrent acute exacerbations of breathlessness and wheezing<BR/>15% or greater variability in FEV1 <BR/>Bronchial responsiveness to methacholine or histamine (PD20 FEV1 2mg or less)<BR/> Receiving inhaled BDP 1000-2000 mcg/d for at least 6 months<BR/>Exclusion criteria:<BR/>Airways disease other than asthma<BR/>Smoker &gt; 5 packs cigarettes per year <BR/>Significant co-existent disease<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 800 to 2000 mcg total daily dose via MDI</P>
<P>BUD: 800 to 1600 mcg total daily dose via Turbohaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 <BR/>Morning PEFR <BR/>Evening PEFR <BR/>Number of puffs of inhaled corticosteroid per day <BR/>Number asthma exacerbations/week<BR/>Number night awakenings requiring beta2 agonist use/week<BR/>Daily beta2 agonist use (puffs/day) <BR/>Withdrawal due to asthma exacerbation<BR/>Incidence of local oral side effects </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reply from author but unable to clarify details of randomisation procedure.<BR/>Dose down titration study design: patients were randomised to receive either BDP or BUD at a dose considered to be equivalent to their pre-study dose of BDP. BDP 250 mcg/puff via MDI was considered equivalent to BUD 200 mcg/actuation via Turbuhaler DPI. <BR/>During the study daily dose of ICS was reduced according to pre-defined criteria based on experience of asthma symptoms in the week prior to assessment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dal-Negro-1997">
<CHAR_METHODS>
<P>Setting: multicentre study Italy, hospital outpatient clinic<BR/>Length of intervention period: 8 weeks<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Design: parallel group<BR/>Masking: not stated<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: no demographic data presented<BR/>Jadad score: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>79 adult adults<BR/>Inclusion criteria:<BR/>Adult patients with stable asthma (not defined)<BR/>Regular treatment with BDP 1000 mcg/d<BR/>No further details<BR/>Exclusion criteria:<BR/>No details</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 200 mcg 4xdaily (800 mcg/d) via Pulvinal DPI </P>
<P>BUD: 200 mcg 4xdaily (800 mcg/d) via Turbuhaler DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 <BR/>FVC<BR/>FEF25-75<BR/>MEF50<BR/>Morning PEFR<BR/>Asthma symptom score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study in abstract form only.<BR/>No reply from trial sponsors to clarify details of randomisation procedure, further inclusion/exclusion criteria, patient withdrawals or outcomes data.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-08 13:25:04 +0000" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Ebden-1986">
<CHAR_METHODS>
<P>Setting: Wales, hospital outpatient clinic<BR/>Length of intervention: 6 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Masking: double blind<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: no details<BR/>Jadad score: 3<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 adults: 20M 8F<BR/>Age range: 19-72 years<BR/>Inclusion criteria<BR/>Patients with chronic asthma whose "attending physician considered their asthma to be poorly controlled and require further treatment"<BR/>15% reversibility in PEFR after inhaled beta2 agonist<BR/>Good inhaler technique<BR/>Exclusion criteria:<BR/>Use of oral steroids within 2 months of the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-08 13:25:03 +0000" MODIFIED_BY="Emma J Welsh">
<P>BDP: 250 mcg 3puffs 2xdaily (1500 mcg/day) via MDI</P>
<P>BUD: 200 mcg 4 puffs 2xdaily (1600 mcg/day) via MDI+ collapsible spacer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 <BR/>FVC <BR/>Morning PEFR <BR/>Evening PEFR <BR/>Daily beta2 agonist (puffs/day)<BR/>Daytime wheeze score <BR/>Morning serum cortisol <BR/>Serum cortisol 30 minutes post 250mcg tetracosactrin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-08 13:25:04 +0000" MODIFIED_BY="Emma J Welsh">
<P>Reply from author but unable to clarify details of randomisation procedure or if carryover effects were excluded.<BR/>Majority of patients demonstrated a significant improvement in at least one efficacy outcome compared to baseline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Field-1982">
<CHAR_METHODS>
<P>Setting: UK, paediatric outpatient clinic <BR/>Length of intervention: 4 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, method not stated <BR/>Allocation concealment: unclear<BR/>Masking: double blind<BR/>Excluded: not stated<BR/>Withdrawals: stated <BR/>Baseline characteristics: no details <BR/>Jadad score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>31 children: 19M 12F<BR/>Age range: 4-14 years<BR/>Inclusion criteria:<BR/>"fairly severe asthma requiring regular inhaled corticosteroids"<BR/>Exclusion criteria: not stated </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 400 mcg/day in 4 divided doses children remained on delivery device used before trial (either aerosol MDI or Rotahaler DPI)</P>
<P>BUD: 200 mcg 2xdaily (400 mcg/day) via aerosol MDI with tube spacer<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 (% predicted) <BR/>FVC (% predicted) <BR/>Morning PEFR (% predicted) <BR/>Evening PEFR (% predicted) <BR/>FEF 50 (% predicted)<BR/>FEF 25 (% predicted)<BR/>Daily symptom score </P>
<P>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reply from authors but unable to clarify details of randomisation procedure.<BR/>Not stated if carryover effects were tested for.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Greefhorst-1992">
<CHAR_METHODS>
<P>Setting: muticentre study, The Netherlands, primary care or hospital outpatient setting unclear <BR/>Length of intervention period: 6 weeks<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Design: crossover, no washout<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: not stated<BR/>Baseline characteristics: no demographic data presented<BR/>Jadad score: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>145 adults<BR/>Inclusion criteria:<BR/>Adult asthmatic patients already treated with inhaled corticosteroids<BR/>No further details<BR/>Exclusion criteria:<BR/>No details</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 200 mcg 2xdaily (400 mcg/d) via Rotahaler DPI</P>
<P>BUD: 200 mcg 2xdaily (400 mcg/d) via Turbuhaler DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Morning PEFR<BR/>Evening PEFR<BR/>Asthma symptom score<BR/>Rescue beta2 agonist use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study in abstract form only.<BR/>No reply from author to clarify details of randomisation method used, further inclusion/exclusion criteria, patient withdrawals or data for outcomes.<BR/>Not stated if carryover effects were tested for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hamalainen-1998">
<CHAR_METHODS>
<P>Setting: multicentre study Germany, hospital outpatient clinic<BR/>Length of intervention period: 8 weeks<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Design: crossover, no washout <BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: not stated<BR/>Baseline characteristics: no demographic data presented<BR/>Jadad score: 1<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>79 adults: 39M 40F<BR/>Mean (SD) age: 51 (15) years<BR/>Inclusion criteria:<BR/>Adults with asthma currently treated with inhaled BDP 1000 mcg/day via MDI<BR/>Non smokers<BR/>No further details<BR/>Exclusion criteria:<BR/>No details</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 200 mcg 4 actuations/day (800 mcg/d) via Easyhaler DPI</P>
<P>BUD: 200 mcg 4 actuations/day (800 mcg/d) via Turbuhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Morning PEFR<BR/>Morning serum cortisol <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study in abstract form only. <BR/>No reply from author to clarify details of randomisation method used, further inclusion/exclusion criteria, patient withdrawals or data for outcomes.<BR/>Not stated if carryover effects were tested for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Keelan-1984">
<CHAR_METHODS>
<P>Setting: Ireland, hospital outpatient clinic<BR/>Length of intervention: 4 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, method not stated <BR/>Allocation concealment: unclear<BR/>Masking: double-blind<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: no tabulated demographic data presented<BR/>Jadad score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>36 adults: 21M 15F<BR/>Age range: 15-65 years<BR/>Inclusion criteria:<BR/>Adults with asthma insufficiently controlled by bronchodilators and /or anti-allergic therapy and who required 400 micrograms of BDP per day.<BR/>Exclusion criteria:<BR/>Bronchopulmonary disease other than asthma, or other disease<BR/>Use of oral steroids or ACTH preparation within last month<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 50 mcg 2 puffs 4xdaily (400 mcg/day) via MDI and placebo via MDI+spacer</P>
<P>BUD: 50 mcg 2 puffs 4xdaily (400 mcg/day) via MDI+ spacer and placebo via MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 <BR/>FVC <BR/>Morning PEFR<BR/>Evening PEFR<BR/>Asthma symptom score <BR/>Beta2 agonist use <BR/>Serum cortisol (time not specified) </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation procedure.<BR/>Not stated if carryover effects were tested for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Micheletto-1997">
<CHAR_METHODS>
<P>Setting: Italy, hospital outpatient clinic<BR/>Length of intervention period: 8 weeks<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Design: parallel group<BR/>Masking: unclear<BR/>Excluded: not stated<BR/>Withdrawals: not stated<BR/>Baseline characteristics: no details<BR/>Jadad score: 1</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>32 adults<BR/>Age range: not stated<BR/>Inclusion criteria:<BR/>Adult patients with stable asthma receiving inhaled BDP 1000 mcg/day<BR/>No other details<BR/>Exclusion criteria:<BR/>Not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 200 mcg 4xdaily (800 mcg/day) via Pulvinal DPI</P>
<P>BUD: 200 mcg 4xdaily (800 mcg/day) via Turbuhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1<BR/>FVC<BR/>Clinic PEFR<BR/>FEF 25-75<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daily beta2 agonist use<BR/>Serum ECP<BR/>Morning serum cortisol<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study in abstract form only. <BR/>No reply from trial sponsors to clarify details of randomisation procedure, further inclusion/exclusion criteria, patient withdrawals or data for outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nicolaizik-1994">
<CHAR_METHODS>
<P>Setting: UK, hospital outpatient clinic<BR/>Length of intervention: 2 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: stated <BR/>Baseline characteristics: no tabulated demographic data presented<BR/>Jadad score: 2<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>14 children: 11M 3F<BR/>Age range: 8 to 14 years<BR/>Inclusion criteria:<BR/>Asthma inadequately controlled on inhaled sodium cromoglycate and beta2 agonists and/or optimal doses of slow release oral theophyllines<BR/>Reliable in medication compliance, diary card recording, use of MDI<BR/>Exclusion criteria:<BR/>Any steroid medication within the last month or regular corticosteroid treatment in the last 12 months.<BR/>Significant bronchopulmonary disease other than asthma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 50 mcg 4 puffs 2xdaily (400 mcg/day) via MDI</P>
<P>BUD: 50 mcg 4 puffs 2xdaily (400 mcg/day) via MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 <BR/>FVC <BR/>Morning PEFR <BR/>Evening PEFR<BR/>Daily symptom score <BR/>Weekly use of beta2 agonists <BR/>Bronchial responsiveness to histamine PC20 FEV1, PD20 FEV1) <BR/>Serum cortisol (area under curve for 12 hours, 20min interval samples)<BR/>Serum growth hormone (area under curve for 12 hours, 20min samples)<BR/>12pm serum ACTH <BR/>8am serum ACTH <BR/>24 hour urinary free cortisol </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reply from authors but unable to clarify details of randomisation procedure<BR/>Not stated if carryover effects were tested for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pedersen-1988">
<CHAR_METHODS>
<P>Setting: Denmark, hospital outpatient clinic<BR/>Length of intervention: 6 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, computer generated algorithm<BR/>Allocation concealment: yes, using sealed envelopes<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: no tabulated demographic data presented<BR/>Jadad score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>31 children: 15M 16F<BR/>Age range: 5-15 years<BR/>Inclusion criteria:<BR/>Children with asthma receiving high dose inhaled corticosteroids (either BDP or BUD)<BR/>Exclusion criteria:<BR/>Receipt of oral or parenteral steroids in last 6 months</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: total daily dose 800-1200 mcg via either aerosol MDI or MDI+spacer</P>
<P>BUD: total daily dose 800-1200 mcg via either aerosol MDI or MDI+spacer<BR/>Children continued with the same dose of inhaled steroid throughout the trial, which was their dose at baseline on entering the study<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>24 hour urinary free cortisol </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author confirmed method of random order generation and use of allocation concealment.<BR/>Carryover effects were tested for and excluded.<BR/>Children continued using the delivery device that they had been using prior to study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-08 13:25:07 +0000" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Petrie-1990">
<CHAR_METHODS>
<P>Setting: multicentre study UK, hospital outpatient clinic <BR/>Length of intervention: 4 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Masking: none<BR/>Excluded: stated <BR/>Withdrawals: stated <BR/>Baseline characteristics: no tabulated demographic data presented<BR/>Jadad score: 2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-08 13:25:07 +0000" MODIFIED_BY="Emma J Welsh">
<P>40 adults<BR/>Age range of study completers: 26-76 years<BR/>Inclusion criteria:<BR/>Adults with chronic stable asthma<BR/>15% or greater reversibility in PEFR following beta2 agonists or &gt; 20% variability in daily PEFR during 2 week run in period<BR/>All patients receiving 800-1600 mcg inhaled BDP or BUD on entry to study.<BR/>Exclusion criteria:<BR/>Respiratory tract infection within last 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 100 mcg 4puffs 2xdaily ( 800mcg/day) via Diskhaler DPI</P>
<P>BUD: 200 mcg 2 puffs 2xdaily (800 mcg/day) via Turbohaler DPI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 <BR/>Morning PEFR <BR/>Evening PEFR <BR/>Daily beta2 agonist use </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation procedure</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rafferty-1985">
<CHAR_METHODS>
<P>Setting: UK, hospital outpatient clinic<BR/>Length of intervention: variable <BR/>Design: crossover <BR/>Randomisation: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Masking: double blind<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: no data regarding baseline spirometry of subjects, wide range for duration of asthma, duration of oral steroid use and inhaled steroid use.<BR/>Jadad score: 3<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 adults randomised, 26 completed study: 12 M 14F<BR/>Age range: 23-72 years<BR/>Inclusion criteria:<BR/>"Severe chronic asthma", being treated with at least 5mg oral prednisolone per day and inhaled BDP 400 mcg daily for at least 9 months<BR/>Exclusion criteria:<BR/>Any patient whose dose of oral prednisolone had been adjusted in the last 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. BDP: 200 mcg 1puff 4xdaily (800 mcg/d) via MDI</P>
<P>2. BUD 200 mcg 2 puffs 2xdaily (800 mcg/d) via MDI+Inhalet spacer </P>
<P>3. BUD 200 mcg 4 puffs 1xdaily (800 mcg/d) via MDI+Inhalet spacer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reduction in daily prednisolone dose (mg/d) <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No reply from author to clarify details of randomisation procedure or regimen for tapering prednisolone dose.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Selroos-1994">
<CHAR_METHODS>
<P>Setting: Finland, hospital outpatient clinic<BR/>Length of intervention: 2 years<BR/>Design: parallel group, dose down titration<BR/>Randomisation: yes, computer randomisation algorithm<BR/>Allocation concealment: unclear<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: stated (none) <BR/>Baseline characteristics: comparable<BR/>Jadad score: 3<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>102 adults: 38M 74F<BR/>Inclusion criteria:<BR/>Not stated explicitly but study included adult asthmatics who required moderate to high doses of inhaled BDP<BR/>Excluson criteria: <BR/>None stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: variable dose via aerosol MDI + Volumatic spacer</P>
<P>BUD: variable dose via Turbuhaler DPI <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Daily dose inhaled corticosteroid (mg)<BR/>FEV1 <BR/>FEV1 (% predicted) <BR/>Daily PEFR <BR/>Daily PEFR (% predicted) <BR/>Incidence of local oral side-effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author confirmed method of random order generation.<BR/>Dose down titration study design: two year 'run-in' period during which time all patients had their daily dose of BDP down-titrated to the minimal dose effective in controlling symptoms. However there was no pre-defined scheme based on objective measures of control for doing this. During study dose down titration was attempted if patient was a) completely or almost completely symptom free and b) FEV1 and PEFR were no lower than at previous assessment. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Springer-1987">
<CHAR_METHODS>
<P>Setting: Israel, paediatric outpatient clinic<BR/>Length of intervention: 4 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, method not stated <BR/>Allocation concealment: unclear<BR/>Masking: double blind<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: no tabulated demographic data presented<BR/>Jadad score: 3<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>10 children<BR/>Age range: 9-15<BR/>Inclusion criteria:<BR/>Asthma dependant on treatment with inhaled steroids.<BR/>Exclusion criteria:<BR/>Use of oral steroids in the previous month.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 50 mcg 4 puffs 4xdaily (400 mcg/d) </P>
<P>BUD: 50 mcg 4 puffs 4xdaily (400 mcg/d)</P>
<P>Delivery device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 (% predicted) <BR/>PEFR (% predicted) <BR/>Daily symptom score<BR/>24 hour urinary tetrahydrocortisone glucosiduronate <BR/>24 hour urinary tetrahydrocortisol glucosiduronate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reply from authors but unable to clarify details of randomisation procedure<BR/>Not stated if carryover effects were tested for.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stiksa-1982a">
<CHAR_METHODS>
<P>Setting: Sweden, hospital outpatient clinic <BR/>Length of intervention period: 2 weeks<BR/>Randomisation: yes, computer generated sequence<BR/>Allocation concealment: yes <BR/>Design: crossover, no washout<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: stated (none)<BR/>Baseline characteristics: no baseline demographic data presented<BR/>Jadad score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>27 adults: 19M 8F<BR/>Age range: 19-76 years<BR/>Inclusion criteria:<BR/>Asthmatics with 'severe steroid-dependent' asthma<BR/>Exclusion criteria:<BR/>Not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. BDP 200 mcg 4xdaily (800 mcg/d)</P>
<P>2. BUD 200 mcg 4xdaily (800 mcg/d)</P>
<P>Delivery device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Morning PEFR<BR/>Evening PEFR<BR/>Daytime breathlessness score<BR/>Night-time breathlessness score<BR/>Sleeping difficulty due to asthma score<BR/>Rescue beta2 agonist use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author confirmed randomisation method and use of allocation concealment. <BR/>Author also confirmed that all enrolled patients were oral steroid dependent and that there were no withdrawals from the study.<BR/>Not stated if carryover effects were tested for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stiksa-1982b">
<CHAR_METHODS>
<P>Setting: Sweden, hospital outpatient clinic <BR/>Length of intervention period: 2 weeks<BR/>Randomisation: yes, computer generated sequence<BR/>Allocation concealment: yes <BR/>Design: crossover, no washout<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: stated (none)<BR/>Baseline characteristics: no baseline demographic data presented<BR/>Jadad score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>27 adults: 19M 8F<BR/>Age range: 19-76 years<BR/>Inclusion criteria:<BR/>Asthmatics with 'severe steroid-dependent' asthma<BR/>Exclusion criteria:<BR/>Not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. BDP 400 mcg 2xdaily (800 mcg/d)</P>
<P>2. BUD 400 mcg 2xdaily (800 mcg/d)</P>
<P>Delivery device: MDI</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Morning PEFR<BR/>Evening PEFR<BR/>Daytime breathlessness score<BR/>Night-time breathlessness score<BR/>Sleeping difficulty due to asthma score<BR/>Rescue beta2 agonist use</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>See Stiksa 1982a</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-08 13:25:11 +0000" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Stiksa-1985">
<CHAR_METHODS>
<P>Setting: Sweden, hospital outpatient clinic <BR/>Length of intervention period: 3 weeks <BR/>Randomisation: yes, computer generated sequence<BR/>Allocation concealment: yes <BR/>Design: crossover, no washout<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable <BR/>Jadad score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 adults: 11M 9F<BR/>Mean (SD) age: 56.4 (7) years <BR/>Inclusion criteria: <BR/>Asthmatics currently receiving inhaled BDP 200 mcg/d for 8 months or longer<BR/>Exclusion criteria:<BR/>Not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. BDP: 200 mcg 1puff 4xdaily (800 mcg/d) via MDI</P>
<P>2. BUD 200 mcg 2 puffs 2xdaily (800 mcg/d) via MDI+Inhalet spacer </P>
<P>3. BUD 200 mcg 4 puffs 1xdaily (800 mcg/d) via MDI+Inhalet spacer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Morning PEFR<BR/>Evening PEFR<BR/>Daytime breathlessness score<BR/>Night-time breathlessness score<BR/>Sleeping difficulty due to asthma score<BR/>Daily beta2 agonist use <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-08 13:25:11 +0000" MODIFIED_BY="Emma J Welsh">
<P>Author confirmed randomisation method and use of allocation concealment<BR/>10 patients were receiving treatment with oral prednisolone at enrolment.<BR/>Not stated if carryover effects were tested for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Svendsen-1992">
<CHAR_METHODS>
<P>Setting: Denmark, hospital outpatient clinic<BR/>Length of intervention: 6 weeks <BR/>Design: crossover, no washout<BR/>Randomised: yes, method not stated<BR/>Allocation concealment: unclear<BR/>Masking: double-blind<BR/>Excluded: not stated<BR/>Withdrawals: stated<BR/>Baseline characteristics: comparable<BR/>Jadad score: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>39 adults<BR/>Age range: 18 years or older<BR/>Inclusion criteria:<BR/>Asthma poorly controlled with inhaled steroids, daily dose 300 - 500 mcg/day<BR/>FEV1, FVC or PEFR &lt; 70% predicted <BR/>15% or greater improvement in FEV1 after inhaled beta2 agonist <BR/>Bronchial hyper-responsiveness to histamine (PC20 FEV1 2 mg/ml or less)<BR/>Exclusion criteria: <BR/>Regular oral steroids during 3 months prior to the trial<BR/>Unable to use aerosols correctly<BR/>Pregnancy or significant co-existent disease<BR/>Respiratory infections within last 4 weeks <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 250 mcg 3 puffs 2xdaily (1500 mcg/day) via MDI and placebo via MDI+Inhalet spacer</P>
<P>BUD: 200 mcg 4 puffs 2xdaily (1600 mcg) via MDI+Inhalet spacer and placebo via MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1 <BR/>FVC <BR/>Morning PEFR <BR/>Evening PEFR <BR/>Clinic PEFR <BR/>Histamine BHR (PC20 FEV1) <BR/>Sleep disturbance, wheeze and activity restriction score <BR/>Rescue beta2 agonist use (puffs/day) <BR/>Plasma cortisol (time not stated) <BR/>Plasma cortisol 30 min post 250 mcg iv tetracosactrin </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reply from author but unable clarify details of randomisation procedure<BR/>Not stated if carryover effects were tested for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tjwa-1995">
<CHAR_METHODS>
<P>Setting: The Netherlands, hospital outpatient clinic<BR/>Length of intervention: 8 weeks<BR/>Design: crossover, 4 week washout<BR/>Randomisation: yes, by computerised randomisation algorithm<BR/>Allocation concealment: unclear<BR/>Masking: none<BR/>Excluded: not stated<BR/>Withdrawals: stated <BR/>Baseline characteristics: comparable <BR/>Jadad score: 3<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 adults: 14M 2F<BR/>Inclusion criteria:<BR/>18 years of age or older<BR/>Asthma for more than 2 years<BR/>%predicted FEV1 40-85<BR/>15% or greater improvement in FEV1 after inhaled beta2 agonist<BR/>Bronchial hyper-responsiveness to histamine (PC20 FEV1 less than or equal to 1.0mg/ml)<BR/>Currently receiving inhaled steroid 150-800 mcg/daily<BR/>Exclusion criteria:<BR/>Pregnancy or significant co-existent disease<BR/>Asthma exacerbation or respiratory tract infection in previous 2 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 200 mcg 1 actuation 2xdaily (400 mcg daily) via Rotahaler DPI</P>
<P>BUD: 200 mcg 1 actuation 2xdaily (400 mcg daily) via Turbuhaler DPI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1<BR/>FVC<BR/>Morning PEFR <BR/>Evening PEFR <BR/>Daytime wheeze score Daytime breathlessness score <BR/>Daytime cough score<BR/>Night-time wheeze score<BR/>Night-time breathlessness score<BR/>Night-time cough score<BR/>Daytime beta2 agonist use (puffs/day)<BR/>Night-time beta2 agonist use (puffs/day)<BR/>Bronchial responsiveness to histamine (PC20 FEV1) <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author confirmed method of random order generation and provided original data for all outcomes.<BR/>Carryover effects were tested for and excluded.<BR/>Significant improvement in at least one efficacy measure for both BDP and BUD groups compared to placebo washout</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Willey-1982">
<CHAR_METHODS>
<P>Setting: UK, hospital outpatient clinic<BR/>Length of intervention: 4 weeks<BR/>Design: crossover, no washout<BR/>Randomisation: yes, computerised randomisation algorithm<BR/>Allocation concealment: yes<BR/>Masking: double blind<BR/>Excluded: not stated<BR/>Withdrawals: stated <BR/>Jadad score: 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>30 adults: 8M 12F<BR/>Age range: 18-67 years<BR/>Inclusion criteria:<BR/>Diagnosis of chronic asthma<BR/>Current treatment with BDP 400 mcg/day<BR/>Required at least two courses of oral corticosteroid therapy for exacerbations of asthma within the last 12 months<BR/>Able to use an aerosol MDI efficiently<BR/>Exclusion criteria:<BR/>Oral steroids within the last month</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>BDP: 50 mcg 2 puffs 4xdaily (400 mcg daily) via MDI plus placebo MDI+spacer</P>
<P>BUD: 50 mcg 4 puffs 2xdaily (400 mcg daily) via MDI + spacer plus placebo MDI<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FEV1<BR/>FVC<BR/>Morning PEFR <BR/>Evening PEFR <BR/>Morning wheeze score<BR/>Evening wheeze score<BR/>Morning breathlessness score<BR/>Evening breathlessness score<BR/>Morning cough score <BR/>Evening cough score<BR/>Nightime salbutamol use score<BR/>Daytime salbutamol use score </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author confirmed details of randomisation procedure.<BR/>Not stated if carryover effects were tested for.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACTH: adrenocorticotrophic hormone<BR/>ATS: American Thoracic Society<BR/>BDP: beclomethasone dipropionate<BR/>BUD: budesonide<BR/>DPI: dry powder inhaler<BR/>ECP: eosinophil cationic protein<BR/>FEF25-75: forced expiratory flow at 25 to 75% of FVC<BR/>FEF 50: forced expiratory flow rate at 50% of FVC<BR/>FEV1: forced expired volume in one second<BR/>FVC: forced vital capacity<BR/>ICS: inhaled corticosteroid<BR/>MDI: metered dose inhaler<BR/>PC20 FEV1: concentration of inhalant required to produce a 20% fall in FEV1<BR/>PD20 FEV1: dose of inhalant required to produce a 20% fall in FEV1<BR/>PEFR: peak expiratory flow rate</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-12-08 13:25:14 +0000" MODIFIED_BY="Emma J Welsh" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Birkebaek-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study concerned with the effects of BDP and BUD on markers of bone and collagen turnover only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bjorkander-1982b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unequal nominal daily doses of BDP and BUD compared: BDP 400 mcg/d v BUD 200 mcg/d</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Graaff-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clear if study randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kiviranta-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Described as randomised in paper publication, however following contact with authors it was apparent that patients were not allocated to intervention groups in a randomised manner</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Piquet-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unequal nominal daily doses of BDP and BUD compared: BDP 1500-2000 mcg/d v BUD 800 mcg/d</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosenhall-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unequal doses of BDP and BUD compared: BDP 400 mcg/d v BUD 200 or 800 mcg/d</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-08 13:25:14 +0000" MODIFIED_BY="Emma J Welsh" STUDY_ID="STD-Struijs-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-08 13:25:14 +0000" MODIFIED_BY="Emma J Welsh">
<P>Patients enrolled with chronic obstructive airways disease, not asthma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Baxter_x002d_Jones-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Brand-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Dal-Negro-1999b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Hernandez-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Jager-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kraszko-1999">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lee-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Reichel-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Baran-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bisgaard-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bjorkander-1982a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boe-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Brambilla-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dal-Negro-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ebden-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Field-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Greefhorst-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hamalainen-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Keelan-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Micheletto-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nicolaizik-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pedersen-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Petrie-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rafferty-1985">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Selroos-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Springer-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stiksa-1982a">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stiksa-1982b">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stiksa-1985">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Svendsen-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tjwa-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Willey-1982">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-12-08 13:25:24 +0000" MODIFIED_BY="Emma J Welsh">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-07-21 14:02:48 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<TITLE>Trial recruiting non-OCS, non-ICS treated asthmatics: baseline asthma control</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>B.L. FEV1 (% pred)</P>
</TH>
<TH>
<P>B.L. symp freq</P>
</TH>
</TR>
<TR>
<TD>
<P>Bisgaard 1988</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Keelan 1984</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>symptoms 'insufficiently controlled' by bronchodilators and/or anti-allergy therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicolaizik 1994</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>symptoms 'inadequately controlled'</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>B.L: baseline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-07-21 14:02:48 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<TITLE>Trials recruiting non-OCS, but ICS-treated asthmatics: baseline asthma control</TITLE>
<TABLE COLS="4" ROWS="20">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>B.L. ICS dose</P>
</TH>
<TH>
<P>B.L. FEV1 (% pred)</P>
</TH>
<TH>
<P>B.L. symp freq</P>
</TH>
</TR>
<TR>
<TD>
<P>Baran 1987</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Bjorkander 1982</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>&gt;70</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Boe 1989</P>
</TD>
<TD>
<P>ICS 400-800 mcg/d</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Brambilla 1994</P>
</TD>
<TD>
<P>BDP 1000-2000 mcgd</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>recurrent acute exacerbations of dyspoea and wheezing<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Dal Negro 1997</P>
</TD>
<TD>
<P>BDP 1000 mcg/d</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Ebden 1986</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not clearly stated but in opinion of investigator patients were poorly controlled <BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Field 1982</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Greefhorst 1992</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Hamalainen 1998</P>
</TD>
<TD>
<P>BDP or BUD 800-1000 mcg/d</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Michleletto 1997</P>
</TD>
<TD>
<P>BDP 1000 mcg/d</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Pedersen 1988</P>
</TD>
<TD>
<P>BDP or BUD 800-1200 mcg/d</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Petrie 1990</P>
</TD>
<TD>
<P>BDP or BUD 800-1600 mcg/d</P>
</TD>
<TD>
<P>mean 72%, range 34-114)</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Selroos 1994</P>
</TD>
<TD>
<P>BDP 1000 mcg/d</P>
</TD>
<TD>
<P>not stated but mean PEFR 75-77% predicted</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Springer 1987</P>
</TD>
<TD>
<P>BDP 400 mcg/d</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Svendsen 1993</P>
</TD>
<TD>
<P>ICS 300-500 mcg/d</P>
</TD>
<TD>
<P>&lt;70</P>
</TD>
<TD>
<P>stated by authors that asthma was 'poorly controlled' </P>
</TD>
</TR>
<TR>
<TD>
<P>Tjwa 1995</P>
</TD>
<TD>
<P>ICS 150-800 mcg/d</P>
</TD>
<TD>
<P>40-85</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Willey 1982</P>
</TD>
<TD>
<P>BDP 400 mcg/d or greater</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>symptom frequency not stated, but at least 2 courses or oral steroids in last 12 months for exacerbations<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>B.L: baseline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-07-21 14:02:48 +0100" MODIFIED_BY="Toby J Lasserson" NO="3">
<TITLE>Trials recruiting OCS-treated asthmatics: baseline asthma control</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>B.L. FEV1 (% pred)</P>
</TH>
<TH>
<P>B.L. symp freq</P>
</TH>
</TR>
<TR>
<TD>
<P>Rafferty 1985</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Stiksa 1985</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Stiksa 1982a</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P>Stiksa 1982b</P>
</TD>
<TD>
<P>not stated</P>
</TD>
<TD>
<P>not stated</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>B.L: baseline</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2014-12-08 13:25:24 +0000" MODIFIED_BY="Emma J Welsh" NO="4">
<TITLE>Outcome data not included in meta-analysis</TITLE>
<TABLE COLS="2" ROWS="12">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Missing data</P>
</TH>
</TR>
<TR>
<TD>
<P>Bisgaard 1988</P>
</TD>
<TD>
<P>Morning PEFR<BR/>Evening PEFR<BR/>Daily beta3 agonist use<BR/>No numerical data presented for above outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Boe 1989</P>
</TD>
<TD>
<P>FEV1<BR/>FVC<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daily asthma symptom score<BR/>No numerical data for above outcomes<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Dal Negro 1997</P>
</TD>
<TD>
<P>FEV1<BR/>Unclear if error bars plotted represent standard deviation values or standard error<BR/>
<BR/>FVC<BR/>FEF25-75<BR/>FEF 50<BR/>Rescue use beta2 agonist<BR/>Daily wheeze score<BR/>Outcomes reported as medians with ranges</P>
</TD>
</TR>
<TR>
<TD>
<P>Ebden 1986</P>
</TD>
<TD>
<P>Rescue use beta2 agonist<BR/>Daily wheeze score<BR/>Outcomes reported as medians with ranges</P>
</TD>
</TR>
<TR>
<TD>
<P>Greefhorst 1992</P>
</TD>
<TD>
<P>Morning PEFR<BR/>Evening PEFR<BR/>No SD values for above outcomes<BR/>Asthma symptom score<BR/>Rescue beta2 agonist use<BR/>No numerical data available</P>
</TD>
</TR>
<TR>
<TD>
<P>Hamalainen 1998</P>
</TD>
<TD>
<P>Morning PEFR<BR/>Morning plasma cortisol<BR/>No standard deviation values available for above outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Keelan 1984</P>
</TD>
<TD>
<P>FEV1<BR/>FVC<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Asthma symptom score<BR/>Beta2 agonist use<BR/>Serum cortisol (time not specified)<BR/>No numerical data presented for above outcomes<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Micheletto 1997</P>
</TD>
<TD>
<P>FEV1<BR/>Serum ECP<BR/>Unclear if error bars plotted represent standard deviation values or standard error for above outcomes<BR/>
<BR/>FVC<BR/>Clinic PEFR<BR/>FEF 25-75<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daily beta2 agonist use<BR/>Morning serum cortisol<BR/>No numerical data available for above outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Nicolaizik 1994</P>
</TD>
<TD>
<P>Serum cortisol<BR/>Serum ACTH<BR/>24 hour urinary free cortisol<BR/>Above outcomes expressed using medians and analyses using non-parametric tests<BR/>Histamine BHR (PC20 FEV1)<BR/>No SD values for log transformed data available</P>
</TD>
</TR>
<TR>
<TD>
<P>Petrie 1990</P>
</TD>
<TD>
<P>FEV1<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Daily beta2 agonist use (puffs/day)<BR/>No numerical data presented for above outcomes<BR/>Questionnaire concerning delivery device: ease of use, carrying convenience, overall preference<BR/>No SD values presented for above outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P>Svendsen 1993</P>
</TD>
<TD>
<P>FEV1<BR/>FVC<BR/>Morning PEFR<BR/>Evening PEFR<BR/>Clinic PEFR<BR/>Histamine BHR (PC20 FEV1)<BR/>Sleep disturbance, wheeze and activity restriction score<BR/>Rescue beta2 agonist use (puffs/day)<BR/>Plasma cortisol (time not stated)<BR/>Plasma cortisol 30 min post 250 mcg iv tetracosactrin<BR/>No SD values available for any of the above outcomes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-12-08 11:44:12 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-12-08 11:39:32 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>BDP v BUD crossover design studies, no OCS: all doses</NAME>
<CONT_OUTCOME CHI2="6.615157052096611E-4" CI_END="1.8945713293020514" CI_START="-11.977410944268055" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.041419807483002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.9794807138235786" P_Q="1.0" P_Z="0.15427334876128318" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.4245983102846849">
<NAME>FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.615157052096611E-4" CI_END="1.8945713293020514" CI_START="-11.977410944268055" DF="1" EFFECT_SIZE="-5.041419807483002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.9794807138235786" P_Z="0.15427334876128318" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="1.4245983102846849">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="7.91587108032922" CI_START="-17.71587108032923" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" MEAN_1="78.5" MEAN_2="83.4" ORDER="66" SD_1="25.1" SD_2="22.9" SE="6.538829887395473" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="29.290096258497798"/>
<CONT_DATA CI_END="3.1483751749924487" CI_START="-13.348375174992437" EFFECT_SIZE="-5.099999999999994" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="90.0" ORDER="67" SD_1="9.49" SD_2="9.33" SE="4.208432012044391" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="70.7099037415022"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.40662309131113" CI_END="-0.03119202272262589" CI_START="-0.42894843556055373" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2300702291415898" ESTIMABLE="YES" I2="69.52450256111523" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2014-12-08 11:39:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0057741357789269365" P_Q="0.5019006210002097" P_Z="0.023367975010972052" Q="0.4509153413816262" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="114" UNITS="" WEIGHT="100.00000000000001" Z="2.267364389250624">
<NAME>FEV1 (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.955707749929498" CI_END="-0.040067306191339525" CI_START="-0.49740668926431103" DF="4" EFFECT_SIZE="-0.2687369977278253" ESTIMABLE="YES" I2="74.93060124507686" ID="CMP-001.02.01" MODIFIED="2014-12-08 11:39:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.003079184252953504" P_Z="0.02125706818319376" STUDIES="5" TAU2="0.0" TOTAL_1="87" TOTAL_2="87" WEIGHT="75.64098531551255" Z="2.3033871840244253">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.29715638268182376" CI_START="-0.4771563826818235" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.63" ORDER="68" SD_1="0.65" SD_2="0.63" SE="0.19753239637853742" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="26.38770026582124"/>
<CONT_DATA CI_END="0.7107191406452886" CI_START="-0.6107191406452881" EFFECT_SIZE="0.050000000000000266" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.05" ORDER="69" SD_1="0.86" SD_2="0.79" SE="0.33710779680491915" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.060259000330582"/>
<CONT_DATA CI_END="0.4241023511374425" CI_START="-0.4641023511374425" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="1.83" ORDER="70" SD_1="0.56" SD_2="0.55" SE="0.22658699580220104" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="20.054334034654786"/>
<CONT_DATA CI_END="0.5681527667074239" CI_START="-0.9281527667074242" EFFECT_SIZE="-0.18000000000000016" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.74" ORDER="71" SD_1="0.93" SD_2="0.94" SE="0.3817176094095389" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="7.066328395053369"/>
<CONT_DATA CI_END="-0.7299399109364457" CI_START="-1.8300600890635539" EFFECT_SIZE="-1.2799999999999998" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.28" MODIFIED="2014-12-08 11:39:08 +0000" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="1.02" SD_2="1.15" SE="0.2806480595573989" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.072363619652563"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.556401599320045E-33" CI_END="0.2929557302198247" CI_START="-0.5129557302198249" DF="0" EFFECT_SIZE="-0.11000000000000008" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-001.02.03" NO="3" P_CHI2="0.0" P_Z="0.5926245950401037" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="24.359014684487462" Z="0.5350365365986776">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="0.2929557302198247" CI_START="-0.5129557302198249" EFFECT_SIZE="-0.1100000000000001" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="1.87" ORDER="73" SD_1="0.66" SD_2="0.83" SE="0.20559343610305503" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="24.359014684487462"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0487921451998725" CI_END="0.07485427868731259" CI_START="-0.3782610800428994" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1517034006777934" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2014-12-08 11:39:32 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9940025886222579" P_Q="0.976069281448043" P_Z="0.18938683939436196" Q="8.998324657419955E-4" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="151" UNITS="" WEIGHT="99.99999999999999" Z="1.3123951591221985">
<NAME>FEV1 (% predicted, litre measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0478923127341306" CI_END="0.09634782380831922" CI_START="-0.4029650167807398" DF="6" EFFECT_SIZE="-0.1533085964862103" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2014-12-08 11:39:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9837314455155409" P_Z="0.2287553006438643" STUDIES="7" TAU2="0.0" TOTAL_1="124" TOTAL_2="124" WEIGHT="82.35161052180071" Z="1.2035714013637975">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.4676965784296662" CI_START="-0.7436062963260321" EFFECT_SIZE="-0.137954858948183" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.63" ORDER="74" SD_1="0.65" SD_2="0.63" SE="0.309011513555938" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.993039838225465"/>
<CONT_DATA CI_END="0.8588200331972844" CI_START="-0.7418928167571992" EFFECT_SIZE="0.05846360822004261" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.05" ORDER="75" SD_1="0.86" SD_2="0.79" SE="0.40835261835949593" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.012918098964533"/>
<CONT_DATA CI_END="0.3338888548529608" CI_START="-0.7358823026018328" EFFECT_SIZE="-0.200996723874436" ESTIMABLE="YES" MEAN_1="78.5" MEAN_2="83.4" ORDER="76" SD_1="25.1" SD_2="22.9" SE="0.2729058201816493" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="17.940551833258553"/>
<CONT_DATA CI_END="0.7654323660710078" CI_START="-0.8350163705388689" EFFECT_SIZE="-0.03479200223393048" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="1.83" ORDER="77" SD_1="0.56" SD_2="0.55" SE="0.40828524126821003" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.015562973708764"/>
<CONT_DATA CI_END="0.3756568638206944" CI_START="-1.4137717485850576" EFFECT_SIZE="-0.5190574423821815" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="90.0" ORDER="78" SD_1="9.49" SD_2="9.33" SE="0.45649527912771265" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.41193058134872"/>
<CONT_DATA CI_END="0.6163440671201013" CI_START="-0.9880887057125851" EFFECT_SIZE="-0.18587231929624193" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.74" ORDER="79" SD_1="0.93" SD_2="0.94" SE="0.4093015957150864" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="7.97580481735214"/>
<CONT_DATA CI_END="0.38319892299515645" CI_START="-0.6299521697484034" EFFECT_SIZE="-0.12337662337662349" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.1" MODIFIED="2014-12-08 11:39:32 +0000" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="0.8" SD_2="0.8" SE="0.25846166070784116" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.001802378942536"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3950816459266676" CI_START="-0.6835079913954133" DF="0" EFFECT_SIZE="-0.14421317273437287" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" NO="3" P_CHI2="1.0" P_Z="0.6001984025668765" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="17.648389478199277" Z="0.5241152239463261">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="0.3950816459266676" CI_START="-0.6835079913954133" EFFECT_SIZE="-0.14421317273437287" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="1.87" ORDER="81" SD_1="0.66" SD_2="0.83" SE="0.2751554737306038" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="17.648389478199277"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.98860104313428" CI_START="-8.78860104313429" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9003209033914635" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.1252559764038534">
<NAME>FVC (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.98860104313428" CI_START="-8.78860104313429" DF="0" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.9003209033914635" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.1252559764038534">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="9.98860104313428" CI_START="-8.78860104313429" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" MEAN_1="100.3" MEAN_2="99.7" ORDER="82" SD_1="17.7" SD_2="17.5" SE="4.790190593903955" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.073465239932124" CI_END="0.17368491571443306" CI_START="-0.2912541015156629" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.058784592900614926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.9993416534254264" P_Q="0.9164251460534716" P_Z="0.6201651302934728" Q="0.011011947022264035" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="102" UNITS="" WEIGHT="100.0" Z="0.49561633100813546">
<NAME>FVC (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.062453292909859966" CI_END="0.21804074351021557" CI_START="-0.32100570306244586" DF="3" EFFECT_SIZE="-0.05148247977611513" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="0.9959259244093677" P_Z="0.7081224442067175" STUDIES="4" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="74.39429141393617" Z="0.3743788938320955">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.3848277358572072" CI_START="-0.5048277358572073" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.13" ORDER="83" SD_1="0.71" SD_2="0.76" SE="0.22695709684767254" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="27.311671376723602"/>
<CONT_DATA CI_END="0.7765185034637754" CI_START="-0.7765185034637754" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.32" ORDER="84" SD_1="0.94" SD_2="1.0" SE="0.39619019001821165" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.96248367205713"/>
<CONT_DATA CI_END="0.4964855302332951" CI_START="-0.5364855302332951" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.3" ORDER="85" SD_1="0.67" SD_2="0.62" SE="0.26351786783189235" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="20.25889144928214"/>
<CONT_DATA CI_END="0.45006008906355444" CI_START="-0.6500600890635537" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="3.18" MEAN_2="3.28" ORDER="86" SD_1="1.02" SD_2="1.15" SE="0.2806480595573989" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="17.861244915873304"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.379406989497779" CI_START="-0.5394069894977791" DF="0" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.03" NO="3" P_CHI2="1.0" P_Z="0.7328752690526982" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="25.605708586063827" Z="0.3413032939150841">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="0.379406989497779" CI_START="-0.5394069894977791" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.9" ORDER="87" SD_1="0.76" SD_2="0.94" SE="0.23439562824701005" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="25.605708586063827"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1694630571026059" CI_END="0.19564306325318126" CI_START="-0.29357839328069596" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.04896766501375734" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.9994079985480161" P_Q="0.8604842746082199" P_Z="0.6947940664084812" Q="0.03089079910255791" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="0.39235752460231865">
<NAME>FVC (% predicted, litre measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.13857225800004797" CI_END="0.23673469085229804" CI_START="-0.31231930271421315" DF="4" EFFECT_SIZE="-0.03779230593095756" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.9977077590097393" P_Z="0.7873024232330711" STUDIES="5" TAU2="0.0" TOTAL_1="102" TOTAL_2="102" WEIGHT="79.39275691634647" Z="0.26981520719391117">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.5250791314948589" CI_START="-0.6851713795223211" EFFECT_SIZE="-0.0800461240137311" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.13" ORDER="88" SD_1="0.71" SD_2="0.76" SE="0.30874304848545214" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.34031570891284"/>
<CONT_DATA CI_END="0.8001519460592184" CI_START="-0.8001519460592184" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.32" ORDER="89" SD_1="0.94" SD_2="1.0" SE="0.408248290463863" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.345575914173732"/>
<CONT_DATA CI_END="0.5670715174207005" CI_START="-0.4998789261137759" EFFECT_SIZE="0.0335962956534623" ESTIMABLE="YES" MEAN_1="100.3" MEAN_2="99.7" ORDER="90" SD_1="17.7" SD_2="17.5" SE="0.27218623708150896" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.024346040941364"/>
<CONT_DATA CI_END="0.7702894361495003" CI_START="-0.8301215479451141" EFFECT_SIZE="-0.029916055897806874" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.3" ORDER="91" SD_1="0.67" SD_2="0.62" SE="0.4082756103475502" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.344325232045847"/>
<CONT_DATA CI_END="0.4155334451486638" CI_START="-0.5971457162719279" EFFECT_SIZE="-0.09080613556163204" ESTIMABLE="YES" MEAN_1="3.18" MEAN_2="3.28" ORDER="92" SD_1="1.02" SD_2="1.15" SE="0.25834126785197986" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.338194020272685"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4468245504170491" CI_START="-0.6308696587891889" DF="0" EFFECT_SIZE="-0.09202255418606992" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.03" NO="3" P_CHI2="1.0" P_Z="0.737839128985398" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="20.607243083653533" Z="0.3347162681757846">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="0.4468245504170491" CI_START="-0.6308696587891889" EFFECT_SIZE="-0.09202255418606992" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.9" ORDER="93" SD_1="0.76" SD_2="0.94" SE="0.27492704399339796" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="20.607243083653533"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.54956536803498" CI_START="-14.54956536803498" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7547702325074095" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.3123556756048751">
<NAME>Clinic PEFR (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.54956536803498" CI_START="-14.54956536803498" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.7547702325074095" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.3123556756048751">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="10.54956536803498" CI_START="-14.54956536803498" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="101.0" MEAN_2="103.0" ORDER="94" SD_1="15.81" SD_2="12.65" SE="6.402957129327043" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.055663346708613" CI_START="-16.855663346708596" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6838006154706033" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.40728236372272963">
<NAME>Morning PEFR (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.055663346708613" CI_START="-16.855663346708596" DF="0" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="1.0" P_Z="0.6838006154706033" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.40728236372272963">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="11.055663346708613" CI_START="-16.855663346708596" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="90.3" ORDER="95" SD_1="30.8" SD_2="20.5" SE="7.120367239800882" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8715719751887616" CI_END="22.451465363550135" CI_START="-28.433338739199712" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.9909366878247905" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="0.9722454805748484" P_Q="0.9967908561408694" P_Z="0.8177748915452845" Q="1.6177097052114955E-5" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.23040781198013163">
<NAME>Morning PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8715557980917094" CI_END="26.316745497712724" CI_START="-32.35857195280215" DF="4" EFFECT_SIZE="-3.0209132275447157" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="0.9286056832483957" P_Z="0.8400586490201732" STUDIES="5" TAU2="0.0" TOTAL_1="84" TOTAL_2="84" WEIGHT="75.20822135953004" Z="0.20181846076595333">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="36.018603001961736" CI_START="-61.018603001961736" EFFECT_SIZE="-12.5" ESTIMABLE="YES" MEAN_1="262.5" MEAN_2="275.0" ORDER="96" SD_1="78.41" SD_2="81.98" SE="24.754844162785787" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="27.49790752099504"/>
<CONT_DATA CI_END="112.03206228931981" CI_START="-96.03206228931981" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="342.0" MEAN_2="334.0" ORDER="97" SD_1="132.0" SD_2="128.0" SE="53.078558131634786" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.981110235188557"/>
<CONT_DATA CI_END="74.83058027590448" CI_START="-38.830580275904474" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="409.0" MEAN_2="391.0" ORDER="98" SD_1="95.9" SD_2="100.7" SE="28.995726821603274" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="20.042506887030324"/>
<CONT_DATA CI_END="66.9187027127066" CI_START="-86.9187027127066" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="245.0" MEAN_2="255.0" ORDER="99" SD_1="101.0" SD_2="91.0" SE="39.24495721320979" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.940881659520327"/>
<CONT_DATA CI_END="60.61370763725296" CI_START="-94.61370763725296" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="420.0" ORDER="100" SD_1="111.0" SD_2="113.0" SE="39.59955807834224" STUDY_ID="STD-Willey-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.745815056795786"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="48.198043120481216" CI_START="-53.998043120481285" DF="0" EFFECT_SIZE="-2.900000000000034" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.03" NO="3" P_CHI2="1.0" P_Z="0.9114299244862291" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="24.79177864046996" Z="0.11123509254091161">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="48.198043120481216" CI_START="-53.998043120481285" EFFECT_SIZE="-2.900000000000034" ESTIMABLE="YES" MEAN_1="311.2" MEAN_2="314.1" ORDER="101" SD_1="94.0" SD_2="94.0" SE="26.07090922258577" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="24.79177864046996"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9268989002760778" CI_END="0.19561703520801632" CI_START="-0.27850742819265384" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.041445196492318745" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.9882322147338779" P_Q="0.9646599379208619" P_Z="0.7318563276388479" Q="0.001963083914842724" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="0.3426572502692579">
<NAME>Morning PEFR (% predicted, L/min measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9249358163612352" CI_END="0.21938637046936313" CI_START="-0.3074704143916108" DF="5" EFFECT_SIZE="-0.04404202196112386" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" NO="1" P_CHI2="0.9683902034840486" P_Z="0.7431520164476084" STUDIES="6" TAU2="0.0" TOTAL_1="111" TOTAL_2="111" WEIGHT="80.9840652665675" Z="0.32768213044045">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.4529411466428519" CI_START="-0.7587236533009469" EFFECT_SIZE="-0.15289125332904752" ESTIMABLE="YES" MEAN_1="262.5" MEAN_2="275.0" ORDER="102" SD_1="78.41" SD_2="81.98" SE="0.3091038431066224" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="15.311570755696097"/>
<CONT_DATA CI_END="0.8597725089526191" CI_START="-0.740953678274078" EFFECT_SIZE="0.059409415339270556" ESTIMABLE="YES" MEAN_1="342.0" MEAN_2="334.0" ORDER="103" SD_1="132.0" SD_2="128.0" SE="0.4083560207873769" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.773050486718477"/>
<CONT_DATA CI_END="0.42462191669935034" CI_START="-0.6431053631410939" EFFECT_SIZE="-0.10924172322087175" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="90.3" ORDER="104" SD_1="30.8" SD_2="20.5" SE="0.2723844132500752" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="19.71805395647969"/>
<CONT_DATA CI_END="0.759159534083772" CI_START="-0.39931908562118923" EFFECT_SIZE="0.17992022423129142" ESTIMABLE="YES" MEAN_1="409.0" MEAN_2="391.0" ORDER="105" SD_1="95.9" SD_2="100.7" SE="0.2955356906664849" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="16.74976361060688"/>
<CONT_DATA CI_END="0.7003167208979918" CI_START="-0.901193873631292" EFFECT_SIZE="-0.10043857636665006" ESTIMABLE="YES" MEAN_1="245.0" MEAN_2="255.0" ORDER="106" SD_1="101.0" SD_2="91.0" SE="0.4085561283681218" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.764458648982954"/>
<CONT_DATA CI_END="0.5460789553008351" CI_START="-0.8419855281374223" EFFECT_SIZE="-0.1479532864182936" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="420.0" ORDER="107" SD_1="111.0" SD_2="113.0" SE="0.35410458926468363" STUDY_ID="STD-Willey-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="11.667167808083406"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5132441707512481" CI_START="-0.5740161155817844" DF="0" EFFECT_SIZE="-0.03038597241526819" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.03" NO="3" P_CHI2="1.0" P_Z="0.9127652020064755" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="19.0159347334325" Z="0.10955134169392651">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="0.5132441707512481" CI_START="-0.5740161155817844" EFFECT_SIZE="-0.03038597241526819" ESTIMABLE="YES" MEAN_1="311.2" MEAN_2="314.1" ORDER="108" SD_1="94.0" SD_2="94.0" SE="0.2773674146334328" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="19.0159347334325"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.26166546325175266" CI_END="20.55803558738905" CI_START="-31.5023410849251" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.472152748768025" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.9921525201320759" P_Q="0.8549814172151198" P_Z="0.6803173284578172" Q="0.03340353241620717" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="106" UNITS="" WEIGHT="99.99999999999999" Z="0.4120301461895066">
<NAME>Evening PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.22826193083554547" CI_END="24.349522987194504" CI_START="-38.592589160052306" DF="3" EFFECT_SIZE="-7.121533086428903" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="0.9729028612315136" P_Z="0.6573918273033226" STUDIES="4" TAU2="0.0" TOTAL_1="79" TOTAL_2="79" WEIGHT="68.41195276636827" Z="0.4435169996029936">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="36.010965933859396" CI_START="-58.010965933859396" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="269.1" MEAN_2="280.1" ORDER="109" SD_1="77.12" SD_2="78.32" SE="23.985627442481544" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="30.65887899063473"/>
<CONT_DATA CI_END="70.04045642256422" CI_START="-86.04045642256422" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="252.0" MEAN_2="260.0" ORDER="110" SD_1="100.0" SD_2="95.0" SE="39.8172910513343" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.125384241622541"/>
<CONT_DATA CI_END="59.066998866183255" CI_START="-85.06699886618325" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="437.0" MEAN_2="450.0" ORDER="111" SD_1="104.0" SD_2="104.0" SE="36.76955262170047" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="13.046131360753751"/>
<CONT_DATA CI_END="78.63216385213936" CI_START="-62.63216385213936" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="360.0" MEAN_2="352.0" ORDER="112" SD_1="135.0" SD_2="144.0" SE="36.0374804890686" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.581558173357259"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="44.41438707827466" CI_START="-48.21438707827461" DF="0" EFFECT_SIZE="-1.8999999999999773" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.03" NO="3" P_CHI2="1.0" P_Z="0.9359147506371743" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="31.58804723363171" Z="0.08040550259970725">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="44.41438707827466" CI_START="-48.21438707827461" EFFECT_SIZE="-1.8999999999999773" ESTIMABLE="YES" MEAN_1="334.0" MEAN_2="335.9" ORDER="113" SD_1="86.0" SD_2="86.0" SE="23.63022353655302" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="31.58804723363171"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00226675544217059" CI_END="0.7173320664566347" CI_START="-0.198318764087475" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.25950665118457983" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" NO="12" P_CHI2="0.9620267124559633" P_Q="1.0" P_Z="0.26658749674469784" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.110955558830508">
<NAME>Daytime breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.00226675544217059" CI_END="0.7173320664566347" CI_START="-0.198318764087475" DF="1" EFFECT_SIZE="0.25950665118457983" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="0.9620267124559633" P_Z="0.26658749674469784" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="1.110955558830508">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.8770945569247939" CI_START="-0.3386537160245399" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.05" ORDER="114" SD_1="0.16" SD_2="0.13" SE="0.31014556454582864" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.72473357270164"/>
<CONT_DATA CI_END="0.9427271302557353" CI_START="-0.44917922736600147" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.6" ORDER="115" SD_1="0.57" SD_2="0.45" SE="0.35508467721879494" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.27526642729837"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.17405040162197355" CI_START="-0.8456770201530461" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.19673908505295346" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.290897896114194">
<NAME>Morning breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17405040162197355" CI_START="-0.8456770201530461" DF="0" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="1.0" P_Z="0.19673908505295346" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.290897896114194">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.17405040162197355" CI_START="-0.8456770201530461" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.45" ORDER="116" SD_1="5.57" SD_2="8.92" SE="0.26013932649234867" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9911969708362657" CI_START="-0.40321836928808474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.40854793264034206" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.8264516672714545">
<NAME>Daytime wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9911969708362657" CI_START="-0.40321836928808474" DF="0" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" NO="1" P_CHI2="1.0" P_Z="0.40854793264034206" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.8264516672714545">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.9911969708362657" CI_START="-0.40321836928808474" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.39" ORDER="117" SD_1="0.4" SD_2="0.46" SE="0.35572473553680595" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3579832708223656" CI_START="-0.6556362545280283" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.5649191146091266" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.5755504046277298">
<NAME>Morning wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3579832708223656" CI_START="-0.6556362545280283" DF="0" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.01" NO="1" P_CHI2="1.0" P_Z="0.5649191146091266" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5755504046277298">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.3579832708223656" CI_START="-0.6556362545280283" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" MEAN_1="5.24" MEAN_2="6.33" ORDER="118" SD_1="6.39" SD_2="7.98" SE="0.25858116101767564" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0891445159283726" CI_START="-0.3116095894195764" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.2766203423573744" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.0879428779547926">
<NAME>Daytime cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0891445159283726" CI_START="-0.3116095894195764" DF="0" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.01" NO="1" P_CHI2="1.0" P_Z="0.2766203423573744" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.0879428779547926">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="1.0891445159283726" CI_START="-0.3116095894195764" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.17" ORDER="119" SD_1="0.35" SD_2="0.3" SE="0.357341797195489" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.16.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.16.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3990686503627424" CI_START="-0.6138327802336648" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.677725759009032" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.4155685311553392">
<NAME>Morning cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3990686503627424" CI_START="-0.6138327802336648" DF="0" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" NO="1" P_CHI2="1.0" P_Z="0.677725759009032" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.4155685311553392">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.3990686503627424" CI_START="-0.6138327802336648" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.26" ORDER="120" SD_1="6.19" SD_2="6.31" SE="0.2583979702142602" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5308269961716794" CI_END="0.38871459506829464" CI_START="-0.224316425068525" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0821990849998848" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="0.9704314250068655" P_Q="1.0" P_Z="0.5991600507701369" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="82" UNITS="" WEIGHT="100.00000000000001" Z="0.5256087893430386">
<NAME>Daily asthma symptom score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5308269961716794" CI_END="0.38871459506829464" CI_START="-0.224316425068525" DF="4" EFFECT_SIZE="0.0821990849998848" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.01" NO="1" P_CHI2="0.9704314250068655" P_Z="0.5991600507701369" STUDIES="5" TAU2="0.0" TOTAL_1="82" TOTAL_2="82" WEIGHT="100.00000000000001" Z="0.5256087893430386">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.5208850012881223" CI_START="-0.6894233789352231" EFFECT_SIZE="-0.0842691888235504" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.16" ORDER="121" SD_1="0.26" SD_2="0.42" SE="0.30875781130931573" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="25.655047382611066"/>
<CONT_DATA CI_END="0.8211232032108191" CI_START="-0.7792331837699751" EFFECT_SIZE="0.020945009720421993" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.4" ORDER="122" SD_1="5.5" SD_2="3.5" SE="0.4082616822564601" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.673424673924533"/>
<CONT_DATA CI_END="0.7324361272958737" CI_START="-0.33723788094754537" EFFECT_SIZE="0.19759912317416417" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="13.6" ORDER="123" SD_1="19.3" SD_2="16.5" SE="0.2728810367641628" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="32.84445165380738"/>
<CONT_DATA CI_END="0.9626193421086242" CI_START="-0.6407802616488538" EFFECT_SIZE="0.16091954022988514" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" ORDER="124" SD_1="0.6" SD_2="0.6" SE="0.40903802733236155" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.617777865113872"/>
<CONT_DATA CI_END="0.9781387758422925" CI_START="-0.7762954715486697" EFFECT_SIZE="0.10092165214681133" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="125" SD_1="9.49" SD_2="9.49" SE="0.4475679811541731" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.209298424543144"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3786632505093883" CI_END="0.3095516630986409" CI_START="-0.18235646960046192" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06359759674908949" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" NO="19" P_CHI2="0.7600367645332655" P_Q="1.0" P_Z="0.6122966467186455" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="128" UNITS="" WEIGHT="99.99999999999999" Z="0.5067978788948548">
<NAME>Symptoms (daytime breathlessness, morning breathlessness, daily symptom scores combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.3786632505093883" CI_END="0.3095516630986409" CI_START="-0.18235646960046192" DF="6" EFFECT_SIZE="0.06359759674908949" ESTIMABLE="YES" I2="0.0" ID="CMP-001.19.01" NO="1" P_CHI2="0.7600367645332655" P_Z="0.6122966467186455" STUDIES="7" TAU2="0.0" TOTAL_1="128" TOTAL_2="128" WEIGHT="99.99999999999999" Z="0.5067978788948548">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.8770945569247939" CI_START="-0.3386537160245399" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.05" ORDER="126" SD_1="0.16" SD_2="0.13" SE="0.31014556454582864" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.37120636562371"/>
<CONT_DATA CI_END="0.8211232032108191" CI_START="-0.7792331837699751" EFFECT_SIZE="0.020945009720421993" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.4" ORDER="127" SD_1="5.5" SD_2="3.5" SE="0.4082616822564601" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.447884832608928"/>
<CONT_DATA CI_END="0.7324361272958737" CI_START="-0.33723788094754537" EFFECT_SIZE="0.19759912317416417" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="13.6" ORDER="128" SD_1="19.3" SD_2="16.5" SE="0.2728810367641628" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.14779634005977"/>
<CONT_DATA CI_END="0.9626193421086242" CI_START="-0.6407802616488538" EFFECT_SIZE="0.16091954022988514" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" ORDER="129" SD_1="0.6" SD_2="0.6" SE="0.40903802733236155" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.412055116463685"/>
<CONT_DATA CI_END="0.9781387758422925" CI_START="-0.7762954715486697" EFFECT_SIZE="0.10092165214681133" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="130" SD_1="9.49" SD_2="9.49" SE="0.4475679811541731" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.861289914618505"/>
<CONT_DATA CI_END="0.9427271302557353" CI_START="-0.44917922736600147" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.6" ORDER="131" SD_1="0.57" SD_2="0.45" SE="0.35508467721879494" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="12.489583865574897"/>
<CONT_DATA CI_END="0.17405040162197355" CI_START="-0.8456770201530461" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.45" ORDER="132" SD_1="5.57" SD_2="8.92" SE="0.26013932649234867" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.270183565050502"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.19.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.19.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03344131276092331" CI_END="0.5736764323858248" CI_START="-0.3386737894998658" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1175013214429795" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.20" NO="20" P_CHI2="0.8549003400847557" P_Q="1.0" P_Z="0.613666731871884" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="0.5048463904313232">
<NAME>Night-time breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.03344131276092331" CI_END="0.5736764323858248" CI_START="-0.3386737894998658" DF="1" EFFECT_SIZE="0.1175013214429795" ESTIMABLE="YES" I2="0.0" ID="CMP-001.20.01" NO="1" P_CHI2="0.8549003400847557" P_Z="0.613666731871884" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="0.5048463904313232">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.760557061729863" CI_START="-0.4511541195732166" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.08" ORDER="133" SD_1="0.18" SD_2="0.2" SE="0.30911567530345013" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.692411806516056"/>
<CONT_DATA CI_END="0.7619896261535924" CI_START="-0.6243817489594453" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.58" ORDER="134" SD_1="0.42" SD_2="0.43" SE="0.35367266593890456" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.307588193483944"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.20.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.16332643328615065" CI_START="-0.8569043141133812" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.21" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.18271841051851442" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.332431580169419">
<NAME>Evening breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16332643328615065" CI_START="-0.8569043141133812" DF="0" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" I2="0.0" ID="CMP-001.21.01" NO="1" P_CHI2="1.0" P_Z="0.18271841051851442" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.332431580169419">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.16332643328615065" CI_START="-0.8569043141133812" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="6.52" ORDER="135" SD_1="4.63" SD_2="9.07" SE="0.2602677282457692" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.21.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8546760593433423" CI_START="-0.5337686038575246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.22" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.6505479013544908" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.45300116871247653">
<NAME>Night-time wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8546760593433423" CI_START="-0.5337686038575246" DF="0" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" I2="0.0" ID="CMP-001.22.01" NO="1" P_CHI2="1.0" P_Z="0.6505479013544908" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.45300116871247653">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.8546760593433423" CI_START="-0.5337686038575246" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="0.39" ORDER="136" SD_1="0.41" SD_2="0.44" SE="0.35420157568015054" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.22.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.22.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.28187277833707003" CI_START="-0.7336977352773082" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.23" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.383217435467999" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.8719834133107602">
<NAME>Evening wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.28187277833707003" CI_START="-0.7336977352773082" DF="0" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" I2="0.0" ID="CMP-001.23.01" NO="1" P_CHI2="1.0" P_Z="0.383217435467999" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.8719834133107602">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.28187277833707003" CI_START="-0.7336977352773082" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" MEAN_1="4.46" MEAN_2="5.99" ORDER="137" SD_1="4.94" SD_2="8.06" SE="0.2590788712509691" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.23.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1308638814016656" CI_START="-0.27309251807994506" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.24" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.2311219624267815" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.1974737817364924">
<NAME>Night-time cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1308638814016656" CI_START="-0.27309251807994506" DF="0" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" I2="0.0" ID="CMP-001.24.01" NO="1" P_CHI2="1.0" P_Z="0.2311219624267815" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.1974737817364924">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="1.1308638814016656" CI_START="-0.27309251807994506" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.11" ORDER="138" SD_1="0.36" SD_2="0.27" SE="0.35815872397550147" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.24.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3188557117127877" CI_START="-0.6956657222978688" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.25" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.4666362517433257" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7279629833361982">
<NAME>Evening cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3188557117127877" CI_START="-0.6956657222978688" DF="0" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" I2="0.0" ID="CMP-001.25.01" NO="1" P_CHI2="1.0" P_Z="0.4666362517433257" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7279629833361982">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.3188557117127877" CI_START="-0.6956657222978688" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.1" ORDER="139" SD_1="4.36" SD_2="5.99" SE="0.2588112439853671" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.25.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.25.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8016711824146951" CI_END="0.25123460905651" CI_START="-0.4288480322372657" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08880671159037785" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.26" NO="26" P_CHI2="0.40623011848790624" P_Q="1.0" P_Z="0.6087399277991502" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="0.5118729570025549">
<NAME>Symptoms (night-time breathlessness, evening breathlessness scores combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.8016711824146951" CI_END="0.25123460905651" CI_START="-0.4288480322372657" DF="2" EFFECT_SIZE="-0.08880671159037785" ESTIMABLE="YES" I2="0.0" ID="CMP-001.26.01" NO="1" P_CHI2="0.40623011848790624" P_Z="0.6087399277991502" STUDIES="3" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="0.5118729570025549">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.760557061729863" CI_START="-0.4511541195732166" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.08" ORDER="140" SD_1="0.18" SD_2="0.2" SE="0.30911567530345013" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="31.50105861950481"/>
<CONT_DATA CI_END="0.7619896261535924" CI_START="-0.6243817489594453" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.58" ORDER="141" SD_1="0.42" SD_2="0.43" SE="0.35367266593890456" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.063800266749475"/>
<CONT_DATA CI_END="0.16332643328615065" CI_START="-0.8569043141133812" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="6.52" ORDER="142" SD_1="4.63" SD_2="9.07" SE="0.2602677282457692" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="44.435141113745715"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.26.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.26.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1790448498493285E-32" CI_END="1.0902109514859657" CI_START="-0.1302109514859658" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4799999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.27" NO="27" P_CHI2="0.0" P_Q="1.0" P_Z="0.12313834915680578" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.5417335763775835">
<NAME>Daytime use of rescue beta2 agonist (puffs/day)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.1790448498493285E-32" CI_END="1.0902109514859657" CI_START="-0.1302109514859658" DF="0" EFFECT_SIZE="0.4799999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-001.27.01" NO="1" P_CHI2="0.0" P_Z="0.12313834915680578" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.5417335763775835">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="1.0902109514859657" CI_START="-0.13021095148596573" EFFECT_SIZE="0.48" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.41" ORDER="143" SD_1="0.7" SD_2="1.03" SE="0.3113378390109368" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.27.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.27.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.522391440304596E-33" CI_END="0.44157934397716114" CI_START="-0.6415793439771609" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999988" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.28" NO="28" P_CHI2="0.0" P_Q="1.0" P_Z="0.7174283697728059" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.36189784679504056">
<NAME>Morning use of rescue beta2 agonist (puffs)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.522391440304596E-33" CI_END="0.44157934397716114" CI_START="-0.6415793439771609" DF="0" EFFECT_SIZE="-0.09999999999999988" ESTIMABLE="YES" I2="100.0" ID="CMP-001.28.01" NO="1" P_CHI2="0.0" P_Z="0.7174283697728059" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.36189784679504056">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.44157934397716114" CI_START="-0.6415793439771609" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.44" ORDER="144" SD_1="1.09" SD_2="1.05" SE="0.27632106928957356" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.28.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.28.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.41510445046283745" CI_START="-0.5151044504628375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.29" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.8331202144951171" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.21070148679394954">
<NAME>Night-time use of rescue beta2 agonist (puffs/night)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.41510445046283745" CI_START="-0.5151044504628375" DF="0" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.29.01" NO="1" P_CHI2="1.0" P_Z="0.8331202144951171" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.21070148679394954">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.41510445046283745" CI_START="-0.5151044504628375" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="0.42" ORDER="145" SD_1="0.71" SD_2="0.63" SE="0.23730254950168572" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.29.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.29.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.651141403435223" CI_START="-3.651141403435222" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.30" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.45973054673146974" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7392906247853945">
<NAME>Evening use of rescue beta2 agonist (puffs)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.651141403435223" CI_START="-3.651141403435222" DF="0" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-001.30.01" NO="1" P_CHI2="1.0" P_Z="0.45973054673146974" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7392906247853945">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="1.651141403435223" CI_START="-3.651141403435222" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.1" ORDER="146" SD_1="4.36" SD_2="5.99" SE="1.3526480202427633" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.30.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.30.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8074648429450684" CI_START="0.052535157054931614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.43" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.31" NO="31" P_CHI2="1.0" P_Q="1.0" P_Z="0.025565455250602106" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="2.2327496960422137">
<NAME>Histamine BHR (log 10 PC20 FEV1)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8074648429450684" CI_START="0.052535157054931614" DF="0" EFFECT_SIZE="0.43" ESTIMABLE="YES" I2="0.0" ID="CMP-001.31.01" NO="1" P_CHI2="1.0" P_Z="0.025565455250602106" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.2327496960422137">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="0.8074648429450684" CI_START="0.052535157054931614" EFFECT_SIZE="0.43" ESTIMABLE="YES" MEAN_1="0.63" MEAN_2="0.2" ORDER="147" SD_1="0.3" SD_2="0.53" SE="0.1925876423865249" STUDY_ID="STD-Tjwa-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.31.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.31.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1000 mcg/d or greater</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.15431352904180887" CI_END="64.41195001164964" CI_START="-15.777178294337286" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="24.317385858656177" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.32" NO="32" P_CHI2="0.9257447396728291" P_Q="0.9279760770985113" P_Z="0.23454998542644578" Q="0.00817063108372957" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="1.1887197551085322">
<NAME>Morning plasma cortisol (nmol/L)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1461428979580793" CI_END="81.85919810915303" CI_START="-37.28863390769263" DF="1" EFFECT_SIZE="22.2852821007302" ESTIMABLE="YES" I2="0.0" ID="CMP-001.32.01" NO="1" P_CHI2="0.7022490738072722" P_Z="0.46344920459464856" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="45.295879444158516" Z="0.7331791030250701">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="82.67823652570421" CI_START="-49.078236525704185" EFFECT_SIZE="16.80000000000001" ESTIMABLE="YES" MEAN_1="379.2" MEAN_2="362.4" ORDER="148" SD_1="106.32" SD_2="111.45" SE="33.61196279387954" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="37.041371910873615"/>
<CONT_DATA CI_END="186.4532364039645" CI_START="-92.65323640396454" EFFECT_SIZE="46.89999999999998" ESTIMABLE="YES" MEAN_1="411.09" MEAN_2="364.19" ORDER="149" SD_1="200.71" SD_2="143.36" SE="71.2019391706902" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.254507533284904"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.32.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="80.20950935965377" CI_START="-28.209509359653758" DF="0" EFFECT_SIZE="26.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.32.03" NO="3" P_CHI2="1.0" P_Z="0.34719746702401943" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="54.70412055584148" Z="0.940039196074489">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="80.20950935965377" CI_START="-28.209509359653758" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="248.0" MEAN_2="222.0" ORDER="150" SD_1="91.78" SD_2="107.08" SE="27.658421168578325" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="54.70412055584148"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04467975828947206" CI_END="78.48186693091708" CI_START="-24.792385968687903" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="26.844740481114584" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.33" NO="33" P_CHI2="0.8325941253445903" P_Q="0.8325941253445903" P_Z="0.30823522790388447" Q="0.044679758289472064" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.0189320772614427">
<NAME>Plasma cortisol 30 min post 250 mcg tetracosactrin (nmol/L)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="254.21507698208373" CI_START="-254.21507698208373" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.33.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.125926853162209" Z="0.0">
<NAME>400 mcg/d or less</NAME>
<CONT_DATA CI_END="254.21507698208373" CI_START="-254.21507698208373" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="722.86" MEAN_2="722.86" ORDER="151" SD_1="277.17" SD_2="353.63" SE="129.70395322939595" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.125926853162209"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.33.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>500-800 mcg/d or greater</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7433863618945116E-32" CI_END="80.73652109489397" CI_START="-24.736521094893963" DF="0" EFFECT_SIZE="28.000000000000004" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.33.03" NO="3" P_CHI2="0.0" P_Z="0.29804920464196094" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="95.87407314683779" Z="1.0406259348881282">
<NAME>1000 mcg/d or greater</NAME>
<CONT_DATA CI_END="80.73652109489396" CI_START="-24.736521094893966" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="495.0" MEAN_2="467.0" ORDER="152" SD_1="101.98" SD_2="91.78" SE="26.906882734005784" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="95.87407314683779"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-12-08 11:41:22 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>BDP v BUD crossover design studies, no OCS: all study age groups</NAME>
<CONT_OUTCOME CHI2="6.615157052096611E-4" CI_END="1.8945713293020514" CI_START="-11.977410944268055" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.041419807483002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.9794807138235786" P_Q="1.0" P_Z="0.15427334876128318" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.4245983102846849">
<NAME>FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.615157052096611E-4" CI_END="1.8945713293020514" CI_START="-11.977410944268055" DF="1" EFFECT_SIZE="-5.041419807483002" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="0.9794807138235786" P_Z="0.15427334876128318" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="1.4245983102846849">
<NAME>Children</NAME>
<CONT_DATA CI_END="7.91587108032922" CI_START="-17.71587108032923" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" MEAN_1="78.5" MEAN_2="83.4" ORDER="153" SD_1="25.1" SD_2="22.9" SE="6.538829887395473" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="29.290096258497798"/>
<CONT_DATA CI_END="3.1483751749924487" CI_START="-13.348375174992437" EFFECT_SIZE="-5.099999999999994" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="90.0" ORDER="154" SD_1="9.49" SD_2="9.33" SE="4.208432012044391" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="70.7099037415022"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.32035202110659733" CI_END="0.11049175691108089" CI_START="-0.2669409068780454" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07822457498348225" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2014-12-08 11:40:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9972427003501628" P_Q="0.8709417280521109" P_Z="0.41654938262734487" Q="0.026394043687967737" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="114" UNITS="" WEIGHT="100.0" Z="0.8124222643286506">
<NAME>FEV1 (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.05422710564799785" CI_END="0.2320581036512604" CI_START="-0.35160410315062124" DF="1" EFFECT_SIZE="-0.059772999749680436" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="0.8158645759073251" P_Z="0.6880955784329692" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="41.81728364765492" Z="0.4014408518900787">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.29715638268182376" CI_START="-0.4771563826818235" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.63" ORDER="155" SD_1="0.65" SD_2="0.63" SE="0.19753239637853742" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="23.75998302929283"/>
<CONT_DATA CI_END="0.4241023511374425" CI_START="-0.4641023511374425" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="1.83" ORDER="156" SD_1="0.56" SD_2="0.55" SE="0.22658699580220104" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="18.05730061836209"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.23973087177063185" CI_END="0.15592113359581233" CI_START="-0.338893443830004" DF="3" EFFECT_SIZE="-0.09148615511709585" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" MODIFIED="2014-12-08 11:40:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9709340251592219" P_Z="0.4686026014316632" STUDIES="4" TAU2="0.0" TOTAL_1="80" TOTAL_2="81" WEIGHT="58.18271635234508" Z="0.724754594120401">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.7107191406452886" CI_START="-0.6107191406452881" EFFECT_SIZE="0.050000000000000266" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.05" ORDER="157" SD_1="0.86" SD_2="0.79" SE="0.33710779680491915" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.158028093402422"/>
<CONT_DATA CI_END="0.2929557302198247" CI_START="-0.5129557302198249" EFFECT_SIZE="-0.1100000000000001" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="1.87" ORDER="158" SD_1="0.66" SD_2="0.83" SE="0.20559343610305503" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="21.933316267934515"/>
<CONT_DATA CI_END="0.5681527667074239" CI_START="-0.9281527667074242" EFFECT_SIZE="-0.18000000000000016" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.74" ORDER="159" SD_1="0.93" SD_2="0.94" SE="0.3817176094095389" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.362655368014232"/>
<CONT_DATA CI_END="0.3048484198021312" CI_START="-0.5048484198021314" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.1" MODIFIED="2014-12-08 11:40:22 +0000" MODIFIED_BY="[Empty name]" ORDER="160" SD_1="0.8" SD_2="0.8" SE="0.2065591117977289" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="21.72871662299391"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0487921451998725" CI_END="0.07485427868731259" CI_START="-0.37826108004289943" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.15170340067779342" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2014-12-08 11:41:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9940025886222579" P_Q="0.7142919994748879" P_Z="0.18938683939436188" Q="0.1340277895659051" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="151" UNITS="" WEIGHT="100.0" Z="1.3123951591221987">
<NAME>FEV1 (% predicted and litre measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.692293721599832" CI_END="0.135515430506115" CI_START="-0.5299599396723088" DF="3" EFFECT_SIZE="-0.19722225458309692" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="0.8750150480201841" P_Z="0.2453486377353159" STUDIES="4" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="46.36108522654151" Z="1.1617214798769193">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.4676965784296662" CI_START="-0.7436062963260321" EFFECT_SIZE="-0.137954858948183" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.63" ORDER="161" SD_1="0.65" SD_2="0.63" SE="0.309011513555938" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.993039838225469"/>
<CONT_DATA CI_END="0.3338888548529608" CI_START="-0.7358823026018328" EFFECT_SIZE="-0.200996723874436" ESTIMABLE="YES" MEAN_1="78.5" MEAN_2="83.4" ORDER="162" SD_1="25.1" SD_2="22.9" SE="0.2729058201816493" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="17.940551833258557"/>
<CONT_DATA CI_END="0.7654323660710078" CI_START="-0.8350163705388689" EFFECT_SIZE="-0.03479200223393048" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="1.83" ORDER="163" SD_1="0.56" SD_2="0.55" SE="0.40828524126821003" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.015562973708766"/>
<CONT_DATA CI_END="0.3756568638206944" CI_START="-1.4137717485850576" EFFECT_SIZE="-0.5190574423821815" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="90.0" ORDER="164" SD_1="9.49" SD_2="9.33" SE="0.45649527912771265" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.411930581348721"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.22247063403413547" CI_END="0.19698130280978968" CI_START="-0.4217025649731301" DF="3" EFFECT_SIZE="-0.11236063108167019" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" MODIFIED="2014-12-08 11:41:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9738827737918548" P_Z="0.47652216803170755" STUDIES="4" TAU2="0.0" TOTAL_1="80" TOTAL_2="81" WEIGHT="53.638914773458495" Z="0.7119073299565518">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.8588200331972844" CI_START="-0.7418928167571992" EFFECT_SIZE="0.05846360822004261" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.05" ORDER="165" SD_1="0.86" SD_2="0.79" SE="0.40835261835949593" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.012918098964533"/>
<CONT_DATA CI_END="0.3950816459266676" CI_START="-0.6835079913954133" EFFECT_SIZE="-0.14421317273437287" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="1.87" ORDER="166" SD_1="0.66" SD_2="0.83" SE="0.2751554737306038" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="17.64838947819928"/>
<CONT_DATA CI_END="0.6163440671201013" CI_START="-0.9880887057125851" EFFECT_SIZE="-0.18587231929624193" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.74" ORDER="167" SD_1="0.93" SD_2="0.94" SE="0.4093015957150864" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="7.975804817352141"/>
<CONT_DATA CI_END="0.38319892299515645" CI_START="-0.6299521697484034" EFFECT_SIZE="-0.12337662337662349" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.1" MODIFIED="2014-12-08 11:41:22 +0000" MODIFIED_BY="[Empty name]" ORDER="168" SD_1="0.8" SD_2="0.8" SE="0.25846166070784116" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.00180237894254"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.98860104313428" CI_START="-8.78860104313429" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9003209033914635" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.1252559764038534">
<NAME>FVC (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.98860104313428" CI_START="-8.78860104313429" DF="0" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="1.0" P_Z="0.9003209033914635" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.1252559764038534">
<NAME>Children</NAME>
<CONT_DATA CI_END="9.98860104313428" CI_START="-8.78860104313429" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" MEAN_1="100.3" MEAN_2="99.7" ORDER="169" SD_1="17.7" SD_2="17.5" SE="4.790190593903955" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.073465239932124" CI_END="0.17368491571443306" CI_START="-0.2912541015156629" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.058784592900614926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.9993416534254264" P_Q="0.8989056564544127" P_Z="0.6201651302934728" Q="0.016140152666533732" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="102" UNITS="" WEIGHT="100.0" Z="0.49561633100813546">
<NAME>FVC (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.013228476658234848" CI_END="0.2940867700594674" CI_START="-0.38001714338991366" DF="1" EFFECT_SIZE="-0.04296518666522312" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.01" NO="1" P_CHI2="0.9084331435959939" P_Z="0.8027084290587893" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="47.57056282600574" Z="0.249843434440175">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.3848277358572072" CI_START="-0.5048277358572073" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.13" ORDER="170" SD_1="0.71" SD_2="0.76" SE="0.22695709684767254" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="27.311671376723602"/>
<CONT_DATA CI_END="0.4964855302332951" CI_START="-0.5364855302332951" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.3" ORDER="171" SD_1="0.67" SD_2="0.62" SE="0.26351786783189235" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="20.25889144928214"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.044096610607355424" CI_END="0.24791628978950578" CI_START="-0.39419217544308816" DF="2" EFFECT_SIZE="-0.07313794282679117" ESTIMABLE="YES" I2="0.0" ID="CMP-002.05.02" NO="2" P_CHI2="0.9781929916754606" P_Z="0.6552428195242734" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="69" WEIGHT="52.42943717399426" Z="0.44649071490417064">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.7765185034637754" CI_START="-0.7765185034637754" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.32" ORDER="172" SD_1="0.94" SD_2="1.0" SE="0.39619019001821165" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.96248367205713"/>
<CONT_DATA CI_END="0.379406989497779" CI_START="-0.5394069894977791" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.9" ORDER="173" SD_1="0.76" SD_2="0.94" SE="0.23439562824701005" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="25.605708586063827"/>
<CONT_DATA CI_END="0.45006008906355444" CI_START="-0.6500600890635537" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="3.18" MEAN_2="3.28" ORDER="174" SD_1="1.02" SD_2="1.15" SE="0.2806480595573989" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="17.861244915873304"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1694630571026059" CI_END="0.19564306325318126" CI_START="-0.29357839328069596" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.048967665013757336" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.9994079985480161" P_Q="0.821348513041934" P_Z="0.6947940664084813" Q="0.05099055516899233" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="0.3923575246023186">
<NAME>FVC (% predicted and litre measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0771496927077176" CI_END="0.33904578064672986" CI_START="-0.3767765988491295" DF="2" EFFECT_SIZE="-0.01886540910119981" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.01" NO="1" P_CHI2="0.9621596885895468" P_Z="0.9177175659341762" STUDIES="3" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="46.708986981900054" Z="0.10330921036027672">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.5250791314948589" CI_START="-0.6851713795223211" EFFECT_SIZE="-0.0800461240137311" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.13" ORDER="175" SD_1="0.71" SD_2="0.76" SE="0.30874304848545214" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.34031570891284"/>
<CONT_DATA CI_END="0.5670715174207005" CI_START="-0.4998789261137759" EFFECT_SIZE="0.0335962956534623" ESTIMABLE="YES" MEAN_1="100.3" MEAN_2="99.7" ORDER="176" SD_1="17.7" SD_2="17.5" SE="0.27218623708150896" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.024346040941364"/>
<CONT_DATA CI_END="0.7702894361495003" CI_START="-0.8301215479451141" EFFECT_SIZE="-0.029916055897806874" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.3" ORDER="177" SD_1="0.67" SD_2="0.62" SE="0.4082756103475502" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.344325232045847"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.041322809225895936" CI_END="0.25972804321410126" CI_START="-0.4104319659147527" DF="2" EFFECT_SIZE="-0.07535196135032574" ESTIMABLE="YES" I2="0.0" ID="CMP-002.06.02" NO="2" P_CHI2="0.9795505872011124" P_Z="0.6593926597399913" STUDIES="3" TAU2="0.0" TOTAL_1="68" TOTAL_2="69" WEIGHT="53.291013018099946" Z="0.44075184552737545">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.8001519460592184" CI_START="-0.8001519460592184" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.32" ORDER="178" SD_1="0.94" SD_2="1.0" SE="0.408248290463863" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.345575914173732"/>
<CONT_DATA CI_END="0.4468245504170491" CI_START="-0.6308696587891889" EFFECT_SIZE="-0.09202255418606992" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.9" ORDER="179" SD_1="0.76" SD_2="0.94" SE="0.27492704399339796" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="20.607243083653533"/>
<CONT_DATA CI_END="0.4155334451486638" CI_START="-0.5971457162719279" EFFECT_SIZE="-0.09080613556163204" ESTIMABLE="YES" MEAN_1="3.18" MEAN_2="3.28" ORDER="180" SD_1="1.02" SD_2="1.15" SE="0.25834126785197986" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.338194020272685"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.54956536803498" CI_START="-14.54956536803498" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7547702325074095" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.3123556756048751">
<NAME>Clinic PEFR (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.54956536803498" CI_START="-14.54956536803498" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.07.01" NO="1" P_CHI2="1.0" P_Z="0.7547702325074095" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.3123556756048751">
<NAME>Children</NAME>
<CONT_DATA CI_END="10.54956536803498" CI_START="-14.54956536803498" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="101.0" MEAN_2="103.0" ORDER="181" SD_1="15.81" SD_2="12.65" SE="6.402957129327043" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.07.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.055663346708613" CI_START="-16.855663346708596" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6838006154706033" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.40728236372272963">
<NAME>Morning PEFR (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.055663346708613" CI_START="-16.855663346708596" DF="0" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" I2="0.0" ID="CMP-002.08.01" NO="1" P_CHI2="1.0" P_Z="0.6838006154706033" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.40728236372272963">
<NAME>Children</NAME>
<CONT_DATA CI_END="11.055663346708613" CI_START="-16.855663346708596" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="90.3" ORDER="182" SD_1="30.8" SD_2="20.5" SE="7.120367239800882" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.08.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adults</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8715719751887616" CI_END="22.45146536355013" CI_START="-28.433338739199716" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.990936687824791" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" NO="9" P_CHI2="0.9722454805748484" P_Q="0.8059712690445516" P_Z="0.8177748915452845" Q="0.06033244550708812" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.00000000000001" Z="0.23040781198013166">
<NAME>Morning PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6399828906312977" CI_END="37.25848119037011" CI_START="-36.541563588102385" DF="1" EFFECT_SIZE="0.3584588011338638" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.01" NO="1" P_CHI2="0.4237172388961786" P_Z="0.9848094138503357" STUDIES="2" TAU2="0.0" TOTAL_1="44" TOTAL_2="44" WEIGHT="47.54041440802537" Z="0.019039726663383206">
<NAME>Children</NAME>
<CONT_DATA CI_END="36.018603001961736" CI_START="-61.018603001961736" EFFECT_SIZE="-12.5" ESTIMABLE="YES" MEAN_1="262.5" MEAN_2="275.0" ORDER="183" SD_1="78.41" SD_2="81.98" SE="24.754844162785787" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="27.497907520995046"/>
<CONT_DATA CI_END="74.83058027590448" CI_START="-38.830580275904474" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="409.0" MEAN_2="391.0" ORDER="184" SD_1="95.9" SD_2="100.7" SE="28.995726821603274" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="20.042506887030328"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.17125663905037555" CI_END="29.101116830340615" CI_START="-41.15363097696208" DF="3" EFFECT_SIZE="-6.026257073310733" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.02" NO="2" P_CHI2="0.9820903733660162" P_Z="0.7366894922167614" STUDIES="4" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="52.459585591974644" Z="0.33624053018210565">
<NAME>Adults</NAME>
<CONT_DATA CI_END="112.03206228931981" CI_START="-96.03206228931981" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="342.0" MEAN_2="334.0" ORDER="185" SD_1="132.0" SD_2="128.0" SE="53.078558131634786" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.981110235188558"/>
<CONT_DATA CI_END="48.198043120481216" CI_START="-53.998043120481285" EFFECT_SIZE="-2.900000000000034" ESTIMABLE="YES" MEAN_1="311.2" MEAN_2="314.1" ORDER="186" SD_1="94.0" SD_2="94.0" SE="26.07090922258577" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="24.791778640469968"/>
<CONT_DATA CI_END="66.9187027127066" CI_START="-86.9187027127066" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="245.0" MEAN_2="255.0" ORDER="187" SD_1="101.0" SD_2="91.0" SE="39.24495721320979" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.94088165952033"/>
<CONT_DATA CI_END="60.61370763725296" CI_START="-94.61370763725296" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="420.0" ORDER="188" SD_1="111.0" SD_2="113.0" SE="39.59955807834224" STUDY_ID="STD-Willey-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.745815056795788"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9268989002760777" CI_END="0.19561703520801632" CI_START="-0.27850742819265384" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.04144519649231875" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.10" NO="10" P_CHI2="0.9882322147338779" P_Q="0.9124392647255226" P_Z="0.7318563276388479" Q="0.012091710342434194" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="0.342657250269258">
<NAME>Morning PEFR (% predicted, L/min measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7471613636666568" CI_END="0.30083555959068725" CI_START="-0.3580559424258937" DF="2" EFFECT_SIZE="-0.028610191417603237" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.01" NO="1" P_CHI2="0.6882655989735793" P_Z="0.8648450270913174" STUDIES="3" TAU2="0.0" TOTAL_1="71" TOTAL_2="71" WEIGHT="51.779388322782665" Z="0.17020994988606844">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.4529411466428519" CI_START="-0.7587236533009469" EFFECT_SIZE="-0.15289125332904752" ESTIMABLE="YES" MEAN_1="262.5" MEAN_2="275.0" ORDER="189" SD_1="78.41" SD_2="81.98" SE="0.3091038431066224" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="15.311570755696097"/>
<CONT_DATA CI_END="0.42462191669935034" CI_START="-0.6431053631410939" EFFECT_SIZE="-0.10924172322087175" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="90.3" ORDER="190" SD_1="30.8" SD_2="20.5" SE="0.2723844132500752" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="19.71805395647969"/>
<CONT_DATA CI_END="0.759159534083772" CI_START="-0.39931908562118923" EFFECT_SIZE="0.17992022423129142" ESTIMABLE="YES" MEAN_1="409.0" MEAN_2="391.0" ORDER="191" SD_1="95.9" SD_2="100.7" SE="0.2955356906664849" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="16.74976361060688"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.16764582626698693" CI_END="0.2861587885629157" CI_START="-0.39661368928699264" DF="3" EFFECT_SIZE="-0.055227450362038466" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.02" NO="2" P_CHI2="0.9826351750800965" P_Z="0.7511894239393316" STUDIES="4" TAU2="0.0" TOTAL_1="66" TOTAL_2="66" WEIGHT="48.220611677217335" Z="0.3170714027854059">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.8597725089526191" CI_START="-0.740953678274078" EFFECT_SIZE="0.059409415339270556" ESTIMABLE="YES" MEAN_1="342.0" MEAN_2="334.0" ORDER="192" SD_1="132.0" SD_2="128.0" SE="0.4083560207873769" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.773050486718477"/>
<CONT_DATA CI_END="0.5132441707512481" CI_START="-0.5740161155817844" EFFECT_SIZE="-0.03038597241526819" ESTIMABLE="YES" MEAN_1="311.2" MEAN_2="314.1" ORDER="193" SD_1="94.0" SD_2="94.0" SE="0.2773674146334328" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="19.0159347334325"/>
<CONT_DATA CI_END="0.7003167208979918" CI_START="-0.901193873631292" EFFECT_SIZE="-0.10043857636665006" ESTIMABLE="YES" MEAN_1="245.0" MEAN_2="255.0" ORDER="194" SD_1="101.0" SD_2="91.0" SE="0.4085561283681218" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.764458648982954"/>
<CONT_DATA CI_END="0.5460789553008351" CI_START="-0.8419855281374223" EFFECT_SIZE="-0.1479532864182936" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="420.0" ORDER="195" SD_1="111.0" SD_2="113.0" SE="0.35410458926468363" STUDY_ID="STD-Willey-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="11.667167808083406"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.26166546325175266" CI_END="20.55803558738905" CI_START="-31.5023410849251" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.472152748768025" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.11" NO="11" P_CHI2="0.9921525201320759" P_Q="0.7629031587334283" P_Z="0.6803173284578172" Q="0.09100518304729258" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="106" UNITS="" WEIGHT="100.0" Z="0.4120301461895066">
<NAME>Evening PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.004165264764900512" CI_END="30.06778171701725" CI_START="-50.470235169919036" DF="1" EFFECT_SIZE="-10.201226726450894" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.01" NO="1" P_CHI2="0.9485411638804032" P_Z="0.6195333814606008" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="41.784263232257274" Z="0.4965117780349601">
<NAME>Children</NAME>
<CONT_DATA CI_END="36.010965933859396" CI_START="-58.010965933859396" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="269.1" MEAN_2="280.1" ORDER="196" SD_1="77.12" SD_2="78.32" SE="23.985627442481544" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="30.65887899063473"/>
<CONT_DATA CI_END="70.04045642256422" CI_START="-86.04045642256422" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="252.0" MEAN_2="260.0" ORDER="197" SD_1="100.0" SD_2="95.0" SE="39.8172910513343" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.125384241622541"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1664950154395595" CI_END="32.03805533152875" CI_START="-36.1937884292456" DF="2" EFFECT_SIZE="-2.0778665488584274" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.02" NO="2" P_CHI2="0.9201234124811893" P_Z="0.9049793018484522" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="73" WEIGHT="58.21573676774272" Z="0.11937369345379788">
<NAME>Adults</NAME>
<CONT_DATA CI_END="44.41438707827466" CI_START="-48.21438707827461" EFFECT_SIZE="-1.8999999999999773" ESTIMABLE="YES" MEAN_1="334.0" MEAN_2="335.9" ORDER="198" SD_1="86.0" SD_2="86.0" SE="23.63022353655302" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="31.58804723363171"/>
<CONT_DATA CI_END="59.066998866183255" CI_START="-85.06699886618325" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="437.0" MEAN_2="450.0" ORDER="199" SD_1="104.0" SD_2="104.0" SE="36.76955262170047" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="13.046131360753751"/>
<CONT_DATA CI_END="78.63216385213936" CI_START="-62.63216385213936" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="360.0" MEAN_2="352.0" ORDER="200" SD_1="135.0" SD_2="144.0" SE="36.0374804890686" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.581558173357259"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00226675544217059" CI_END="0.7173320664566347" CI_START="-0.198318764087475" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.25950665118457983" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.12" NO="12" P_CHI2="0.9620267124559633" P_Q="0.9620267124559633" P_Z="0.26658749674469784" Q="0.00226675544217059" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.110955558830508">
<NAME>Daytime breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8770945569247939" CI_START="-0.3386537160245399" DF="0" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.01" NO="1" P_CHI2="1.0" P_Z="0.38536950642836487" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.72473357270164" Z="0.8680453671628945">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.8770945569247939" CI_START="-0.3386537160245399" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.05" ORDER="201" SD_1="0.16" SD_2="0.13" SE="0.31014556454582864" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.72473357270164"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9427271302557353" CI_START="-0.44917922736600147" DF="0" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.02" NO="2" P_CHI2="1.0" P_Z="0.48707277771717894" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.27526642729837" Z="0.6949721215168363">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.9427271302557353" CI_START="-0.44917922736600147" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.6" ORDER="202" SD_1="0.57" SD_2="0.45" SE="0.35508467721879494" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.27526642729837"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.17405040162197355" CI_START="-0.8456770201530461" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.19673908505295346" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.290897896114194">
<NAME>Morning breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.13.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17405040162197355" CI_START="-0.8456770201530461" DF="0" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" I2="0.0" ID="CMP-002.13.02" NO="2" P_CHI2="1.0" P_Z="0.19673908505295346" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.290897896114194">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.17405040162197355" CI_START="-0.8456770201530461" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.45" ORDER="203" SD_1="5.57" SD_2="8.92" SE="0.26013932649234867" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9911969708362657" CI_START="-0.40321836928808474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.14" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.40854793264034206" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.8264516672714545">
<NAME>Daytime wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.14.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9911969708362657" CI_START="-0.40321836928808474" DF="0" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.02" NO="2" P_CHI2="1.0" P_Z="0.40854793264034206" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.8264516672714545">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.9911969708362657" CI_START="-0.40321836928808474" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.39" ORDER="204" SD_1="0.4" SD_2="0.46" SE="0.35572473553680595" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3579832708223656" CI_START="-0.6556362545280283" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.15" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.5649191146091266" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.5755504046277298">
<NAME>Morning wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.15.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3579832708223656" CI_START="-0.6556362545280283" DF="0" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" I2="0.0" ID="CMP-002.15.02" NO="2" P_CHI2="1.0" P_Z="0.5649191146091266" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5755504046277298">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.3579832708223656" CI_START="-0.6556362545280283" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" MEAN_1="5.24" MEAN_2="6.33" ORDER="205" SD_1="6.39" SD_2="7.98" SE="0.25858116101767564" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0891445159283726" CI_START="-0.3116095894195764" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.2766203423573744" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.0879428779547926">
<NAME>Daytime cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.16.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0891445159283726" CI_START="-0.3116095894195764" DF="0" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" I2="0.0" ID="CMP-002.16.02" NO="2" P_CHI2="1.0" P_Z="0.2766203423573744" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.0879428779547926">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.0891445159283726" CI_START="-0.3116095894195764" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.17" ORDER="206" SD_1="0.35" SD_2="0.3" SE="0.357341797195489" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3990686503627424" CI_START="-0.6138327802336648" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.17" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.677725759009032" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.4155685311553392">
<NAME>Morning cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.17.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3990686503627424" CI_START="-0.6138327802336648" DF="0" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" I2="0.0" ID="CMP-002.17.02" NO="2" P_CHI2="1.0" P_Z="0.677725759009032" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.4155685311553392">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.3990686503627424" CI_START="-0.6138327802336648" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.26" ORDER="207" SD_1="6.19" SD_2="6.31" SE="0.2583979702142602" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5308269961716794" CI_END="0.38871459506829464" CI_START="-0.224316425068525" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0821990849998848" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.18" NO="18" P_CHI2="0.9704314250068655" P_Q="0.8709708145980722" P_Z="0.5991600507701369" Q="0.0263820427193798" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="82" UNITS="" WEIGHT="100.0" Z="0.5256087893430386">
<NAME>Daily asthma symptom score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5044449534522997" CI_END="0.4245587272214606" CI_START="-0.23909309831690526" DF="3" EFFECT_SIZE="0.09273281445227768" ESTIMABLE="YES" I2="0.0" ID="CMP-002.18.01" NO="1" P_CHI2="0.9179138507384575" P_Z="0.5838732364563781" STUDIES="4" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="85.32657532607547" Z="0.5477359347698879">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.5208850012881223" CI_START="-0.6894233789352231" EFFECT_SIZE="-0.0842691888235504" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.16" ORDER="208" SD_1="0.26" SD_2="0.42" SE="0.30875781130931573" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="25.655047382611066"/>
<CONT_DATA CI_END="0.7324361272958737" CI_START="-0.33723788094754537" EFFECT_SIZE="0.19759912317416417" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="13.6" ORDER="209" SD_1="19.3" SD_2="16.5" SE="0.2728810367641628" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="32.84445165380738"/>
<CONT_DATA CI_END="0.9626193421086242" CI_START="-0.6407802616488538" EFFECT_SIZE="0.16091954022988514" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" ORDER="210" SD_1="0.6" SD_2="0.6" SE="0.40903802733236155" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.617777865113872"/>
<CONT_DATA CI_END="0.9781387758422925" CI_START="-0.7762954715486697" EFFECT_SIZE="0.10092165214681133" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="211" SD_1="9.49" SD_2="9.49" SE="0.4475679811541731" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.209298424543144"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.22176349181913E-35" CI_END="0.8211232032108191" CI_START="-0.7792331837699751" DF="0" EFFECT_SIZE="0.020945009720421997" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-002.18.02" NO="2" P_CHI2="0.0" P_Z="0.9590841544286623" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.673424673924533" Z="0.05130290358051493">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.8211232032108191" CI_START="-0.7792331837699751" EFFECT_SIZE="0.020945009720421993" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.4" ORDER="212" SD_1="5.5" SD_2="3.5" SE="0.4082616822564601" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.673424673924533"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3786632505093888" CI_END="0.3095516630986409" CI_START="-0.18235646960046192" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06359759674908948" ESTIMABLE="YES" I2="0.0" I2_Q="28.950574579071052" ID="CMP-002.19" NO="19" P_CHI2="0.7600367645332655" P_Q="0.23547691527171066" P_Z="0.6122966467186456" Q="1.4074709177105198" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="128" UNITS="" WEIGHT="99.99999999999999" Z="0.5067978788948547">
<NAME>Symptoms (daytime breathlessness, morning breathlessness, daily symptom scores combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1079751723347201" CI_END="0.5310993971916672" CI_START="-0.13344507234408845" DF="3" EFFECT_SIZE="0.19882716242378937" ESTIMABLE="YES" I2="0.0" ID="CMP-002.19.01" NO="1" P_CHI2="0.9908634925936503" P_Z="0.24086976078999045" STUDIES="4" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="54.79234773676566" Z="1.1728156515128605">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.8770945569247939" CI_START="-0.3386537160245399" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.05" ORDER="213" SD_1="0.16" SD_2="0.13" SE="0.31014556454582864" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.37120636562371"/>
<CONT_DATA CI_END="0.7324361272958737" CI_START="-0.33723788094754537" EFFECT_SIZE="0.19759912317416417" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="13.6" ORDER="214" SD_1="19.3" SD_2="16.5" SE="0.2728810367641628" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.14779634005977"/>
<CONT_DATA CI_END="0.9626193421086242" CI_START="-0.6407802616488538" EFFECT_SIZE="0.16091954022988514" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" ORDER="215" SD_1="0.6" SD_2="0.6" SE="0.40903802733236155" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.412055116463685"/>
<CONT_DATA CI_END="0.9781387758422925" CI_START="-0.7762954715486697" EFFECT_SIZE="0.10092165214681133" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="216" SD_1="9.49" SD_2="9.49" SE="0.4475679811541731" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.861289914618505"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8632171604641488" CI_END="0.26550099581196174" CI_START="-0.46610629695552075" DF="2" EFFECT_SIZE="-0.1003026505717795" ESTIMABLE="YES" I2="0.0" ID="CMP-002.19.02" NO="2" P_CHI2="0.39391960761828126" P_Z="0.5909786908592715" STUDIES="3" TAU2="0.0" TOTAL_1="58" TOTAL_2="58" WEIGHT="45.20765226323432" Z="0.5374183243333888">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.8211232032108191" CI_START="-0.7792331837699751" EFFECT_SIZE="0.020945009720421993" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.4" ORDER="217" SD_1="5.5" SD_2="3.5" SE="0.4082616822564601" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.447884832608928"/>
<CONT_DATA CI_END="0.9427271302557353" CI_START="-0.44917922736600147" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.6" ORDER="218" SD_1="0.57" SD_2="0.45" SE="0.35508467721879494" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="12.489583865574897"/>
<CONT_DATA CI_END="0.17405040162197355" CI_START="-0.8456770201530461" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.45" ORDER="219" SD_1="5.57" SD_2="8.92" SE="0.26013932649234867" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.270183565050502"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03344131276092331" CI_END="0.5736764323858248" CI_START="-0.3386737894998658" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1175013214429795" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.20" NO="20" P_CHI2="0.8549003400847557" P_Q="0.8549003400847557" P_Z="0.613666731871884" Q="0.03344131276092331" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="0.5048463904313232">
<NAME>Night-time breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.760557061729863" CI_START="-0.4511541195732166" DF="0" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" I2="0.0" ID="CMP-002.20.01" NO="1" P_CHI2="1.0" P_Z="0.6167479365872593" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.692411806516056" Z="0.5004646591489">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.760557061729863" CI_START="-0.4511541195732166" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.08" ORDER="220" SD_1="0.18" SD_2="0.2" SE="0.30911567530345013" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.692411806516056"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7619896261535924" CI_START="-0.6243817489594453" DF="0" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" I2="0.0" ID="CMP-002.20.02" NO="2" P_CHI2="1.0" P_Z="0.8457520643384093" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.307588193483944" Z="0.19454129545018084">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.7619896261535924" CI_START="-0.6243817489594453" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.58" ORDER="221" SD_1="0.42" SD_2="0.43" SE="0.35367266593890456" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.307588193483944"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.16332643328615065" CI_START="-0.8569043141133812" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.21" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.18271841051851442" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.332431580169419">
<NAME>Evening breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.21.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16332643328615065" CI_START="-0.8569043141133812" DF="0" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" I2="0.0" ID="CMP-002.21.02" NO="2" P_CHI2="1.0" P_Z="0.18271841051851442" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.332431580169419">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.16332643328615065" CI_START="-0.8569043141133812" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="6.52" ORDER="222" SD_1="4.63" SD_2="9.07" SE="0.2602677282457692" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8546760593433423" CI_START="-0.5337686038575246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.22" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.6505479013544908" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.45300116871247653">
<NAME>Night-time wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.22.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8546760593433423" CI_START="-0.5337686038575246" DF="0" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" I2="0.0" ID="CMP-002.22.02" NO="2" P_CHI2="1.0" P_Z="0.6505479013544908" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.45300116871247653">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.8546760593433423" CI_START="-0.5337686038575246" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="0.39" ORDER="223" SD_1="0.41" SD_2="0.44" SE="0.35420157568015054" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.28187277833707003" CI_START="-0.7336977352773082" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.23" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.383217435467999" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.8719834133107602">
<NAME>Evening wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.23.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.28187277833707003" CI_START="-0.7336977352773082" DF="0" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" I2="0.0" ID="CMP-002.23.02" NO="2" P_CHI2="1.0" P_Z="0.383217435467999" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.8719834133107602">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.28187277833707003" CI_START="-0.7336977352773082" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" MEAN_1="4.46" MEAN_2="5.99" ORDER="224" SD_1="4.94" SD_2="8.06" SE="0.2590788712509691" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1308638814016656" CI_START="-0.27309251807994506" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.24" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.2311219624267815" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.1974737817364924">
<NAME>Night-time cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.24.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1308638814016656" CI_START="-0.27309251807994506" DF="0" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" I2="0.0" ID="CMP-002.24.02" NO="2" P_CHI2="1.0" P_Z="0.2311219624267815" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.1974737817364924">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.1308638814016656" CI_START="-0.27309251807994506" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.11" ORDER="225" SD_1="0.36" SD_2="0.27" SE="0.35815872397550147" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3188557117127877" CI_START="-0.6956657222978688" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.25" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.4666362517433257" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7279629833361982">
<NAME>Evening cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.25.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3188557117127877" CI_START="-0.6956657222978688" DF="0" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" I2="0.0" ID="CMP-002.25.02" NO="2" P_CHI2="1.0" P_Z="0.4666362517433257" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7279629833361982">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.3188557117127877" CI_START="-0.6956657222978688" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.1" ORDER="226" SD_1="4.36" SD_2="5.99" SE="0.2588112439853671" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8016711824146951" CI_END="0.25123460905650996" CI_START="-0.42884803223726575" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08880671159037787" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.26" NO="26" P_CHI2="0.40623011848790624" P_Q="0.3411931002843138" P_Z="0.6087399277991501" Q="0.9059436844426709" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="0.511872957002555">
<NAME>Symptoms (night-time breathlessness, evening breathlessness scores combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.760557061729863" CI_START="-0.4511541195732166" DF="0" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" I2="0.0" ID="CMP-002.26.01" NO="1" P_CHI2="1.0" P_Z="0.6167479365872593" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="31.50105861950481" Z="0.5004646591489">
<NAME>Children</NAME>
<CONT_DATA CI_END="0.760557061729863" CI_START="-0.4511541195732166" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.08" ORDER="227" SD_1="0.18" SD_2="0.2" SE="0.30911567530345013" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="31.50105861950481"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8957274979720241" CI_END="0.21006570279865222" CI_START="-0.6116465445112237" DF="1" EFFECT_SIZE="-0.20079042085628573" ESTIMABLE="YES" I2="0.0" ID="CMP-002.26.02" NO="2" P_CHI2="0.3439300313825977" P_Z="0.3381341727954018" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="46" WEIGHT="68.49894138049518" Z="0.9578584099417752">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.7619896261535924" CI_START="-0.6243817489594453" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.58" ORDER="228" SD_1="0.42" SD_2="0.43" SE="0.35367266593890456" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.063800266749475"/>
<CONT_DATA CI_END="0.16332643328615065" CI_START="-0.8569043141133812" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="6.52" ORDER="229" SD_1="4.63" SD_2="9.07" SE="0.2602677282457692" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="44.435141113745715"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1790448498493285E-32" CI_END="1.0902109514859657" CI_START="-0.1302109514859658" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4799999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.27" NO="27" P_CHI2="0.0" P_Q="1.0" P_Z="0.12313834915680578" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.5417335763775835">
<NAME>Daytime use of rescue beta2 agonists (puffs/day)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.27.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.1790448498493285E-32" CI_END="1.0902109514859657" CI_START="-0.1302109514859658" DF="0" EFFECT_SIZE="0.4799999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-002.27.02" NO="2" P_CHI2="0.0" P_Z="0.12313834915680578" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.5417335763775835">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.0902109514859657" CI_START="-0.13021095148596573" EFFECT_SIZE="0.48" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.41" ORDER="230" SD_1="0.7" SD_2="1.03" SE="0.3113378390109368" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.522391440304596E-33" CI_END="0.44157934397716114" CI_START="-0.6415793439771609" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999988" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.28" NO="28" P_CHI2="0.0" P_Q="1.0" P_Z="0.7174283697728059" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.36189784679504056">
<NAME>Morning use of rescue beta2 agonists (puffs)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.28.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.522391440304596E-33" CI_END="0.44157934397716114" CI_START="-0.6415793439771609" DF="0" EFFECT_SIZE="-0.09999999999999988" ESTIMABLE="YES" I2="100.0" ID="CMP-002.28.02" NO="2" P_CHI2="0.0" P_Z="0.7174283697728059" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.36189784679504056">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.44157934397716114" CI_START="-0.6415793439771609" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.44" ORDER="231" SD_1="1.09" SD_2="1.05" SE="0.27632106928957356" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.41510445046283745" CI_START="-0.5151044504628375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.29" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.8331202144951171" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.21070148679394954">
<NAME>Night-time use of rescue beta2 agonists (puffs/night)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.29.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.41510445046283745" CI_START="-0.5151044504628375" DF="0" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.29.02" NO="2" P_CHI2="1.0" P_Z="0.8331202144951171" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.21070148679394954">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.41510445046283745" CI_START="-0.5151044504628375" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="0.42" ORDER="232" SD_1="0.71" SD_2="0.63" SE="0.23730254950168572" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.651141403435223" CI_START="-3.651141403435222" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.30" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.45973054673146974" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7392906247853945">
<NAME>Evening use of rescue beta2 agonists (puffs)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.30.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.651141403435223" CI_START="-3.651141403435222" DF="0" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-002.30.02" NO="2" P_CHI2="1.0" P_Z="0.45973054673146974" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7392906247853945">
<NAME>Adults</NAME>
<CONT_DATA CI_END="1.651141403435223" CI_START="-3.651141403435222" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.1" ORDER="233" SD_1="4.36" SD_2="5.99" SE="1.3526480202427633" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8074648429450684" CI_START="0.052535157054931614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.43" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.31" NO="31" P_CHI2="1.0" P_Q="1.0" P_Z="0.025565455250602106" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="2.2327496960422137">
<NAME>Histamine BHR (log 10 PC20 FEV1)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.31.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8074648429450684" CI_START="0.052535157054931614" DF="0" EFFECT_SIZE="0.43" ESTIMABLE="YES" I2="0.0" ID="CMP-002.31.02" NO="2" P_CHI2="1.0" P_Z="0.025565455250602106" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.2327496960422137">
<NAME>Adults</NAME>
<CONT_DATA CI_END="0.8074648429450684" CI_START="0.052535157054931614" EFFECT_SIZE="0.43" ESTIMABLE="YES" MEAN_1="0.63" MEAN_2="0.2" ORDER="234" SD_1="0.3" SD_2="0.53" SE="0.1925876423865249" STUDY_ID="STD-Tjwa-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.15431352904180887" CI_END="64.41195001164964" CI_START="-15.777178294337286" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="24.317385858656177" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.32" NO="32" P_CHI2="0.9257447396728291" P_Q="0.77804495221028" P_Z="0.23454998542644578" Q="0.07944941085956644" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="1.1887197551085322">
<NAME>Morning plasma cortisol (nmol/L)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="82.67823652570421" CI_START="-49.078236525704185" DF="0" EFFECT_SIZE="16.80000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.32.01" NO="1" P_CHI2="1.0" P_Z="0.6172003880424061" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="37.041371910873615" Z="0.4998220455920281">
<NAME>Children</NAME>
<CONT_DATA CI_END="82.67823652570421" CI_START="-49.078236525704185" EFFECT_SIZE="16.80000000000001" ESTIMABLE="YES" MEAN_1="379.2" MEAN_2="362.4" ORDER="235" SD_1="106.32" SD_2="111.45" SE="33.61196279387954" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="37.041371910873615"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.07486411818224242" CI_END="79.27119680302708" CI_START="-21.790797604955916" DF="1" EFFECT_SIZE="28.74019959903558" ESTIMABLE="YES" I2="0.0" ID="CMP-002.32.02" NO="2" P_CHI2="0.7843819872261161" P_Z="0.26495481233703844" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="62.95862808912638" Z="1.1147564710666882">
<NAME>Adults</NAME>
<CONT_DATA CI_END="186.4532364039645" CI_START="-92.65323640396454" EFFECT_SIZE="46.89999999999998" ESTIMABLE="YES" MEAN_1="411.09" MEAN_2="364.19" ORDER="236" SD_1="200.71" SD_2="143.36" SE="71.2019391706902" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.254507533284904"/>
<CONT_DATA CI_END="80.20950935965377" CI_START="-28.209509359653758" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="248.0" MEAN_2="222.0" ORDER="237" SD_1="91.78" SD_2="107.08" SE="27.658421168578325" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="54.70412055584148"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04467975828947206" CI_END="78.48186693091708" CI_START="-24.792385968687903" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="26.844740481114584" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.33" NO="33" P_CHI2="0.8325941253445903" P_Q="1.0" P_Z="0.30823522790388447" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.0189320772614427">
<NAME>Plasma cortisol 30 min post 250 mcg tetracosactrin (nmol/L)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.33.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Children</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04467975828947206" CI_END="78.48186693091708" CI_START="-24.792385968687903" DF="1" EFFECT_SIZE="26.844740481114584" ESTIMABLE="YES" I2="0.0" ID="CMP-002.33.02" NO="2" P_CHI2="0.8325941253445903" P_Z="0.30823522790388447" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="1.0189320772614427">
<NAME>Adults</NAME>
<CONT_DATA CI_END="254.21507698208373" CI_START="-254.21507698208373" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="722.86" MEAN_2="722.86" ORDER="238" SD_1="277.17" SD_2="353.63" SE="129.70395322939595" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.125926853162209"/>
<CONT_DATA CI_END="80.73652109489396" CI_START="-24.736521094893966" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="495.0" MEAN_2="467.0" ORDER="239" SD_1="101.98" SD_2="91.78" SE="26.906882734005784" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="95.87407314683779"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-12-08 11:42:51 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>BDP v BUD crossover design studies, no OCS: all study durations</NAME>
<CONT_OUTCOME CHI2="6.615157052096611E-4" CI_END="1.8945713293020514" CI_START="-11.977410944268055" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.041419807483002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.9794807138235786" P_Q="1.0" P_Z="0.15427334876128318" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.4245983102846849">
<NAME>FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.615157052096611E-4" CI_END="1.8945713293020514" CI_START="-11.977410944268055" DF="1" EFFECT_SIZE="-5.041419807483002" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="0.9794807138235786" P_Z="0.15427334876128318" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="100.0" Z="1.4245983102846849">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="7.91587108032922" CI_START="-17.71587108032923" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" MEAN_1="78.5" MEAN_2="83.4" ORDER="240" SD_1="25.1" SD_2="22.9" SE="6.538829887395473" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="29.290096258497798"/>
<CONT_DATA CI_END="3.1483751749924487" CI_START="-13.348375174992437" EFFECT_SIZE="-5.099999999999994" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="90.0" ORDER="241" SD_1="9.49" SD_2="9.33" SE="4.208432012044391" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="70.7099037415022"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3203520211065974" CI_END="0.11049175691108089" CI_START="-0.2669409068780454" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07822457498348225" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2014-12-08 11:42:09 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9972427003501628" P_Q="0.7565585843519649" P_Z="0.41654938262734487" Q="0.0961019514156704" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="114" UNITS="" WEIGHT="100.0" Z="0.8124222643286506">
<NAME>FEV1 (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.19818305006336592" CI_END="0.1633890132113413" CI_START="-0.2823367164277166" DF="3" EFFECT_SIZE="-0.05947385160818767" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" MODIFIED="2014-12-08 11:42:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9778820909554589" P_Z="0.6009451260274788" STUDIES="4" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="71.70402836405125" Z="0.5230418592542159">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.29715638268182376" CI_START="-0.4771563826818235" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.63" ORDER="242" SD_1="0.65" SD_2="0.63" SE="0.19753239637853742" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="23.75998302929283"/>
<CONT_DATA CI_END="0.7107191406452886" CI_START="-0.6107191406452881" EFFECT_SIZE="0.050000000000000266" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.05" ORDER="243" SD_1="0.86" SD_2="0.79" SE="0.33710779680491915" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.158028093402422"/>
<CONT_DATA CI_END="0.4241023511374425" CI_START="-0.4641023511374425" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="1.83" ORDER="244" SD_1="0.56" SD_2="0.55" SE="0.22658699580220104" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="18.05730061836209"/>
<CONT_DATA CI_END="0.3048484198021312" CI_START="-0.5048484198021314" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.1" MODIFIED="2014-12-08 11:42:09 +0000" MODIFIED_BY="[Empty name]" ORDER="245" SD_1="0.8" SD_2="0.8" SE="0.2065591117977289" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="21.72871662299391"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.026067019627561007" CI_END="0.2290299818322069" CI_START="-0.48051049654937295" DF="1" EFFECT_SIZE="-0.12574025735858302" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="0.8717367735131589" P_Z="0.48726543507275544" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="39" WEIGHT="28.295971635948746" Z="0.6946647396121781">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.2929557302198247" CI_START="-0.5129557302198249" EFFECT_SIZE="-0.1100000000000001" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="1.87" ORDER="246" SD_1="0.66" SD_2="0.83" SE="0.20559343610305503" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="21.933316267934515"/>
<CONT_DATA CI_END="0.5681527667074239" CI_START="-0.9281527667074242" EFFECT_SIZE="-0.18000000000000016" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.74" ORDER="247" SD_1="0.93" SD_2="0.94" SE="0.3817176094095389" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.362655368014232"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0487921451998727" CI_END="0.07485427868731262" CI_START="-0.3782610800428994" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1517034006777934" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2014-12-08 11:42:51 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9940025886222579" P_Q="0.9778141619413954" P_Z="0.18938683939436196" Q="7.733632646607373E-4" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="151" UNITS="" WEIGHT="100.0" Z="1.3123951591221985">
<NAME>FEV1 (% predicted, litre measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0408838682672905" CI_END="0.11288516268833806" CI_START="-0.41251831307327425" DF="5" EFFECT_SIZE="-0.14981657519246808" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2014-12-08 11:42:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9592012825446676" P_Z="0.2636734351277582" STUDIES="6" TAU2="0.0" TOTAL_1="112" TOTAL_2="112" WEIGHT="74.37580570444858" Z="1.1177508532417986">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.4676965784296662" CI_START="-0.7436062963260321" EFFECT_SIZE="-0.137954858948183" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.63" ORDER="248" SD_1="0.65" SD_2="0.63" SE="0.309011513555938" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.993039838225469"/>
<CONT_DATA CI_END="0.8588200331972844" CI_START="-0.7418928167571992" EFFECT_SIZE="0.05846360822004261" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.05" ORDER="249" SD_1="0.86" SD_2="0.79" SE="0.40835261835949593" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.012918098964533"/>
<CONT_DATA CI_END="0.3338888548529608" CI_START="-0.7358823026018328" EFFECT_SIZE="-0.200996723874436" ESTIMABLE="YES" MEAN_1="78.5" MEAN_2="83.4" ORDER="250" SD_1="25.1" SD_2="22.9" SE="0.2729058201816493" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="17.940551833258557"/>
<CONT_DATA CI_END="0.7654323660710078" CI_START="-0.8350163705388689" EFFECT_SIZE="-0.03479200223393048" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="1.83" ORDER="251" SD_1="0.56" SD_2="0.55" SE="0.40828524126821003" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.015562973708766"/>
<CONT_DATA CI_END="0.3756568638206944" CI_START="-1.4137717485850576" EFFECT_SIZE="-0.5190574423821815" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="90.0" ORDER="252" SD_1="9.49" SD_2="9.33" SE="0.45649527912771265" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.411930581348721"/>
<CONT_DATA CI_END="0.38319892299515645" CI_START="-0.6299521697484034" EFFECT_SIZE="-0.12337662337662349" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.1" MODIFIED="2014-12-08 11:42:51 +0000" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="0.8" SD_2="0.8" SE="0.25846166070784116" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.00180237894254"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.007134913667921607" CI_END="0.29038245860620027" CI_START="-0.6047425148486438" DF="1" EFFECT_SIZE="-0.15718002812122178" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" NO="2" P_CHI2="0.9326840119623004" P_Z="0.4912499112183758" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="39" WEIGHT="25.624194295551423" Z="0.6883221971063207">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.3950816459266676" CI_START="-0.6835079913954133" EFFECT_SIZE="-0.14421317273437287" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="1.87" ORDER="254" SD_1="0.66" SD_2="0.83" SE="0.2751554737306038" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="17.64838947819928"/>
<CONT_DATA CI_END="0.6163440671201013" CI_START="-0.9880887057125851" EFFECT_SIZE="-0.18587231929624193" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.74" ORDER="255" SD_1="0.93" SD_2="0.94" SE="0.4093015957150864" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="7.975804817352141"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.98860104313428" CI_START="-8.78860104313429" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9003209033914635" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.1252559764038534">
<NAME>FVC (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.98860104313428" CI_START="-8.78860104313429" DF="0" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.9003209033914635" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.1252559764038534">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="9.98860104313428" CI_START="-8.78860104313429" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" MEAN_1="100.3" MEAN_2="99.7" ORDER="256" SD_1="17.7" SD_2="17.5" SE="4.790190593903955" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.073465239932124" CI_END="0.17368491571443306" CI_START="-0.2912541015156629" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.058784592900614926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.9993416534254264" P_Q="0.9164251460534716" P_Z="0.6201651302934728" Q="0.011011947022264035" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="102" UNITS="" WEIGHT="100.0" Z="0.49561633100813546">
<NAME>FVC (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.062453292909859966" CI_END="0.21804074351021557" CI_START="-0.32100570306244586" DF="3" EFFECT_SIZE="-0.05148247977611513" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" NO="1" P_CHI2="0.9959259244093677" P_Z="0.7081224442067175" STUDIES="4" TAU2="0.0" TOTAL_1="75" TOTAL_2="75" WEIGHT="74.39429141393617" Z="0.3743788938320955">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.3848277358572072" CI_START="-0.5048277358572073" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.13" ORDER="257" SD_1="0.71" SD_2="0.76" SE="0.22695709684767254" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="27.311671376723602"/>
<CONT_DATA CI_END="0.7765185034637754" CI_START="-0.7765185034637754" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.32" ORDER="258" SD_1="0.94" SD_2="1.0" SE="0.39619019001821165" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.96248367205713"/>
<CONT_DATA CI_END="0.4964855302332951" CI_START="-0.5364855302332951" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.3" ORDER="259" SD_1="0.67" SD_2="0.62" SE="0.26351786783189235" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="20.25889144928214"/>
<CONT_DATA CI_END="0.45006008906355444" CI_START="-0.6500600890635537" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="3.18" MEAN_2="3.28" ORDER="260" SD_1="1.02" SD_2="1.15" SE="0.2806480595573989" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="17.861244915873304"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.379406989497779" CI_START="-0.5394069894977791" DF="0" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" NO="2" P_CHI2="1.0" P_Z="0.7328752690526982" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="25.605708586063827" Z="0.3413032939150841">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.379406989497779" CI_START="-0.5394069894977791" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.9" ORDER="261" SD_1="0.76" SD_2="0.94" SE="0.23439562824701005" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="25.605708586063827"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1694630571026059" CI_END="0.19564306325318126" CI_START="-0.29357839328069596" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.04896766501375734" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.9994079985480161" P_Q="0.8604842746082199" P_Z="0.6947940664084812" Q="0.03089079910255791" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="0.39235752460231865">
<NAME>FVC (% predicted, litre measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.13857225800004797" CI_END="0.23673469085229804" CI_START="-0.31231930271421315" DF="4" EFFECT_SIZE="-0.03779230593095756" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="0.9977077590097393" P_Z="0.7873024232330711" STUDIES="5" TAU2="0.0" TOTAL_1="102" TOTAL_2="102" WEIGHT="79.39275691634647" Z="0.26981520719391117">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.5250791314948589" CI_START="-0.6851713795223211" EFFECT_SIZE="-0.0800461240137311" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.13" ORDER="262" SD_1="0.71" SD_2="0.76" SE="0.30874304848545214" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.34031570891284"/>
<CONT_DATA CI_END="0.8001519460592184" CI_START="-0.8001519460592184" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.32" ORDER="263" SD_1="0.94" SD_2="1.0" SE="0.408248290463863" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.345575914173732"/>
<CONT_DATA CI_END="0.5670715174207005" CI_START="-0.4998789261137759" EFFECT_SIZE="0.0335962956534623" ESTIMABLE="YES" MEAN_1="100.3" MEAN_2="99.7" ORDER="264" SD_1="17.7" SD_2="17.5" SE="0.27218623708150896" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.024346040941364"/>
<CONT_DATA CI_END="0.7702894361495003" CI_START="-0.8301215479451141" EFFECT_SIZE="-0.029916055897806874" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.3" ORDER="265" SD_1="0.67" SD_2="0.62" SE="0.4082756103475502" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.344325232045847"/>
<CONT_DATA CI_END="0.4155334451486638" CI_START="-0.5971457162719279" EFFECT_SIZE="-0.09080613556163204" ESTIMABLE="YES" MEAN_1="3.18" MEAN_2="3.28" ORDER="266" SD_1="1.02" SD_2="1.15" SE="0.25834126785197986" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.338194020272685"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4468245504170491" CI_START="-0.6308696587891889" DF="0" EFFECT_SIZE="-0.09202255418606992" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="1.0" P_Z="0.737839128985398" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="20.607243083653533" Z="0.3347162681757846">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.4468245504170491" CI_START="-0.6308696587891889" EFFECT_SIZE="-0.09202255418606992" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.9" ORDER="267" SD_1="0.76" SD_2="0.94" SE="0.27492704399339796" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="20.607243083653533"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.06.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.54956536803498" CI_START="-14.54956536803498" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7547702325074095" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.3123556756048751">
<NAME>Clinic PEFR (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.54956536803498" CI_START="-14.54956536803498" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" NO="1" P_CHI2="1.0" P_Z="0.7547702325074095" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.3123556756048751">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="10.54956536803498" CI_START="-14.54956536803498" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="101.0" MEAN_2="103.0" ORDER="268" SD_1="15.81" SD_2="12.65" SE="6.402957129327043" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.07.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.055663346708613" CI_START="-16.855663346708596" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6838006154706033" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.40728236372272963">
<NAME>Morning PEFR (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.055663346708613" CI_START="-16.855663346708596" DF="0" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" NO="1" P_CHI2="1.0" P_Z="0.6838006154706033" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.40728236372272963">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="11.055663346708613" CI_START="-16.855663346708596" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="90.3" ORDER="269" SD_1="30.8" SD_2="20.5" SE="7.120367239800882" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.08.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.08.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8715719751887616" CI_END="22.451465363550135" CI_START="-28.433338739199712" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.9909366878247905" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" NO="9" P_CHI2="0.9722454805748484" P_Q="0.9047598846842186" P_Z="0.8177748915452845" Q="0.014316281962368442" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.23040781198013163">
<NAME>Morning PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.8345470434507665" CI_END="29.903994025165275" CI_START="-33.56957889859343" DF="3" EFFECT_SIZE="-1.8327924367140762" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" NO="1" P_CHI2="0.8411872992151199" P_Z="0.9098819143069368" STUDIES="4" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="64.26733970000971" Z="0.11318748895423852">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="36.018603001961736" CI_START="-61.018603001961736" EFFECT_SIZE="-12.5" ESTIMABLE="YES" MEAN_1="262.5" MEAN_2="275.0" ORDER="270" SD_1="78.41" SD_2="81.98" SE="24.754844162785787" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="27.49790752099504"/>
<CONT_DATA CI_END="112.03206228931981" CI_START="-96.03206228931981" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="342.0" MEAN_2="334.0" ORDER="271" SD_1="132.0" SD_2="128.0" SE="53.078558131634786" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.981110235188557"/>
<CONT_DATA CI_END="74.83058027590448" CI_START="-38.830580275904474" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="409.0" MEAN_2="391.0" ORDER="272" SD_1="95.9" SD_2="100.7" SE="28.995726821603274" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="20.042506887030324"/>
<CONT_DATA CI_END="60.61370763725296" CI_START="-94.61370763725296" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="420.0" ORDER="273" SD_1="111.0" SD_2="113.0" SE="39.59955807834224" STUDY_ID="STD-Willey-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.745815056795786"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.022708649775626553" CI_END="37.48840523237557" CI_START="-47.636262857888894" DF="1" EFFECT_SIZE="-5.073928812756666" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" NO="2" P_CHI2="0.8802172031762012" P_Z="0.8152561899576225" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="35.732660299990286" Z="0.23365066686845617">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="48.198043120481216" CI_START="-53.998043120481285" EFFECT_SIZE="-2.900000000000034" ESTIMABLE="YES" MEAN_1="311.2" MEAN_2="314.1" ORDER="274" SD_1="94.0" SD_2="94.0" SE="26.07090922258577" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="24.79177864046996"/>
<CONT_DATA CI_END="66.9187027127066" CI_START="-86.9187027127066" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="245.0" MEAN_2="255.0" ORDER="275" SD_1="101.0" SD_2="91.0" SE="39.24495721320979" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.940881659520327"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.09.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9268989002760778" CI_END="0.19561703520801632" CI_START="-0.27850742819265384" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.041445196492318745" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" NO="10" P_CHI2="0.9882322147338779" P_Q="0.9548484993877824" P_Z="0.7318563276388479" Q="0.0032057439322826136" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="0.3426572502692579">
<NAME>Morning PEFR (% predicted, L/min measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9035686889780016" CI_END="0.24175759917700407" CI_START="-0.3161532476016225" DF="4" EFFECT_SIZE="-0.03719782421230921" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.01" NO="1" P_CHI2="0.9240483046126181" P_Z="0.7938187533628602" STUDIES="5" TAU2="0.0" TOTAL_1="99" TOTAL_2="99" WEIGHT="72.21960661758455" Z="0.26135500386966515">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.4529411466428519" CI_START="-0.7587236533009469" EFFECT_SIZE="-0.15289125332904752" ESTIMABLE="YES" MEAN_1="262.5" MEAN_2="275.0" ORDER="276" SD_1="78.41" SD_2="81.98" SE="0.3091038431066224" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="15.311570755696097"/>
<CONT_DATA CI_END="0.8597725089526191" CI_START="-0.740953678274078" EFFECT_SIZE="0.059409415339270556" ESTIMABLE="YES" MEAN_1="342.0" MEAN_2="334.0" ORDER="277" SD_1="132.0" SD_2="128.0" SE="0.4083560207873769" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.773050486718477"/>
<CONT_DATA CI_END="0.42462191669935034" CI_START="-0.6431053631410939" EFFECT_SIZE="-0.10924172322087175" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="90.3" ORDER="278" SD_1="30.8" SD_2="20.5" SE="0.2723844132500752" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="19.71805395647969"/>
<CONT_DATA CI_END="0.759159534083772" CI_START="-0.39931908562118923" EFFECT_SIZE="0.17992022423129142" ESTIMABLE="YES" MEAN_1="409.0" MEAN_2="391.0" ORDER="279" SD_1="95.9" SD_2="100.7" SE="0.2955356906664849" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="16.74976361060688"/>
<CONT_DATA CI_END="0.5460789553008351" CI_START="-0.8419855281374223" EFFECT_SIZE="-0.1479532864182936" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="420.0" ORDER="280" SD_1="111.0" SD_2="113.0" SE="0.35410458926468363" STUDY_ID="STD-Willey-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="11.667167808083406"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.02012446736579361" CI_END="0.39728585965216495" CI_START="-0.5022597091954043" DF="1" EFFECT_SIZE="-0.05248692477161969" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" NO="2" P_CHI2="0.8871900203682035" P_Z="0.8190857698916667" STUDIES="2" TAU2="0.0" TOTAL_1="38" TOTAL_2="38" WEIGHT="27.780393382415454" Z="0.22872100263565381">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.5132441707512481" CI_START="-0.5740161155817844" EFFECT_SIZE="-0.03038597241526819" ESTIMABLE="YES" MEAN_1="311.2" MEAN_2="314.1" ORDER="281" SD_1="94.0" SD_2="94.0" SE="0.2773674146334328" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="19.0159347334325"/>
<CONT_DATA CI_END="0.7003167208979918" CI_START="-0.901193873631292" EFFECT_SIZE="-0.10043857636665006" ESTIMABLE="YES" MEAN_1="245.0" MEAN_2="255.0" ORDER="282" SD_1="101.0" SD_2="91.0" SE="0.4085561283681218" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.764458648982954"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.10.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2616654632517526" CI_END="20.55803558738905" CI_START="-31.5023410849251" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.472152748768026" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" NO="11" P_CHI2="0.9921525201320759" P_Q="0.9823230650941649" P_Z="0.6803173284578172" Q="4.909133934312623E-4" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="106" UNITS="" WEIGHT="99.99999999999999" Z="0.4120301461895067">
<NAME>Evening PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.19667977992456565" CI_END="29.24659069205665" CI_START="-40.719310481269325" DF="2" EFFECT_SIZE="-5.736359894606337" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.01" NO="1" P_CHI2="0.9063408658752372" P_Z="0.7479172800991429" STUDIES="3" TAU2="0.0" TOTAL_1="63" TOTAL_2="63" WEIGHT="55.365821405614525" Z="0.3213868072087305">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="36.010965933859396" CI_START="-58.010965933859396" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="269.1" MEAN_2="280.1" ORDER="283" SD_1="77.12" SD_2="78.32" SE="23.985627442481544" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="30.65887899063473"/>
<CONT_DATA CI_END="70.04045642256422" CI_START="-86.04045642256422" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="252.0" MEAN_2="260.0" ORDER="284" SD_1="100.0" SD_2="95.0" SE="39.8172910513343" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.125384241622541"/>
<CONT_DATA CI_END="78.63216385213936" CI_START="-62.63216385213936" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="360.0" MEAN_2="352.0" ORDER="285" SD_1="135.0" SD_2="144.0" SE="36.0374804890686" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.581558173357259"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.06449476993375573" CI_END="33.817785072029366" CI_START="-44.10662670258115" DF="1" EFFECT_SIZE="-5.144420815275894" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.02" NO="2" P_CHI2="0.7995278508370064" P_Z="0.7958002397198018" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="43" WEIGHT="44.63417859438546" Z="0.25878615672897926">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="44.41438707827466" CI_START="-48.21438707827461" EFFECT_SIZE="-1.8999999999999773" ESTIMABLE="YES" MEAN_1="334.0" MEAN_2="335.9" ORDER="286" SD_1="86.0" SD_2="86.0" SE="23.63022353655302" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="31.58804723363171"/>
<CONT_DATA CI_END="59.066998866183255" CI_START="-85.06699886618325" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="437.0" MEAN_2="450.0" ORDER="287" SD_1="104.0" SD_2="104.0" SE="36.76955262170047" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="13.046131360753751"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.11.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00226675544217059" CI_END="0.7173320664566347" CI_START="-0.198318764087475" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.25950665118457983" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.12" NO="12" P_CHI2="0.9620267124559633" P_Q="0.9620267124559633" P_Z="0.26658749674469784" Q="0.00226675544217059" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.110955558830508">
<NAME>Daytime breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8770945569247939" CI_START="-0.3386537160245399" DF="0" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.01" NO="1" P_CHI2="1.0" P_Z="0.38536950642836487" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.72473357270164" Z="0.8680453671628945">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.8770945569247939" CI_START="-0.3386537160245399" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.05" ORDER="288" SD_1="0.16" SD_2="0.13" SE="0.31014556454582864" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.72473357270164"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9427271302557353" CI_START="-0.44917922736600147" DF="0" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.02" NO="2" P_CHI2="1.0" P_Z="0.48707277771717894" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.27526642729837" Z="0.6949721215168363">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.9427271302557353" CI_START="-0.44917922736600147" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.6" ORDER="289" SD_1="0.57" SD_2="0.45" SE="0.35508467721879494" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.27526642729837"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.12.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.17405040162197355" CI_START="-0.8456770201530461" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.19673908505295346" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.290897896114194">
<NAME>Morning breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17405040162197355" CI_START="-0.8456770201530461" DF="0" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" I2="0.0" ID="CMP-003.13.01" NO="1" P_CHI2="1.0" P_Z="0.19673908505295346" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.290897896114194">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.17405040162197355" CI_START="-0.8456770201530461" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.45" ORDER="290" SD_1="5.57" SD_2="8.92" SE="0.26013932649234867" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.13.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.13.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9911969708362657" CI_START="-0.40321836928808474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.14" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.40854793264034206" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.8264516672714545">
<NAME>Daytime wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.14.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9911969708362657" CI_START="-0.40321836928808474" DF="0" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" I2="0.0" ID="CMP-003.14.02" NO="2" P_CHI2="1.0" P_Z="0.40854793264034206" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.8264516672714545">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.9911969708362657" CI_START="-0.40321836928808474" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.39" ORDER="291" SD_1="0.4" SD_2="0.46" SE="0.35572473553680595" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.14.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3579832708223656" CI_START="-0.6556362545280283" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.15" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.5649191146091266" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.5755504046277298">
<NAME>Morning wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3579832708223656" CI_START="-0.6556362545280283" DF="0" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" I2="0.0" ID="CMP-003.15.01" NO="1" P_CHI2="1.0" P_Z="0.5649191146091266" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5755504046277298">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.3579832708223656" CI_START="-0.6556362545280283" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" MEAN_1="5.24" MEAN_2="6.33" ORDER="292" SD_1="6.39" SD_2="7.98" SE="0.25858116101767564" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.15.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.15.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0891445159283726" CI_START="-0.3116095894195764" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.2766203423573744" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.0879428779547926">
<NAME>Daytime cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.16.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0891445159283726" CI_START="-0.3116095894195764" DF="0" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" I2="0.0" ID="CMP-003.16.02" NO="2" P_CHI2="1.0" P_Z="0.2766203423573744" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.0879428779547926">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="1.0891445159283726" CI_START="-0.3116095894195764" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.17" ORDER="293" SD_1="0.35" SD_2="0.3" SE="0.357341797195489" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.16.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3990686503627424" CI_START="-0.6138327802336648" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.17" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.677725759009032" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.4155685311553392">
<NAME>Morning cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3990686503627424" CI_START="-0.6138327802336648" DF="0" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" I2="0.0" ID="CMP-003.17.01" NO="1" P_CHI2="1.0" P_Z="0.677725759009032" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.4155685311553392">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.3990686503627424" CI_START="-0.6138327802336648" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.26" ORDER="294" SD_1="6.19" SD_2="6.31" SE="0.2583979702142602" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.17.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.17.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5308269961716794" CI_END="0.38871459506829464" CI_START="-0.224316425068525" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08219908499988482" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.18" NO="18" P_CHI2="0.9704314250068655" P_Q="1.0" P_Z="0.5991600507701369" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="82" UNITS="" WEIGHT="100.0" Z="0.5256087893430387">
<NAME>Daily asthma symptom score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5308269961716794" CI_END="0.38871459506829464" CI_START="-0.224316425068525" DF="4" EFFECT_SIZE="0.08219908499988482" ESTIMABLE="YES" I2="0.0" ID="CMP-003.18.01" NO="1" P_CHI2="0.9704314250068655" P_Z="0.5991600507701369" STUDIES="5" TAU2="0.0" TOTAL_1="82" TOTAL_2="82" WEIGHT="100.0" Z="0.5256087893430387">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.5208850012881223" CI_START="-0.6894233789352231" EFFECT_SIZE="-0.0842691888235504" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.16" ORDER="295" SD_1="0.26" SD_2="0.42" SE="0.30875781130931573" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="25.655047382611066"/>
<CONT_DATA CI_END="0.8211232032108191" CI_START="-0.7792331837699751" EFFECT_SIZE="0.020945009720421993" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.4" ORDER="296" SD_1="5.5" SD_2="3.5" SE="0.4082616822564601" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.673424673924533"/>
<CONT_DATA CI_END="0.7324361272958737" CI_START="-0.33723788094754537" EFFECT_SIZE="0.19759912317416417" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="13.6" ORDER="297" SD_1="19.3" SD_2="16.5" SE="0.2728810367641628" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="32.84445165380738"/>
<CONT_DATA CI_END="0.9626193421086242" CI_START="-0.6407802616488538" EFFECT_SIZE="0.16091954022988514" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" ORDER="298" SD_1="0.6" SD_2="0.6" SE="0.40903802733236155" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.617777865113872"/>
<CONT_DATA CI_END="0.9781387758422925" CI_START="-0.7762954715486697" EFFECT_SIZE="0.10092165214681133" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="299" SD_1="9.49" SD_2="9.49" SE="0.4475679811541731" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.209298424543144"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.18.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.18.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.378663250509389" CI_END="0.3095516630986409" CI_START="-0.18235646960046192" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06359759674908948" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.19" NO="19" P_CHI2="0.7600367645332653" P_Q="0.5813240554227925" P_Z="0.6122966467186456" Q="0.30409915368012025" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="128" UNITS="" WEIGHT="100.0" Z="0.5067978788948547">
<NAME>Symptoms (daytime breathlessness, morning breathlessness, daily symptom scores combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.0745640968292687" CI_END="0.3003747719426143" CI_START="-0.22546584435931596" DF="5" EFFECT_SIZE="0.03745446379164916" ESTIMABLE="YES" I2="0.0" ID="CMP-003.19.01" NO="1" P_CHI2="0.6884913029339162" P_Z="0.7800853604864987" STUDIES="6" TAU2="0.0" TOTAL_1="112" TOTAL_2="112" WEIGHT="87.5104161344251" Z="0.2792077972529275">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.8770945569247939" CI_START="-0.3386537160245399" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.05" ORDER="300" SD_1="0.16" SD_2="0.13" SE="0.31014556454582864" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.37120636562371"/>
<CONT_DATA CI_END="0.8211232032108191" CI_START="-0.7792331837699751" EFFECT_SIZE="0.020945009720421993" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.4" ORDER="301" SD_1="5.5" SD_2="3.5" SE="0.4082616822564601" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.447884832608928"/>
<CONT_DATA CI_END="0.7324361272958737" CI_START="-0.33723788094754537" EFFECT_SIZE="0.19759912317416417" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="13.6" ORDER="302" SD_1="19.3" SD_2="16.5" SE="0.2728810367641628" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.14779634005977"/>
<CONT_DATA CI_END="0.9626193421086242" CI_START="-0.6407802616488538" EFFECT_SIZE="0.16091954022988514" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" ORDER="303" SD_1="0.6" SD_2="0.6" SE="0.40903802733236155" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.412055116463685"/>
<CONT_DATA CI_END="0.9781387758422925" CI_START="-0.7762954715486697" EFFECT_SIZE="0.10092165214681133" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="304" SD_1="9.49" SD_2="9.49" SE="0.4475679811541731" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.861289914618505"/>
<CONT_DATA CI_END="0.17405040162197355" CI_START="-0.8456770201530461" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.45" ORDER="305" SD_1="5.57" SD_2="8.92" SE="0.26013932649234867" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.270183565050502"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9427271302557353" CI_START="-0.44917922736600147" DF="0" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" I2="0.0" ID="CMP-003.19.02" NO="2" P_CHI2="1.0" P_Z="0.48707277771717894" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="12.489583865574897" Z="0.6949721215168363">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.9427271302557353" CI_START="-0.44917922736600147" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.6" ORDER="306" SD_1="0.57" SD_2="0.45" SE="0.35508467721879494" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="12.489583865574897"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.19.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03344131276092331" CI_END="0.5736764323858248" CI_START="-0.3386737894998658" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1175013214429795" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.20" NO="20" P_CHI2="0.8549003400847557" P_Q="0.8549003400847557" P_Z="0.613666731871884" Q="0.03344131276092331" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="0.5048463904313232">
<NAME>Night-time breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.760557061729863" CI_START="-0.4511541195732166" DF="0" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" I2="0.0" ID="CMP-003.20.01" NO="1" P_CHI2="1.0" P_Z="0.6167479365872593" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.692411806516056" Z="0.5004646591489">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.760557061729863" CI_START="-0.4511541195732166" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.08" ORDER="307" SD_1="0.18" SD_2="0.2" SE="0.30911567530345013" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.692411806516056"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7619896261535924" CI_START="-0.6243817489594453" DF="0" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" I2="0.0" ID="CMP-003.20.02" NO="2" P_CHI2="1.0" P_Z="0.8457520643384093" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.307588193483944" Z="0.19454129545018084">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.7619896261535924" CI_START="-0.6243817489594453" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.58" ORDER="308" SD_1="0.42" SD_2="0.43" SE="0.35367266593890456" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.307588193483944"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.20.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.16332643328615065" CI_START="-0.8569043141133812" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.21" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.18271841051851442" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.332431580169419">
<NAME>Evening breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16332643328615065" CI_START="-0.8569043141133812" DF="0" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" I2="0.0" ID="CMP-003.21.01" NO="1" P_CHI2="1.0" P_Z="0.18271841051851442" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.332431580169419">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.16332643328615065" CI_START="-0.8569043141133812" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="6.52" ORDER="309" SD_1="4.63" SD_2="9.07" SE="0.2602677282457692" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.21.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.21.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8546760593433423" CI_START="-0.5337686038575246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.22" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.6505479013544908" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.45300116871247653">
<NAME>Night-time wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.22.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8546760593433423" CI_START="-0.5337686038575246" DF="0" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" I2="0.0" ID="CMP-003.22.02" NO="2" P_CHI2="1.0" P_Z="0.6505479013544908" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.45300116871247653">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.8546760593433423" CI_START="-0.5337686038575246" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="0.39" ORDER="310" SD_1="0.41" SD_2="0.44" SE="0.35420157568015054" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.22.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.28187277833707003" CI_START="-0.7336977352773082" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.23" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.383217435467999" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.8719834133107602">
<NAME>Evening wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.28187277833707003" CI_START="-0.7336977352773082" DF="0" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" I2="0.0" ID="CMP-003.23.01" NO="1" P_CHI2="1.0" P_Z="0.383217435467999" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.8719834133107602">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.28187277833707003" CI_START="-0.7336977352773082" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" MEAN_1="4.46" MEAN_2="5.99" ORDER="311" SD_1="4.94" SD_2="8.06" SE="0.2590788712509691" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.23.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.23.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1308638814016656" CI_START="-0.27309251807994506" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.24" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.2311219624267815" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.1974737817364924">
<NAME>Night-time cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.24.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1308638814016656" CI_START="-0.27309251807994506" DF="0" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" I2="0.0" ID="CMP-003.24.02" NO="2" P_CHI2="1.0" P_Z="0.2311219624267815" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.1974737817364924">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="1.1308638814016656" CI_START="-0.27309251807994506" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.11" ORDER="312" SD_1="0.36" SD_2="0.27" SE="0.35815872397550147" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.24.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3188557117127877" CI_START="-0.6956657222978688" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.25" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.4666362517433257" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7279629833361982">
<NAME>Evening cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3188557117127877" CI_START="-0.6956657222978688" DF="0" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" I2="0.0" ID="CMP-003.25.01" NO="1" P_CHI2="1.0" P_Z="0.4666362517433257" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7279629833361982">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.3188557117127877" CI_START="-0.6956657222978688" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.1" ORDER="313" SD_1="4.36" SD_2="5.99" SE="0.2588112439853671" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.25.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.25.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8016711824146951" CI_END="0.25123460905651" CI_START="-0.4288480322372657" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08880671159037785" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.26" NO="26" P_CHI2="0.40623011848790624" P_Q="0.6090719353245169" P_Z="0.6087399277991502" Q="0.26152864892886596" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="0.5118729570025549">
<NAME>Symptoms (night-time breathlessness, evening breathlessness scores combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.5401425334858287" CI_END="0.2514652345904882" CI_START="-0.5289707044985341" DF="1" EFFECT_SIZE="-0.13875273495402296" ESTIMABLE="YES" I2="35.07094452247323" ID="CMP-003.26.01" NO="1" P_CHI2="0.21459704858269002" P_Z="0.48585341734332343" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="75.93619973325053" Z="0.6969191182655063">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.760557061729863" CI_START="-0.4511541195732166" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.08" ORDER="314" SD_1="0.18" SD_2="0.2" SE="0.30911567530345013" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="31.50105861950481"/>
<CONT_DATA CI_END="0.16332643328615065" CI_START="-0.8569043141133812" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="6.52" ORDER="315" SD_1="4.63" SD_2="9.07" SE="0.2602677282457692" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="44.435141113745715"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7619896261535924" CI_START="-0.6243817489594453" DF="0" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" I2="0.0" ID="CMP-003.26.02" NO="2" P_CHI2="1.0" P_Z="0.8457520643384093" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.063800266749475" Z="0.19454129545018084">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.7619896261535924" CI_START="-0.6243817489594453" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.58" ORDER="316" SD_1="0.42" SD_2="0.43" SE="0.35367266593890456" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.063800266749475"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.26.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1790448498493285E-32" CI_END="1.0902109514859657" CI_START="-0.1302109514859658" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4799999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.27" NO="27" P_CHI2="0.0" P_Q="1.0" P_Z="0.12313834915680578" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.5417335763775835">
<NAME>Daytime use of rescue beta2 agonists (puffs/day)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.27.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.1790448498493285E-32" CI_END="1.0902109514859657" CI_START="-0.1302109514859658" DF="0" EFFECT_SIZE="0.4799999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-003.27.02" NO="2" P_CHI2="0.0" P_Z="0.12313834915680578" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.5417335763775835">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="1.0902109514859657" CI_START="-0.13021095148596573" EFFECT_SIZE="0.48" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.41" ORDER="317" SD_1="0.7" SD_2="1.03" SE="0.3113378390109368" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.27.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.522391440304596E-33" CI_END="0.44157934397716114" CI_START="-0.6415793439771609" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999988" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.28" NO="28" P_CHI2="0.0" P_Q="1.0" P_Z="0.7174283697728059" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.36189784679504056">
<NAME>Morning use of rescue beta2 agonists (puffs)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.522391440304596E-33" CI_END="0.44157934397716114" CI_START="-0.6415793439771609" DF="0" EFFECT_SIZE="-0.09999999999999988" ESTIMABLE="YES" I2="100.0" ID="CMP-003.28.01" NO="1" P_CHI2="0.0" P_Z="0.7174283697728059" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.36189784679504056">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="0.44157934397716114" CI_START="-0.6415793439771609" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.44" ORDER="318" SD_1="1.09" SD_2="1.05" SE="0.27632106928957356" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.28.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.28.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.41510445046283745" CI_START="-0.5151044504628375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.29" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.8331202144951171" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.21070148679394954">
<NAME>Night-time use of rescue beta2 agonists (puffs/night)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.29.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.41510445046283745" CI_START="-0.5151044504628375" DF="0" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.29.02" NO="2" P_CHI2="1.0" P_Z="0.8331202144951171" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.21070148679394954">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.41510445046283745" CI_START="-0.5151044504628375" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="0.42" ORDER="319" SD_1="0.71" SD_2="0.63" SE="0.23730254950168572" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.29.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.651141403435223" CI_START="-3.651141403435222" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.30" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.45973054673146974" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7392906247853945">
<NAME>Evening use of rescue beta2 agonists (puffs)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.651141403435223" CI_START="-3.651141403435222" DF="0" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.30.01" NO="1" P_CHI2="1.0" P_Z="0.45973054673146974" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7392906247853945">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="1.651141403435223" CI_START="-3.651141403435222" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.1" ORDER="320" SD_1="4.36" SD_2="5.99" SE="1.3526480202427633" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.30.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.30.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8074648429450684" CI_START="0.052535157054931614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.43" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.31" NO="31" P_CHI2="1.0" P_Q="1.0" P_Z="0.025565455250602106" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="2.2327496960422137">
<NAME>Histamine BHR (log 10 PC20 FEV1)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.31.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8074648429450684" CI_START="0.052535157054931614" DF="0" EFFECT_SIZE="0.43" ESTIMABLE="YES" I2="0.0" ID="CMP-003.31.02" NO="2" P_CHI2="1.0" P_Z="0.025565455250602106" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.2327496960422137">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.8074648429450684" CI_START="0.052535157054931614" EFFECT_SIZE="0.43" ESTIMABLE="YES" MEAN_1="0.63" MEAN_2="0.2" ORDER="321" SD_1="0.3" SD_2="0.53" SE="0.1925876423865249" STUDY_ID="STD-Tjwa-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.31.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.15431352904180887" CI_END="64.41195001164964" CI_START="-15.777178294337286" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="24.317385858656177" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.32" NO="32" P_CHI2="0.9257447396728291" P_Q="0.9279760770985113" P_Z="0.23454998542644578" Q="0.00817063108372957" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="59" UNITS="" WEIGHT="100.0" Z="1.1887197551085322">
<NAME>Morning plasma cortisol (nmol/L)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1461428979580793" CI_END="81.85919810915303" CI_START="-37.28863390769263" DF="1" EFFECT_SIZE="22.2852821007302" ESTIMABLE="YES" I2="0.0" ID="CMP-003.32.01" NO="1" P_CHI2="0.7022490738072722" P_Z="0.46344920459464856" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="33" WEIGHT="45.295879444158516" Z="0.7331791030250701">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="82.67823652570421" CI_START="-49.078236525704185" EFFECT_SIZE="16.80000000000001" ESTIMABLE="YES" MEAN_1="379.2" MEAN_2="362.4" ORDER="322" SD_1="106.32" SD_2="111.45" SE="33.61196279387954" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="37.041371910873615"/>
<CONT_DATA CI_END="186.4532364039645" CI_START="-92.65323640396454" EFFECT_SIZE="46.89999999999998" ESTIMABLE="YES" MEAN_1="411.09" MEAN_2="364.19" ORDER="323" SD_1="200.71" SD_2="143.36" SE="71.2019391706902" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.254507533284904"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="80.20950935965377" CI_START="-28.209509359653758" DF="0" EFFECT_SIZE="26.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.32.02" NO="2" P_CHI2="1.0" P_Z="0.34719746702401943" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="54.70412055584148" Z="0.940039196074489">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="80.20950935965377" CI_START="-28.209509359653758" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="248.0" MEAN_2="222.0" ORDER="324" SD_1="91.78" SD_2="107.08" SE="27.658421168578325" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="54.70412055584148"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.32.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04467975828947206" CI_END="78.48186693091708" CI_START="-24.792385968687903" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="26.844740481114584" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.33" NO="33" P_CHI2="0.8325941253445903" P_Q="0.8325941253445903" P_Z="0.30823522790388447" Q="0.044679758289472064" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.0189320772614427">
<NAME>Plasma cortisol 30 min post 250 mcg tetracosactrin (nmol/L)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="254.21507698208373" CI_START="-254.21507698208373" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.33.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.125926853162209" Z="0.0">
<NAME>1-4 weeks</NAME>
<CONT_DATA CI_END="254.21507698208373" CI_START="-254.21507698208373" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="722.86" MEAN_2="722.86" ORDER="325" SD_1="277.17" SD_2="353.63" SE="129.70395322939595" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.125926853162209"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7433863618945116E-32" CI_END="80.73652109489397" CI_START="-24.736521094893963" DF="0" EFFECT_SIZE="28.000000000000004" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-003.33.02" NO="2" P_CHI2="0.0" P_Z="0.29804920464196094" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="95.87407314683779" Z="1.0406259348881282">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="80.73652109489396" CI_START="-24.736521094893966" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="495.0" MEAN_2="467.0" ORDER="326" SD_1="101.98" SD_2="91.78" SE="26.906882734005784" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="95.87407314683779"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.33.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-12-08 11:44:12 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>BDP v BUD crossover design studies, no OCS: all delivery devices</NAME>
<CONT_OUTCOME CHI2="6.615157052096611E-4" CI_END="1.8945713293020514" CI_START="-11.977410944268055" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.041419807483002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="0.9794807138235786" P_Q="0.9794807138235786" P_Z="0.15427334876128318" Q="6.615157052096611E-4" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.4245983102846849">
<NAME>FEV1 (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.1483751749924487" CI_START="-13.348375174992437" DF="0" EFFECT_SIZE="-5.099999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="1.0" P_Z="0.22556876572663453" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="70.7099037415022" Z="1.2118527721022854">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="3.1483751749924487" CI_START="-13.348375174992437" EFFECT_SIZE="-5.099999999999994" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="90.0" ORDER="327" SD_1="9.49" SD_2="9.33" SE="4.208432012044391" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="70.7099037415022"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.91587108032922" CI_START="-17.71587108032923" DF="0" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.02" NO="2" P_CHI2="1.0" P_Z="0.4536345056372598" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="29.290096258497798" Z="0.7493695484333449">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="7.91587108032922" CI_START="-17.71587108032923" EFFECT_SIZE="-4.900000000000006" ESTIMABLE="YES" MEAN_1="78.5" MEAN_2="83.4" ORDER="328" SD_1="25.1" SD_2="22.9" SE="6.538829887395473" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="29.290096258497798"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.32035202110659733" CI_END="0.11049175691108089" CI_START="-0.2669409068780454" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07822457498348225" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2014-12-08 11:43:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9972427003501628" P_Q="0.8668716539419192" P_Z="0.41654938262734487" Q="0.28572871976639747" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="114" UNITS="" WEIGHT="100.0" Z="0.8124222643286506">
<NAME>FEV1 (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.029699969693908708" CI_END="0.3703635703328296" CI_START="-0.36679654336040796" DF="1" EFFECT_SIZE="0.0017835134862107993" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" NO="1" P_CHI2="0.8631727955356341" P_Z="0.992432956910756" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="26.21532871176451" Z="0.009484024254652803">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="0.7107191406452886" CI_START="-0.6107191406452881" EFFECT_SIZE="0.050000000000000266" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.05" ORDER="329" SD_1="0.86" SD_2="0.79" SE="0.33710779680491915" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.158028093402422"/>
<CONT_DATA CI_END="0.4241023511374425" CI_START="-0.4641023511374425" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="1.83" ORDER="330" SD_1="0.56" SD_2="0.55" SE="0.22658699580220104" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="18.05730061836209"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.004923331646291302" CI_END="0.13010193715203455" CI_START="-0.3295600765338295" DF="2" EFFECT_SIZE="-0.09972906969089747" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" MODIFIED="2014-12-08 11:43:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9975413615930232" P_Z="0.39506140280218427" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="67.42201592022126" Z="0.8504743876418139">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.29715638268182376" CI_START="-0.4771563826818235" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.63" ORDER="331" SD_1="0.65" SD_2="0.63" SE="0.19753239637853742" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="23.75998302929283"/>
<CONT_DATA CI_END="0.2929557302198247" CI_START="-0.5129557302198249" EFFECT_SIZE="-0.1100000000000001" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="1.87" ORDER="332" SD_1="0.66" SD_2="0.83" SE="0.20559343610305503" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="21.933316267934515"/>
<CONT_DATA CI_END="0.3048484198021312" CI_START="-0.5048484198021314" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.1" MODIFIED="2014-12-08 11:43:40 +0000" MODIFIED_BY="[Empty name]" ORDER="333" SD_1="0.8" SD_2="0.8" SE="0.2065591117977289" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="21.72871662299391"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5681527667074239" CI_START="-0.9281527667074242" DF="0" EFFECT_SIZE="-0.18000000000000016" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.03" NO="3" P_CHI2="1.0" P_Z="0.6372460394196318" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.362655368014232" Z="0.47155278028287384">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.5681527667074239" CI_START="-0.9281527667074242" EFFECT_SIZE="-0.18000000000000016" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.74" ORDER="334" SD_1="0.93" SD_2="0.94" SE="0.3817176094095389" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="6.362655368014232"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0478923127341309" CI_END="0.09634782380831919" CI_START="-0.40296501678073987" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.15330859648621034" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2014-12-08 11:44:12 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9837314455155409" P_Q="0.9953152601319093" P_Z="0.2287553006438643" Q="0.009391495349432356" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="124" UNITS="" WEIGHT="100.0" Z="1.2035714013637977">
<NAME>FEV1 (% predicted, litre measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9921111685657396" CI_END="0.3383966782503514" CI_START="-0.6181218202955747" DF="2" EFFECT_SIZE="-0.13986257102261163" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" NO="1" P_CHI2="0.6089278518996661" P_Z="0.5665271230325696" STUDIES="3" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="27.24951159040348" Z="0.5731736550965039">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="0.8588200331972844" CI_START="-0.7418928167571992" EFFECT_SIZE="0.05846360822004261" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.05" ORDER="335" SD_1="0.86" SD_2="0.79" SE="0.40835261835949593" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.730129196250868"/>
<CONT_DATA CI_END="0.7654323660710078" CI_START="-0.8350163705388689" EFFECT_SIZE="-0.03479200223393048" ESTIMABLE="YES" MEAN_1="1.81" MEAN_2="1.83" ORDER="336" SD_1="0.56" SD_2="0.55" SE="0.40828524126821003" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.733340881763116"/>
<CONT_DATA CI_END="0.3756568638206944" CI_START="-1.4137717485850576" EFFECT_SIZE="-0.5190574423821815" ESTIMABLE="YES" MEAN_1="84.9" MEAN_2="90.0" ORDER="337" SD_1="9.49" SD_2="9.33" SE="0.45649527912771265" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.786041512389497"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0463896488189588" CI_END="0.16025679326016512" CI_START="-0.4684918597472704" DF="2" EFFECT_SIZE="-0.15411753324355265" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.02" MODIFIED="2014-12-08 11:44:12 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9770721195710448" P_Z="0.33663041676728467" STUDIES="3" TAU2="0.0" TOTAL_1="78" TOTAL_2="78" WEIGHT="63.06542606920583" Z="0.9608444108744533">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.4676965784296662" CI_START="-0.7436062963260321" EFFECT_SIZE="-0.137954858948183" ESTIMABLE="YES" MEAN_1="1.54" MEAN_2="1.63" ORDER="338" SD_1="0.65" SD_2="0.63" SE="0.309011513555938" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.991822928005917"/>
<CONT_DATA CI_END="0.3338888548529608" CI_START="-0.7358823026018328" EFFECT_SIZE="-0.200996723874436" ESTIMABLE="YES" MEAN_1="78.5" MEAN_2="83.4" ORDER="339" SD_1="25.1" SD_2="22.9" SE="0.2729058201816493" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.785307803432943"/>
<CONT_DATA CI_END="0.38319892299515645" CI_START="-0.6299521697484034" EFFECT_SIZE="-0.12337662337662349" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.1" MODIFIED="2014-12-08 11:44:12 +0000" MODIFIED_BY="[Empty name]" ORDER="340" SD_1="0.8" SD_2="0.8" SE="0.25846166070784116" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="24.28829533776697"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.598472581724109E-33" CI_END="0.6163440671201013" CI_START="-0.9880887057125851" DF="0" EFFECT_SIZE="-0.18587231929624196" ESTIMABLE="YES" I2="100.0" ID="CMP-004.03.03" NO="3" P_CHI2="0.0" P_Z="0.649741970407571" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.685062340390692" Z="0.45412068079408885">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.6163440671201013" CI_START="-0.9880887057125851" EFFECT_SIZE="-0.18587231929624193" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.74" ORDER="341" SD_1="0.93" SD_2="0.94" SE="0.4093015957150864" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.685062340390692"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.98860104313428" CI_START="-8.78860104313429" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9003209033914635" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.1252559764038534">
<NAME>FVC (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.98860104313428" CI_START="-8.78860104313429" DF="0" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.02" NO="2" P_CHI2="1.0" P_Z="0.9003209033914635" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.1252559764038534">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="9.98860104313428" CI_START="-8.78860104313429" EFFECT_SIZE="0.5999999999999943" ESTIMABLE="YES" MEAN_1="100.3" MEAN_2="99.7" ORDER="342" SD_1="17.7" SD_2="17.5" SE="4.790190593903955" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.073465239932124" CI_END="0.17368491571443306" CI_START="-0.2912541015156629" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.058784592900614926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" NO="5" P_CHI2="0.9993416534254264" P_Q="0.8077438007328954" P_Z="0.6201651302934728" Q="0.059213238291473846" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="102" UNITS="" WEIGHT="100.0" Z="0.49561633100813546">
<NAME>FVC (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0017667194228716584" CI_END="0.41618095002245653" CI_START="-0.4439125558967986" DF="1" EFFECT_SIZE="-0.013865802937171049" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.01" NO="1" P_CHI2="0.9664729070417526" P_Z="0.9496118376190603" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="29.22137512133927" Z="0.0631942322237142">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="0.7765185034637754" CI_START="-0.7765185034637754" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.32" ORDER="343" SD_1="0.94" SD_2="1.0" SE="0.39619019001821165" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.96248367205713"/>
<CONT_DATA CI_END="0.4964855302332951" CI_START="-0.5364855302332951" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.3" ORDER="344" SD_1="0.67" SD_2="0.62" SE="0.26351786783189235" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="20.25889144928214"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.012485282217778513" CI_END="0.19899208331749174" CI_START="-0.35365124688442917" DF="2" EFFECT_SIZE="-0.07732958178346873" ESTIMABLE="YES" I2="0.0" ID="CMP-004.05.02" NO="2" P_CHI2="0.9937768037547375" P_Z="0.5833467388865028" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="70.77862487866074" Z="0.5485027573924263">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.3848277358572072" CI_START="-0.5048277358572073" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.13" ORDER="345" SD_1="0.71" SD_2="0.76" SE="0.22695709684767254" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="27.311671376723602"/>
<CONT_DATA CI_END="0.379406989497779" CI_START="-0.5394069894977791" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.9" ORDER="346" SD_1="0.76" SD_2="0.94" SE="0.23439562824701005" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="25.605708586063827"/>
<CONT_DATA CI_END="0.45006008906355444" CI_START="-0.6500600890635537" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="3.18" MEAN_2="3.28" ORDER="347" SD_1="1.02" SD_2="1.15" SE="0.2806480595573989" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="17.861244915873304"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.05.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.16946305710260584" CI_END="0.19564306325318126" CI_START="-0.29357839328069596" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.048967665013757336" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" NO="6" P_CHI2="0.9994079985480161" P_Q="0.8960499996717535" P_Z="0.6947940664084813" Q="0.01707014673266634" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="0.3923575246023186">
<NAME>FVC (% predicted, litre measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0026847315338008413" CI_END="0.5508547704590635" CI_START="-0.5807688244481307" DF="1" EFFECT_SIZE="-0.0149570269945336" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.01" NO="1" P_CHI2="0.958676605219223" P_Z="0.9586793480657766" STUDIES="2" TAU2="0.0" TOTAL_1="24" TOTAL_2="24" WEIGHT="18.68990114621958" Z="0.05181092786861413">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="0.8001519460592184" CI_START="-0.8001519460592184" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="3.32" MEAN_2="3.32" ORDER="348" SD_1="0.94" SD_2="1.0" SE="0.408248290463863" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.345575914173732"/>
<CONT_DATA CI_END="0.7702894361495003" CI_START="-0.8301215479451141" EFFECT_SIZE="-0.029916055897806874" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.3" ORDER="349" SD_1="0.67" SD_2="0.62" SE="0.4082756103475502" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.344325232045847"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1497081788361387" CI_END="0.2144855955854574" CI_START="-0.3280562641861608" DF="3" EFFECT_SIZE="-0.05678533430035169" ESTIMABLE="YES" I2="0.0" ID="CMP-004.06.02" NO="2" P_CHI2="0.985267874195629" P_Z="0.6816000949779637" STUDIES="4" TAU2="0.0" TOTAL_1="104" TOTAL_2="105" WEIGHT="81.31009885378042" Z="0.41028063761054906">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.5250791314948589" CI_START="-0.6851713795223211" EFFECT_SIZE="-0.0800461240137311" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.13" ORDER="350" SD_1="0.71" SD_2="0.76" SE="0.30874304848545214" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.34031570891284"/>
<CONT_DATA CI_END="0.4468245504170491" CI_START="-0.6308696587891889" EFFECT_SIZE="-0.09202255418606992" ESTIMABLE="YES" MEAN_1="2.82" MEAN_2="2.9" ORDER="351" SD_1="0.76" SD_2="0.94" SE="0.27492704399339796" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="20.607243083653533"/>
<CONT_DATA CI_END="0.5670715174207005" CI_START="-0.4998789261137759" EFFECT_SIZE="0.0335962956534623" ESTIMABLE="YES" MEAN_1="100.3" MEAN_2="99.7" ORDER="352" SD_1="17.7" SD_2="17.5" SE="0.27218623708150896" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.024346040941364"/>
<CONT_DATA CI_END="0.4155334451486638" CI_START="-0.5971457162719279" EFFECT_SIZE="-0.09080613556163204" ESTIMABLE="YES" MEAN_1="3.18" MEAN_2="3.28" ORDER="353" SD_1="1.02" SD_2="1.15" SE="0.25834126785197986" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.338194020272685"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.06.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.54956536803498" CI_START="-14.54956536803498" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7547702325074095" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.3123556756048751">
<NAME>Clinic PEFR (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.54956536803498" CI_START="-14.54956536803498" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.07.01" NO="1" P_CHI2="1.0" P_Z="0.7547702325074095" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.3123556756048751">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="10.54956536803498" CI_START="-14.54956536803498" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="101.0" MEAN_2="103.0" ORDER="354" SD_1="15.81" SD_2="12.65" SE="6.402957129327043" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.07.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI+spacer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.07.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.055663346708613" CI_START="-16.855663346708596" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6838006154706033" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="0.40728236372272963">
<NAME>Morning PEFR (% predicted)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.08.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="11.055663346708613" CI_START="-16.855663346708596" DF="0" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" I2="0.0" ID="CMP-004.08.02" NO="2" P_CHI2="1.0" P_Z="0.6838006154706033" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="0.40728236372272963">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="11.055663346708613" CI_START="-16.855663346708596" EFFECT_SIZE="-2.8999999999999915" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="90.3" ORDER="355" SD_1="30.8" SD_2="20.5" SE="7.120367239800882" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.08.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8715719751887615" CI_END="22.451465363550135" CI_START="-28.433338739199712" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.9909366878247905" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" NO="9" P_CHI2="0.9722454805748484" P_Q="0.6943390206408999" P_Z="0.8177748915452845" Q="0.7295902281369199" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="0.23040781198013163">
<NAME>Morning PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.027336703803644818" CI_END="65.57566986654456" CI_START="-34.17234849665082" DF="1" EFFECT_SIZE="15.701660684946868" ESTIMABLE="YES" I2="0.0" ID="CMP-004.09.01" NO="1" P_CHI2="0.8686778581478561" P_Z="0.5372026484256673" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="26.02361712221888" Z="0.6170486380573451">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="112.03206228931981" CI_START="-96.03206228931981" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="342.0" MEAN_2="334.0" ORDER="356" SD_1="132.0" SD_2="128.0" SE="53.078558131634786" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.981110235188557"/>
<CONT_DATA CI_END="74.83058027590448" CI_START="-38.830580275904474" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="409.0" MEAN_2="391.0" ORDER="357" SD_1="95.9" SD_2="100.7" SE="28.995726821603274" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="20.042506887030324"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.11464504324819695" CI_END="22.553927187725904" CI_START="-41.536844638123156" DF="2" EFFECT_SIZE="-9.491458725198628" ESTIMABLE="YES" I2="0.0" ID="CMP-004.09.02" NO="2" P_CHI2="0.9442894713934598" P_Z="0.5615654825870108" STUDIES="3" TAU2="0.0" TOTAL_1="63" TOTAL_2="63" WEIGHT="63.03550121826079" Z="0.5805178103545586">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="36.018603001961736" CI_START="-61.018603001961736" EFFECT_SIZE="-12.5" ESTIMABLE="YES" MEAN_1="262.5" MEAN_2="275.0" ORDER="358" SD_1="78.41" SD_2="81.98" SE="24.754844162785787" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="27.49790752099504"/>
<CONT_DATA CI_END="48.198043120481216" CI_START="-53.998043120481285" EFFECT_SIZE="-2.900000000000034" ESTIMABLE="YES" MEAN_1="311.2" MEAN_2="314.1" ORDER="359" SD_1="94.0" SD_2="94.0" SE="26.07090922258577" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="24.79177864046996"/>
<CONT_DATA CI_END="60.61370763725296" CI_START="-94.61370763725296" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="420.0" ORDER="360" SD_1="111.0" SD_2="113.0" SE="39.59955807834224" STUDY_ID="STD-Willey-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.745815056795786"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="66.9187027127066" CI_START="-86.9187027127066" DF="0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.09.03" NO="3" P_CHI2="1.0" P_Z="0.7988700000785148" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.940881659520327" Z="0.25480980768234895">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="66.9187027127066" CI_START="-86.9187027127066" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="245.0" MEAN_2="255.0" ORDER="361" SD_1="101.0" SD_2="91.0" SE="39.24495721320979" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="10.940881659520327"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9268989002760778" CI_END="0.19561703520801638" CI_START="-0.27850742819265384" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.04144519649231874" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.10" NO="10" P_CHI2="0.9882322147338779" P_Q="0.6843668790091595" P_Z="0.731856327638848" Q="0.7585227347228167" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="137" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="0.34265725026925786">
<NAME>Morning PEFR (% predicted, L/min measures combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.057154996397088695" CI_END="0.6077399123151683" CI_START="-0.3307467084059026" DF="1" EFFECT_SIZE="0.1384966019546329" ESTIMABLE="YES" I2="0.0" ID="CMP-004.10.01" NO="1" P_CHI2="0.8110504440410378" P_Z="0.562939406465261" STUDIES="2" TAU2="0.0" TOTAL_1="35" TOTAL_2="35" WEIGHT="25.52281409732536" Z="0.5784810264075949">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="0.8597725089526191" CI_START="-0.740953678274078" EFFECT_SIZE="0.059409415339270556" ESTIMABLE="YES" MEAN_1="342.0" MEAN_2="334.0" ORDER="362" SD_1="132.0" SD_2="128.0" SE="0.4083560207873769" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.773050486718477"/>
<CONT_DATA CI_END="0.759159534083772" CI_START="-0.39931908562118923" EFFECT_SIZE="0.17992022423129142" ESTIMABLE="YES" MEAN_1="409.0" MEAN_2="391.0" ORDER="363" SD_1="95.9" SD_2="100.7" SE="0.2955356906664849" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="16.74976361060688"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1112211691561722" CI_END="0.18897426792896854" CI_START="-0.3959068731898786" DF="3" EFFECT_SIZE="-0.10346630263045505" ESTIMABLE="YES" I2="0.0" ID="CMP-004.10.02" NO="2" P_CHI2="0.9904576515076543" P_Z="0.48803296242139593" STUDIES="4" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="65.7127272536917" Z="0.6934408122008743">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.4529411466428519" CI_START="-0.7587236533009469" EFFECT_SIZE="-0.15289125332904752" ESTIMABLE="YES" MEAN_1="262.5" MEAN_2="275.0" ORDER="364" SD_1="78.41" SD_2="81.98" SE="0.3091038431066224" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="15.3115707556961"/>
<CONT_DATA CI_END="0.5132441707512481" CI_START="-0.5740161155817844" EFFECT_SIZE="-0.03038597241526819" ESTIMABLE="YES" MEAN_1="311.2" MEAN_2="314.1" ORDER="365" SD_1="94.0" SD_2="94.0" SE="0.2773674146334328" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="19.0159347334325"/>
<CONT_DATA CI_END="0.42462191669935034" CI_START="-0.6431053631410939" EFFECT_SIZE="-0.10924172322087175" ESTIMABLE="YES" MEAN_1="87.4" MEAN_2="90.3" ORDER="366" SD_1="30.8" SD_2="20.5" SE="0.2723844132500752" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="19.718053956479693"/>
<CONT_DATA CI_END="0.5460789553008351" CI_START="-0.8419855281374223" EFFECT_SIZE="-0.1479532864182936" ESTIMABLE="YES" MEAN_1="403.0" MEAN_2="420.0" ORDER="367" SD_1="111.0" SD_2="113.0" SE="0.35410458926468363" STUDY_ID="STD-Willey-1982" TOTAL_1="16" TOTAL_2="16" WEIGHT="11.667167808083407"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1538172485142466E-33" CI_END="0.7003167208979918" CI_START="-0.901193873631292" DF="0" EFFECT_SIZE="-0.10043857636665007" ESTIMABLE="YES" I2="100.0" ID="CMP-004.10.03" NO="3" P_CHI2="0.0" P_Z="0.8058077255253009" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.764458648982956" Z="0.24583788956447078">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.7003167208979918" CI_START="-0.901193873631292" EFFECT_SIZE="-0.10043857636665006" ESTIMABLE="YES" MEAN_1="245.0" MEAN_2="255.0" ORDER="368" SD_1="101.0" SD_2="91.0" SE="0.4085561283681218" STUDY_ID="STD-Tjwa-1995" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.764458648982956"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.26166546325175266" CI_END="20.55803558738905" CI_START="-31.5023410849251" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.472152748768026" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.11" NO="11" P_CHI2="0.9921525201320759" P_Q="0.9714758291008748" P_Z="0.6803173284578172" Q="0.05787778124523787" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="105" TOTAL_2="106" UNITS="" WEIGHT="99.99999999999999" Z="0.4120301461895067">
<NAME>Evening PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="70.04045642256422" CI_START="-86.04045642256422" DF="0" EFFECT_SIZE="-8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.01" NO="1" P_CHI2="1.0" P_Z="0.8407628987352629" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.125384241622541" Z="0.20091773671106927">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="70.04045642256422" CI_START="-86.04045642256422" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="252.0" MEAN_2="260.0" ORDER="369" SD_1="100.0" SD_2="95.0" SE="39.8172910513343" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.125384241622541"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.2037876820065148" CI_END="26.086300823498746" CI_START="-33.69854562956975" DF="2" EFFECT_SIZE="-3.8061224030355003" ESTIMABLE="YES" I2="0.0" ID="CMP-004.11.02" NO="2" P_CHI2="0.9031255055553429" P_Z="0.8029299721438153" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="78" WEIGHT="75.8284843976237" Z="0.24955697884267938">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="36.010965933859396" CI_START="-58.010965933859396" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="269.1" MEAN_2="280.1" ORDER="370" SD_1="77.12" SD_2="78.32" SE="23.985627442481544" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="30.65887899063473"/>
<CONT_DATA CI_END="44.41438707827466" CI_START="-48.21438707827461" EFFECT_SIZE="-1.8999999999999773" ESTIMABLE="YES" MEAN_1="334.0" MEAN_2="335.9" ORDER="371" SD_1="86.0" SD_2="86.0" SE="23.63022353655302" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="27" WEIGHT="31.58804723363171"/>
<CONT_DATA CI_END="78.63216385213936" CI_START="-62.63216385213936" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="360.0" MEAN_2="352.0" ORDER="372" SD_1="135.0" SD_2="144.0" SE="36.0374804890686" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.581558173357259"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.333908003612461E-33" CI_END="59.066998866183255" CI_START="-85.06699886618325" DF="0" EFFECT_SIZE="-13.000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-004.11.03" NO="3" P_CHI2="0.0" P_Z="0.7236736105056623" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="13.046131360753751" Z="0.35355339059327384">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="59.066998866183255" CI_START="-85.06699886618325" EFFECT_SIZE="-13.0" ESTIMABLE="YES" MEAN_1="437.0" MEAN_2="450.0" ORDER="373" SD_1="104.0" SD_2="104.0" SE="36.76955262170047" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="13.046131360753751"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.00226675544217059" CI_END="0.7173320664566347" CI_START="-0.198318764087475" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.25950665118457983" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.12" NO="12" P_CHI2="0.9620267124559633" P_Q="0.9620267124559633" P_Z="0.26658749674469784" Q="0.00226675544217059" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="1.110955558830508">
<NAME>Daytime breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.12.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8770945569247939" CI_START="-0.3386537160245399" DF="0" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" I2="0.0" ID="CMP-004.12.02" NO="2" P_CHI2="1.0" P_Z="0.38536950642836487" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.72473357270164" Z="0.8680453671628945">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.8770945569247939" CI_START="-0.3386537160245399" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.05" ORDER="374" SD_1="0.16" SD_2="0.13" SE="0.31014556454582864" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.72473357270164"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9427271302557353" CI_START="-0.44917922736600147" DF="0" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" I2="0.0" ID="CMP-004.12.03" NO="3" P_CHI2="1.0" P_Z="0.48707277771717894" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.27526642729837" Z="0.6949721215168363">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.9427271302557353" CI_START="-0.44917922736600147" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.6" ORDER="375" SD_1="0.57" SD_2="0.45" SE="0.35508467721879494" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.27526642729837"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.17405040162197355" CI_START="-0.8456770201530461" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.13" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.19673908505295346" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.290897896114194">
<NAME>Morning breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.13.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.17405040162197355" CI_START="-0.8456770201530461" DF="0" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" I2="0.0" ID="CMP-004.13.02" NO="2" P_CHI2="1.0" P_Z="0.19673908505295346" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.290897896114194">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.17405040162197355" CI_START="-0.8456770201530461" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.45" ORDER="376" SD_1="5.57" SD_2="8.92" SE="0.26013932649234867" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.13.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9911969708362657" CI_START="-0.40321836928808474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.14" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.40854793264034206" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.8264516672714545">
<NAME>Daytime wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.14.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.14.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI+spacer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9911969708362657" CI_START="-0.40321836928808474" DF="0" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" I2="0.0" ID="CMP-004.14.03" NO="3" P_CHI2="1.0" P_Z="0.40854793264034206" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.8264516672714545">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.9911969708362657" CI_START="-0.40321836928808474" EFFECT_SIZE="0.29398930077409047" ESTIMABLE="YES" MEAN_1="0.52" MEAN_2="0.39" ORDER="377" SD_1="0.4" SD_2="0.46" SE="0.35572473553680595" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3579832708223656" CI_START="-0.6556362545280283" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.15" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.5649191146091266" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.5755504046277298">
<NAME>Morning wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.15.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3579832708223656" CI_START="-0.6556362545280283" DF="0" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" I2="0.0" ID="CMP-004.15.02" NO="2" P_CHI2="1.0" P_Z="0.5649191146091266" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.5755504046277298">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.3579832708223656" CI_START="-0.6556362545280283" EFFECT_SIZE="-0.14882649185283137" ESTIMABLE="YES" MEAN_1="5.24" MEAN_2="6.33" ORDER="378" SD_1="6.39" SD_2="7.98" SE="0.25858116101767564" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.15.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.0891445159283726" CI_START="-0.3116095894195764" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.2766203423573744" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.0879428779547926">
<NAME>Daytime cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.16.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.16.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI+spacer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0891445159283726" CI_START="-0.3116095894195764" DF="0" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" I2="0.0" ID="CMP-004.16.03" NO="3" P_CHI2="1.0" P_Z="0.2766203423573744" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.0879428779547926">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="1.0891445159283726" CI_START="-0.3116095894195764" EFFECT_SIZE="0.38876746325439815" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.17" ORDER="379" SD_1="0.35" SD_2="0.3" SE="0.357341797195489" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3990686503627424" CI_START="-0.6138327802336648" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.17" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.677725759009032" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.4155685311553392">
<NAME>Morning cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.17.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3990686503627424" CI_START="-0.6138327802336648" DF="0" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" I2="0.0" ID="CMP-004.17.02" NO="2" P_CHI2="1.0" P_Z="0.677725759009032" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.4155685311553392">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.3990686503627424" CI_START="-0.6138327802336648" EFFECT_SIZE="-0.1073820649354612" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="4.26" ORDER="380" SD_1="6.19" SD_2="6.31" SE="0.2583979702142602" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.17.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5308269961716795" CI_END="0.38871459506829464" CI_START="-0.224316425068525" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.0821990849998848" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.18" NO="18" P_CHI2="0.9704314250068655" P_Q="0.9502783654200169" P_Z="0.5991600507701369" Q="0.003888422373565475" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="82" TOTAL_2="82" UNITS="" WEIGHT="100.0" Z="0.5256087893430386">
<NAME>Daily asthma symptom score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.05902410934243906" CI_END="0.5695787467698425" CI_START="-0.38202420675898713" DF="2" EFFECT_SIZE="0.09377727000542774" ESTIMABLE="YES" I2="0.0" ID="CMP-004.18.01" NO="1" P_CHI2="0.9709191736412609" P_Z="0.6992776743248335" STUDIES="3" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="41.50050096358155" Z="0.3862957152403547">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="0.8211232032108191" CI_START="-0.7792331837699751" EFFECT_SIZE="0.020945009720421993" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.4" ORDER="381" SD_1="5.5" SD_2="3.5" SE="0.4082616822564601" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.673424673924533"/>
<CONT_DATA CI_END="0.9626193421086242" CI_START="-0.6407802616488538" EFFECT_SIZE="0.16091954022988514" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" ORDER="382" SD_1="0.6" SD_2="0.6" SE="0.40903802733236155" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="14.617777865113872"/>
<CONT_DATA CI_END="0.9781387758422925" CI_START="-0.7762954715486697" EFFECT_SIZE="0.10092165214681133" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="383" SD_1="9.49" SD_2="9.49" SE="0.4475679811541731" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.209298424543144"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4679144644556749" CI_END="0.47473796182972977" CI_START="-0.3267672992751069" DF="1" EFFECT_SIZE="0.07398533127731144" ESTIMABLE="YES" I2="0.0" ID="CMP-004.18.02" NO="2" P_CHI2="0.49394821480309015" P_Z="0.71747112814882" STUDIES="2" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="58.49949903641845" Z="0.36184063093461877">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.5208850012881223" CI_START="-0.6894233789352231" EFFECT_SIZE="-0.0842691888235504" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.16" ORDER="384" SD_1="0.26" SD_2="0.42" SE="0.30875781130931573" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="25.655047382611066"/>
<CONT_DATA CI_END="0.7324361272958737" CI_START="-0.33723788094754537" EFFECT_SIZE="0.19759912317416417" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="13.6" ORDER="385" SD_1="19.3" SD_2="16.5" SE="0.2728810367641628" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="32.84445165380738"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.18.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3786632505093883" CI_END="0.3095516630986409" CI_START="-0.18235646960046192" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06359759674908949" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.19" NO="19" P_CHI2="0.7600367645332655" P_Q="0.8263023000592041" P_Z="0.6122966467186455" Q="0.38158932116725697" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="128" UNITS="" WEIGHT="100.0" Z="0.5067978788948548">
<NAME>Symptoms (daytime breathlessness, morning breathlessness, daily symptom scores combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.05902410934243905" CI_END="0.5695787467698425" CI_START="-0.38202420675898713" DF="2" EFFECT_SIZE="0.0937772700054277" ESTIMABLE="YES" I2="0.0" ID="CMP-004.19.01" NO="1" P_CHI2="0.9709191736412609" P_Z="0.6992776743248336" STUDIES="3" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="26.721229863691118" Z="0.3862957152403546">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="0.8211232032108191" CI_START="-0.7792331837699751" EFFECT_SIZE="0.020945009720421993" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.4" ORDER="386" SD_1="5.5" SD_2="3.5" SE="0.4082616822564601" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.447884832608928"/>
<CONT_DATA CI_END="0.9626193421086242" CI_START="-0.6407802616488538" EFFECT_SIZE="0.16091954022988514" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.3" ORDER="387" SD_1="0.6" SD_2="0.6" SE="0.40903802733236155" STUDY_ID="STD-Nicolaizik-1994" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.412055116463685"/>
<CONT_DATA CI_END="0.9781387758422925" CI_START="-0.7762954715486697" EFFECT_SIZE="0.10092165214681133" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.0" ORDER="388" SD_1="9.49" SD_2="9.49" SE="0.4475679811541731" STUDY_ID="STD-Springer-1987" TOTAL_1="10" TOTAL_2="10" WEIGHT="7.861289914618505"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.9380498199996925" CI_END="0.3281540190320451" CI_START="-0.30276095911322554" DF="2" EFFECT_SIZE="0.012696529959409786" ESTIMABLE="YES" I2="31.927634909873333" ID="CMP-004.19.02" NO="2" P_CHI2="0.23014984722338394" P_Z="0.9371244033942201" STUDIES="3" TAU2="0.0" TOTAL_1="78" TOTAL_2="78" WEIGHT="60.78918627073398" Z="0.07888461143284878">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.8770945569247939" CI_START="-0.3386537160245399" EFFECT_SIZE="0.269220420450127" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.05" ORDER="389" SD_1="0.16" SD_2="0.13" SE="0.31014556454582864" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="16.37120636562371"/>
<CONT_DATA CI_END="0.7324361272958737" CI_START="-0.33723788094754537" EFFECT_SIZE="0.19759912317416417" ESTIMABLE="YES" MEAN_1="17.2" MEAN_2="13.6" ORDER="390" SD_1="19.3" SD_2="16.5" SE="0.2728810367641628" STUDY_ID="STD-Field-1982" TOTAL_1="27" TOTAL_2="27" WEIGHT="21.14779634005977"/>
<CONT_DATA CI_END="0.17405040162197355" CI_START="-0.8456770201530461" EFFECT_SIZE="-0.33581330926553626" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="6.45" ORDER="391" SD_1="5.57" SD_2="8.92" SE="0.26013932649234867" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="23.270183565050502"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9427271302557353" CI_START="-0.44917922736600147" DF="0" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" I2="0.0" ID="CMP-004.19.03" NO="3" P_CHI2="1.0" P_Z="0.48707277771717894" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="12.489583865574897" Z="0.6949721215168363">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.9427271302557353" CI_START="-0.44917922736600147" EFFECT_SIZE="0.24677395144486694" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="0.6" ORDER="392" SD_1="0.57" SD_2="0.45" SE="0.35508467721879494" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="12.489583865574897"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03344131276092331" CI_END="0.5736764323858248" CI_START="-0.3386737894998658" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1175013214429795" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.20" NO="20" P_CHI2="0.8549003400847557" P_Q="0.8549003400847557" P_Z="0.613666731871884" Q="0.03344131276092331" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="0.5048463904313232">
<NAME>Night-time breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.20.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.760557061729863" CI_START="-0.4511541195732166" DF="0" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" I2="0.0" ID="CMP-004.20.02" NO="2" P_CHI2="1.0" P_Z="0.6167479365872593" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.692411806516056" Z="0.5004646591489">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.760557061729863" CI_START="-0.4511541195732166" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.08" ORDER="393" SD_1="0.18" SD_2="0.2" SE="0.30911567530345013" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="56.692411806516056"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7619896261535924" CI_START="-0.6243817489594453" DF="0" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" I2="0.0" ID="CMP-004.20.03" NO="3" P_CHI2="1.0" P_Z="0.8457520643384093" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.307588193483944" Z="0.19454129545018084">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.7619896261535924" CI_START="-0.6243817489594453" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.58" ORDER="394" SD_1="0.42" SD_2="0.43" SE="0.35367266593890456" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="43.307588193483944"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.16332643328615065" CI_START="-0.8569043141133812" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.21" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.18271841051851442" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.332431580169419">
<NAME>Evening breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.21.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16332643328615065" CI_START="-0.8569043141133812" DF="0" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" I2="0.0" ID="CMP-004.21.02" NO="2" P_CHI2="1.0" P_Z="0.18271841051851442" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.332431580169419">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.16332643328615065" CI_START="-0.8569043141133812" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="6.52" ORDER="395" SD_1="4.63" SD_2="9.07" SE="0.2602677282457692" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.21.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8546760593433423" CI_START="-0.5337686038575246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.22" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.6505479013544908" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.45300116871247653">
<NAME>Night-time wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.22.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.22.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI+spacer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8546760593433423" CI_START="-0.5337686038575246" DF="0" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" I2="0.0" ID="CMP-004.22.03" NO="3" P_CHI2="1.0" P_Z="0.6505479013544908" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.45300116871247653">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.8546760593433423" CI_START="-0.5337686038575246" EFFECT_SIZE="0.1604537277429089" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="0.39" ORDER="396" SD_1="0.41" SD_2="0.44" SE="0.35420157568015054" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.28187277833707003" CI_START="-0.7336977352773082" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.23" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.383217435467999" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.8719834133107602">
<NAME>Evening wheeze score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.23.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.28187277833707003" CI_START="-0.7336977352773082" DF="0" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" I2="0.0" ID="CMP-004.23.02" NO="2" P_CHI2="1.0" P_Z="0.383217435467999" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.8719834133107602">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.28187277833707003" CI_START="-0.7336977352773082" EFFECT_SIZE="-0.22591247847011905" ESTIMABLE="YES" MEAN_1="4.46" MEAN_2="5.99" ORDER="397" SD_1="4.94" SD_2="8.06" SE="0.2590788712509691" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.23.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1308638814016656" CI_START="-0.27309251807994506" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.24" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.2311219624267815" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.1974737817364924">
<NAME>Night-time cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.24.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.24.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI+spacer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1308638814016656" CI_START="-0.27309251807994506" DF="0" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" I2="0.0" ID="CMP-004.24.03" NO="3" P_CHI2="1.0" P_Z="0.2311219624267815" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.1974737817364924">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="1.1308638814016656" CI_START="-0.27309251807994506" EFFECT_SIZE="0.4288856816608603" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.11" ORDER="398" SD_1="0.36" SD_2="0.27" SE="0.35815872397550147" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3188557117127877" CI_START="-0.6956657222978688" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.25" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.4666362517433257" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7279629833361982">
<NAME>Evening cough score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.25.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3188557117127877" CI_START="-0.6956657222978688" DF="0" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" I2="0.0" ID="CMP-004.25.02" NO="2" P_CHI2="1.0" P_Z="0.4666362517433257" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7279629833361982">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.3188557117127877" CI_START="-0.6956657222978688" EFFECT_SIZE="-0.18840500529254053" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.1" ORDER="399" SD_1="4.36" SD_2="5.99" SE="0.2588112439853671" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.25.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8016711824146951" CI_END="0.25123460905651" CI_START="-0.4288480322372657" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08880671159037785" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.26" NO="26" P_CHI2="0.40623011848790624" P_Q="0.6090719353245169" P_Z="0.6087399277991502" Q="0.26152864892886596" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="0.5118729570025549">
<NAME>Symptoms (night-time breathlessness, evening breathlessness scores combined)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.26.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5401425334858287" CI_END="0.2514652345904882" CI_START="-0.5289707044985341" DF="1" EFFECT_SIZE="-0.13875273495402296" ESTIMABLE="YES" I2="35.07094452247323" ID="CMP-004.26.02" NO="2" P_CHI2="0.21459704858269002" P_Z="0.48585341734332343" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="51" WEIGHT="75.93619973325053" Z="0.6969191182655063">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.760557061729863" CI_START="-0.4511541195732166" EFFECT_SIZE="0.15470147107832324" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.08" ORDER="400" SD_1="0.18" SD_2="0.2" SE="0.30911567530345013" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="31.50105861950481"/>
<CONT_DATA CI_END="0.16332643328615065" CI_START="-0.8569043141133812" EFFECT_SIZE="-0.34678894041361524" ESTIMABLE="YES" MEAN_1="3.99" MEAN_2="6.52" ORDER="401" SD_1="4.63" SD_2="9.07" SE="0.2602677282457692" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="44.435141113745715"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7619896261535924" CI_START="-0.6243817489594453" DF="0" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" I2="0.0" ID="CMP-004.26.03" NO="3" P_CHI2="1.0" P_Z="0.8457520643384093" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.063800266749475" Z="0.19454129545018084">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.7619896261535924" CI_START="-0.6243817489594453" EFFECT_SIZE="0.06880393859707354" ESTIMABLE="YES" MEAN_1="0.61" MEAN_2="0.58" ORDER="402" SD_1="0.42" SD_2="0.43" SE="0.35367266593890456" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="24.063800266749475"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1790448498493285E-32" CI_END="1.0902109514859657" CI_START="-0.1302109514859658" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4799999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-004.27" NO="27" P_CHI2="0.0" P_Q="1.0" P_Z="0.12313834915680578" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="1.5417335763775835">
<NAME>Daytime use of rescue beta2 agonists (puffs/day)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.27.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.27.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI+spacer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.1790448498493285E-32" CI_END="1.0902109514859657" CI_START="-0.1302109514859658" DF="0" EFFECT_SIZE="0.4799999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-004.27.03" NO="3" P_CHI2="0.0" P_Z="0.12313834915680578" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.5417335763775835">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="1.0902109514859657" CI_START="-0.13021095148596573" EFFECT_SIZE="0.48" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="2.41" ORDER="403" SD_1="0.7" SD_2="1.03" SE="0.3113378390109368" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.522391440304596E-33" CI_END="0.44157934397716114" CI_START="-0.6415793439771609" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999988" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-004.28" NO="28" P_CHI2="0.0" P_Q="1.0" P_Z="0.7174283697728059" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.36189784679504056">
<NAME>Morning use of rescue beta2 agonists (puffs)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.28.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.522391440304596E-33" CI_END="0.44157934397716114" CI_START="-0.6415793439771609" DF="0" EFFECT_SIZE="-0.09999999999999988" ESTIMABLE="YES" I2="100.0" ID="CMP-004.28.02" NO="2" P_CHI2="0.0" P_Z="0.7174283697728059" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.36189784679504056">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="0.44157934397716114" CI_START="-0.6415793439771609" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.44" ORDER="404" SD_1="1.09" SD_2="1.05" SE="0.27632106928957356" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.28.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.41510445046283745" CI_START="-0.5151044504628375" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.29" NO="29" P_CHI2="1.0" P_Q="1.0" P_Z="0.8331202144951171" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="0.21070148679394954">
<NAME>Night-time use of rescue beta2 agonists (puffs/night)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.29.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.29.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI+spacer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.41510445046283745" CI_START="-0.5151044504628375" DF="0" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-004.29.03" NO="3" P_CHI2="1.0" P_Z="0.8331202144951171" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.21070148679394954">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.41510445046283745" CI_START="-0.5151044504628375" EFFECT_SIZE="-0.04999999999999999" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="0.42" ORDER="405" SD_1="0.71" SD_2="0.63" SE="0.23730254950168572" STUDY_ID="STD-Tjwa-1995" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.651141403435223" CI_START="-3.651141403435222" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.30" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.45973054673146974" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.7392906247853945">
<NAME>Evening use of rescue beta2 agonists (puffs)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.30.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.651141403435223" CI_START="-3.651141403435222" DF="0" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-004.30.02" NO="2" P_CHI2="1.0" P_Z="0.45973054673146974" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.7392906247853945">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="1.651141403435223" CI_START="-3.651141403435222" EFFECT_SIZE="-0.9999999999999996" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.1" ORDER="406" SD_1="4.36" SD_2="5.99" SE="1.3526480202427633" STUDY_ID="STD-Willey-1982" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.30.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8074648429450684" CI_START="0.052535157054931614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.43" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.31" NO="31" P_CHI2="1.0" P_Q="1.0" P_Z="0.025565455250602106" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="2.2327496960422137">
<NAME>Histamine BHR (log 10 PC20 FEV1)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.31.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.31.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>MDI v MDI+spacer</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8074648429450684" CI_START="0.052535157054931614" DF="0" EFFECT_SIZE="0.43" ESTIMABLE="YES" I2="0.0" ID="CMP-004.31.03" NO="3" P_CHI2="1.0" P_Z="0.025565455250602106" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="2.2327496960422137">
<NAME>DPI v DPI</NAME>
<CONT_DATA CI_END="0.8074648429450684" CI_START="0.052535157054931614" EFFECT_SIZE="0.43" ESTIMABLE="YES" MEAN_1="0.63" MEAN_2="0.2" ORDER="407" SD_1="0.3" SD_2="0.53" SE="0.1925876423865249" STUDY_ID="STD-Tjwa-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1543135290418089" CI_END="64.41195001164964" CI_START="-15.777178294337293" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="24.31738585865617" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.32" NO="32" P_CHI2="0.9257447396728291" P_Q="0.7405512285031249" P_Z="0.23454998542644578" Q="0.10964278247317041" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="59" UNITS="" WEIGHT="99.99999999999999" Z="1.188719755108532">
<NAME>Morning plasma cortisol (nmol/L)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="186.4532364039645" CI_START="-92.65323640396454" DF="0" EFFECT_SIZE="46.89999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.32.01" NO="1" P_CHI2="1.0" P_Z="0.510094907853465" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.254507533284903" Z="0.6586899253904879">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="186.4532364039645" CI_START="-92.65323640396454" EFFECT_SIZE="46.89999999999998" ESTIMABLE="YES" MEAN_1="411.09" MEAN_2="364.19" ORDER="408" SD_1="200.71" SD_2="143.36" SE="71.2019391706902" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="8.254507533284903"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.04467074656863848" CI_END="64.14499981484987" CI_START="-19.573825197277696" DF="1" EFFECT_SIZE="22.285587308786088" ESTIMABLE="YES" I2="0.0" ID="CMP-004.32.02" NO="2" P_CHI2="0.8326107587280245" P_Z="0.29673170797117876" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="47" WEIGHT="91.74549246671508" Z="1.0434677862049853">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="82.67823652570421" CI_START="-49.078236525704185" EFFECT_SIZE="16.80000000000001" ESTIMABLE="YES" MEAN_1="379.2" MEAN_2="362.4" ORDER="409" SD_1="106.32" SD_2="111.45" SE="33.61196279387954" STUDY_ID="STD-Baran-1987" TOTAL_1="21" TOTAL_2="21" WEIGHT="37.04137191087361"/>
<CONT_DATA CI_END="80.20950935965377" CI_START="-28.209509359653758" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="248.0" MEAN_2="222.0" ORDER="410" SD_1="91.78" SD_2="107.08" SE="27.658421168578325" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="54.70412055584147"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.32.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04467975828947206" CI_END="78.48186693091708" CI_START="-24.792385968687903" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="26.844740481114584" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.33" NO="33" P_CHI2="0.8325941253445903" P_Q="0.8325941253445903" P_Z="0.30823522790388447" Q="0.044679758289472064" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.0189320772614427">
<NAME>Plasma cortisol 30 min post 250 mcg tetracosactrin (nmol/L)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="254.21507698208373" CI_START="-254.21507698208373" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.33.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.125926853162209" Z="0.0">
<NAME>MDI v MDI</NAME>
<CONT_DATA CI_END="254.21507698208373" CI_START="-254.21507698208373" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="722.86" MEAN_2="722.86" ORDER="411" SD_1="277.17" SD_2="353.63" SE="129.70395322939595" STUDY_ID="STD-Bjorkander-1982a" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.125926853162209"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7433863618945116E-32" CI_END="80.73652109489397" CI_START="-24.736521094893963" DF="0" EFFECT_SIZE="28.000000000000004" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-004.33.02" NO="2" P_CHI2="0.0" P_Z="0.29804920464196094" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="95.87407314683779" Z="1.0406259348881282">
<NAME>MDI v MDI+spacer</NAME>
<CONT_DATA CI_END="80.73652109489396" CI_START="-24.736521094893966" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="495.0" MEAN_2="467.0" ORDER="412" SD_1="101.98" SD_2="91.78" SE="26.906882734005784" STUDY_ID="STD-Ebden-1986" TOTAL_1="26" TOTAL_2="26" WEIGHT="95.87407314683779"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.33.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DPI v DPI</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>BDP v BUD parallel design dose-down titration studies, no OCS</NAME>
<CONT_OUTCOME CHI2="0.22138101656870393" CI_END="555.9753039791517" CI_START="332.4591910437023" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="444.217247511427" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="0.6379896792812156" P_Q="0.6379896792812154" P_Z="6.675083913261663E-15" Q="0.2213810165687044" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="142" UNITS="" WEIGHT="100.0" Z="7.790488077119991">
<NAME>Daily dose inhaled corticosteroid (mcg)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.166509041895187E-31" CI_END="624.9992814687992" CI_START="315.00071853120096" DF="0" EFFECT_SIZE="470.00000000000006" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-005.01.02" NO="2" P_CHI2="0.0" P_Z="2.79606348388915E-9" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="51.987425533383444" Z="5.9431441488279235">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="624.999281468799" CI_START="315.00071853120096" EFFECT_SIZE="470.0" ESTIMABLE="YES" MEAN_1="1350.0" MEAN_2="880.0" ORDER="413" SD_1="475.0" SD_2="420.0" SE="79.08271921903342" STUDY_ID="STD-Brambilla-1994" TOTAL_1="63" TOTAL_2="66" WEIGHT="51.987425533383444"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="577.587735230679" CI_START="255.01226476932118" DF="0" EFFECT_SIZE="416.30000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.03" NO="3" P_CHI2="1.0" P_Z="4.2175755811069463E-7" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="76" WEIGHT="48.012574466616556" Z="5.058865794085651">
<NAME>6 months or longer</NAME>
<CONT_DATA CI_END="577.587735230679" CI_START="255.01226476932118" EFFECT_SIZE="416.30000000000007" ESTIMABLE="YES" MEAN_1="1019.2" MEAN_2="602.9" ORDER="414" SD_1="324.7" SD_2="454.4" SE="82.29117295159297" STUDY_ID="STD-Selroos-1994" TOTAL_1="26" TOTAL_2="76" WEIGHT="48.012574466616556"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.25129421835506666" CI_END="0.19629575230916912" CI_START="-0.22768451354032188" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.015694380615576365" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="0.6161652839707668" P_Q="0.6161652839707668" P_Z="0.8846294882578628" Q="0.25129421835506666" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="142" UNITS="" WEIGHT="100.00000000000001" Z="0.14510307787350132">
<NAME>FEV1 (litres)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2008592376514846" CI_START="-0.30085923765148426" DF="0" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" NO="2" P_CHI2="1.0" P_Z="0.6960558506976855" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="71.41198384631372" Z="0.390650151632646">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="0.2008592376514846" CI_START="-0.30085923765148426" EFFECT_SIZE="-0.04999999999999982" ESTIMABLE="YES" MEAN_1="2.04" MEAN_2="2.09" ORDER="415" SD_1="0.76" SD_2="0.69" SE="0.12799175884364716" STUDY_ID="STD-Brambilla-1994" TOTAL_1="63" TOTAL_2="66" WEIGHT="71.41198384631372"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.46648214818595996" CI_START="-0.3264821481859603" DF="0" EFFECT_SIZE="0.06999999999999984" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.03" NO="3" P_CHI2="1.0" P_Z="0.7293149359864977" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="76" WEIGHT="28.5880161536863" Z="0.34603696420009916">
<NAME>6 months or longer</NAME>
<CONT_DATA CI_END="0.46648214818595996" CI_START="-0.3264821481859603" EFFECT_SIZE="0.06999999999999984" ESTIMABLE="YES" MEAN_1="2.42" MEAN_2="2.35" ORDER="416" SD_1="0.88" SD_2="0.92" SE="0.2022905274348716" STUDY_ID="STD-Selroos-1994" TOTAL_1="26" TOTAL_2="76" WEIGHT="28.5880161536863"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="18.761780956022335" CI_START="-54.761780956022335" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-18.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.33721896390736195" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="0.9596747166282621">
<NAME>Morning PEFR</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="18.761780956022335" CI_START="-54.761780956022335" DF="0" EFFECT_SIZE="-18.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.03.02" NO="2" P_CHI2="1.0" P_Z="0.33721896390736195" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="0.9596747166282621">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="18.761780956022335" CI_START="-54.761780956022335" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="347.0" MEAN_2="365.0" ORDER="417" SD_1="114.0" SD_2="98.0" SE="18.756355344279065" STUDY_ID="STD-Brambilla-1994" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="33.2903455984328" CI_START="-49.2903455984328" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7041363392125419" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="0.3797428103124321">
<NAME>Evening PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="33.2903455984328" CI_START="-49.2903455984328" DF="0" EFFECT_SIZE="-8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" NO="2" P_CHI2="1.0" P_Z="0.7041363392125419" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="0.3797428103124321">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="33.2903455984328" CI_START="-49.2903455984328" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="370.0" MEAN_2="378.0" ORDER="418" SD_1="111.0" SD_2="128.0" SE="21.066889965390068" STUDY_ID="STD-Brambilla-1994" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="59.92202596737927" CI_START="-58.722025967379224" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6000000000000227" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9841840608856189" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="76" UNITS="" WEIGHT="100.0" Z="0.019823638379625457">
<NAME>Daily PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-5 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="59.92202596737927" CI_START="-58.722025967379224" DF="0" EFFECT_SIZE="0.6000000000000227" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.03" NO="3" P_CHI2="1.0" P_Z="0.9841840608856189" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="76" WEIGHT="100.0" Z="0.019823638379625457">
<NAME>6 months or longer</NAME>
<CONT_DATA CI_END="59.92202596737926" CI_START="-58.72202596737922" EFFECT_SIZE="0.6000000000000227" ESTIMABLE="YES" MEAN_1="380.1" MEAN_2="379.5" ORDER="419" SD_1="133.8" SD_2="131.5" SE="30.266895940590647" STUDY_ID="STD-Selroos-1994" TOTAL_1="26" TOTAL_2="76" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4321042063308087" CI_START="-0.4321042063308088" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.29309087477152584" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="66" UNITS="" WEIGHT="100.0" Z="1.0513652718376707">
<NAME>Rescue beta2 agonist use (puffs/day)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4321042063308087" CI_START="-0.4321042063308088" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.02" NO="2" P_CHI2="1.0" P_Z="0.29309087477152584" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0" Z="1.0513652718376707">
<NAME>1-5 months</NAME>
<CONT_DATA CI_END="1.432104206330809" CI_START="-0.4321042063308089" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="5.2" ORDER="420" SD_1="2.7" SD_2="2.7" SE="0.47557210932605287" STUDY_ID="STD-Brambilla-1994" TOTAL_1="63" TOTAL_2="66" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.06.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.097281921611571" CI_START="0.43672823627739904" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7605633802816902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="0.8510920568237089" LOG_CI_START="-0.3597887282457467" LOG_EFFECT_SIZE="0.24565166428898116" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.4264758391400435" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0" Z="0.7952366916469162">
<NAME>Withdrawal due to asthma exacerbation (No. of patients)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.097281921611571" CI_START="0.43672823627739904" DF="0" EFFECT_SIZE="1.7605633802816902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-005.07.02" LOG_CI_END="0.8510920568237089" LOG_CI_START="-0.3597887282457467" LOG_EFFECT_SIZE="0.24565166428898116" NO="2" P_CHI2="1.0" P_Z="0.4264758391400435" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0" Z="0.7952366916469162">
<NAME>1-5 months</NAME>
<DICH_DATA CI_END="7.097281921611571" CI_START="0.43672823627739904" EFFECT_SIZE="1.7605633802816902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8510920568237089" LOG_CI_START="-0.3597887282457467" LOG_EFFECT_SIZE="0.24565166428898116" ORDER="421" O_E="0.0" SE="0.7112773671063536" STUDY_ID="STD-Brambilla-1994" TOTAL_1="71" TOTAL_2="75" VAR="0.5059154929577465" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.373835617982161" CI_START="0.9213216120587323" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4788732394366197" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="0.37545064188268" LOG_CI_START="-0.035588741180954404" LOG_EFFECT_SIZE="0.1699309503508628" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.10511041676072405" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0" Z="1.6205675478779766">
<NAME>Sore throat/erythematous throat/Candidiasis (No. of patients)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.373835617982161" CI_START="0.9213216120587323" DF="0" EFFECT_SIZE="1.4788732394366197" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" I2="0.0" ID="CMP-005.08.02" LOG_CI_END="0.37545064188268" LOG_CI_START="-0.035588741180954404" LOG_EFFECT_SIZE="0.1699309503508628" NO="2" P_CHI2="1.0" P_Z="0.10511041676072405" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="100.0" Z="1.6205675478779766">
<NAME>1-5 months</NAME>
<DICH_DATA CI_END="2.373835617982161" CI_START="0.9213216120587323" EFFECT_SIZE="1.4788732394366197" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.37545064188268" LOG_CI_START="-0.035588741180954404" LOG_EFFECT_SIZE="0.1699309503508628" ORDER="422" O_E="0.0" SE="0.24144656828933989" STUDY_ID="STD-Brambilla-1994" TOTAL_1="71" TOTAL_2="75" VAR="0.05829644533869886" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>6 months or longer</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.301443366799521" CI_END="1.7626450223444092" CI_START="0.743732071052794" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.144960974443717" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" I2="69.7102179593219" I2_Q="69.52992656934946" ID="CMP-005.09" LOG_CI_END="0.24616485889061757" LOG_CI_START="-0.12858349055642254" LOG_EFFECT_SIZE="0.05879068416709753" METHOD="MH" NO="9" P_CHI2="0.06921910328068426" P_Q="0.07004748311624209" P_Z="0.5385811364007296" Q="3.2819087301380674" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="151" WEIGHT="100.0" Z="0.6149600059026515">
<NAME>Hoarseness (No. of patients)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>1-4 weeks</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5457185828776623" CI_START="0.6110138518404739" DF="0" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" I2="0.0" ID="CMP-005.09.02" LOG_CI_END="0.18913042811509576" LOG_CI_START="-0.21394894407873566" LOG_EFFECT_SIZE="-0.012409257981819953" NO="2" P_CHI2="1.0" P_Z="0.9039449355872874" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="94.0822498674898" Z="0.12067945122995564">
<NAME>1-5 months</NAME>
<DICH_DATA CI_END="1.5457185828776623" CI_START="0.6110138518404739" EFFECT_SIZE="0.971830985915493" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.18913042811509576" LOG_CI_START="-0.21394894407873566" LOG_EFFECT_SIZE="-0.012409257981819953" ORDER="423" O_E="0.0" SE="0.23677081850172832" STUDY_ID="STD-Brambilla-1994" TOTAL_1="71" TOTAL_2="75" VAR="0.05606042049397837" WEIGHT="94.0822498674898"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.27287200649677" CI_START="0.9334557887850105" DF="0" EFFECT_SIZE="3.8974358974358974" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-005.09.03" LOG_CI_END="1.2114642085299192" LOG_CI_START="-0.029906246693372683" LOG_EFFECT_SIZE="0.5907789809182733" NO="3" P_CHI2="1.0" P_Z="0.06210746412776232" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="76" WEIGHT="5.917750132510211" Z="1.8655277649810231">
<NAME>6 months or longer</NAME>
<DICH_DATA CI_END="16.27287200649677" CI_START="0.9334557887850105" EFFECT_SIZE="3.8974358974358974" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="1.2114642085299192" LOG_CI_START="-0.029906246693372683" LOG_EFFECT_SIZE="0.5907789809182733" ORDER="424" O_E="0.0" SE="0.7291871502810185" STUDY_ID="STD-Selroos-1994" TOTAL_1="26" TOTAL_2="76" VAR="0.5317139001349527" WEIGHT="5.917750132510211"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>BDP v BUD crossover design, OCS treated patients, non OCS sparing</NAME>
<CONT_OUTCOME CHI2="0.04101026675169633" CI_END="37.01199459944534" CI_START="-30.719175706595728" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="3.1464094464248067" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" NO="1" P_CHI2="0.9797036745207833" P_Q="1.0" P_Z="0.8555059603881436" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="0.18209781900252203">
<NAME>Morning PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_DATA CI_END="52.49371340316481" CI_START="-50.49371340316481" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="360.0" MEAN_2="359.0" ORDER="425" SD_1="94.0" SD_2="99.0" SE="26.272785525316102" STUDY_ID="STD-Stiksa-1982a" TOTAL_1="27" TOTAL_2="27" WEIGHT="43.25225402697373"/>
<CONT_DATA CI_END="66.14437474696987" CI_START="-50.14437474696987" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="375.0" MEAN_2="367.0" ORDER="426" SD_1="109.0" SD_2="109.0" SE="29.666042440374046" STUDY_ID="STD-Stiksa-1982b" TOTAL_1="27" TOTAL_2="27" WEIGHT="33.92358632693837"/>
<CONT_DATA CI_END="70.8861167778772" CI_START="-70.8861167778772" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="338.8" MEAN_2="338.8" ORDER="427" SD_1="109.0" SD_2="108.0" SE="36.16705068920544" STUDY_ID="STD-Stiksa-1985" TOTAL_1="18" TOTAL_2="18" WEIGHT="22.8241596460879"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04006294156026648" CI_END="38.38056981282999" CI_START="-29.02978476717965" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="4.675392522825169" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" NO="2" P_CHI2="0.9801678327773254" P_Q="1.0" P_Z="0.7857180006384223" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="0.2718751745312029">
<NAME>Evening PEFR (L/min)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BUD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BDP</GRAPH_LABEL_2>
<CONT_DATA CI_END="55.16003600655663" CI_START="-53.16003600655663" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="422.0" MEAN_2="421.0" ORDER="428" SD_1="104.0" SD_2="99.0" SE="27.633179198068987" STUDY_ID="STD-Stiksa-1982a" TOTAL_1="27" TOTAL_2="27" WEIGHT="38.72891612906837"/>
<CONT_DATA CI_END="65.82643843914184" CI_START="-47.82643843914183" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="430.0" MEAN_2="421.0" ORDER="429" SD_1="104.0" SD_2="109.0" SE="28.99361360075059" STUDY_ID="STD-Stiksa-1982b" TOTAL_1="27" TOTAL_2="27" WEIGHT="35.179718193285574"/>
<CONT_DATA CI_END="70.28545414618183" CI_START="-61.68545414618181" EFFECT_SIZE="4.300000000000011" ESTIMABLE="YES" MEAN_1="386.0" MEAN_2="381.7" ORDER="430" SD_1="101.0" SD_2="101.0" SE="33.666666666666664" STUDY_ID="STD-Stiksa-1985" TOTAL_1="18" TOTAL_2="18" WEIGHT="26.091365677646063"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.09595577420336136" CI_END="0.2941814659969016" CI_START="-0.3593073205973038" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.03256292730020109" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" NO="3" P_CHI2="0.9531548658965538" P_Q="1.0" P_Z="0.8451365716774321" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="0.195327497728654">
<NAME>Daytime breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4707469243083352" CI_START="-0.5964062373211824" EFFECT_SIZE="-0.06282965650642357" ESTIMABLE="YES" MEAN_1="0.34" MEAN_2="0.38" ORDER="431" SD_1="0.68" SD_2="0.57" SE="0.27223795183153504" STUDY_ID="STD-Stiksa-1982a" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.499266151201105"/>
<CONT_DATA CI_END="0.5665711163731663" CI_START="-0.5003769326206523" EFFECT_SIZE="0.03309709187625699" ESTIMABLE="YES" MEAN_1="0.34" MEAN_2="0.32" ORDER="432" SD_1="0.62" SD_2="0.57" SE="0.27218562621807557" STUDY_ID="STD-Stiksa-1982b" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.51368543365353"/>
<CONT_DATA CI_END="0.5679408952668219" CI_START="-0.7393753581394837" EFFECT_SIZE="-0.08571723143633095" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.4" ORDER="433" SD_1="0.55" SD_2="0.59" SE="0.33350517247210903" STUDY_ID="STD-Stiksa-1985" TOTAL_1="18" TOTAL_2="18" WEIGHT="24.98704841514537"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.10814820577018194" CI_END="0.2437531428883061" CI_START="-0.41001472158560637" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08313078934865012" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" NO="4" P_CHI2="0.9473619053335546" P_Q="1.0" P_Z="0.6181710927770945" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="99.99999999999997" Z="0.49844405631914257">
<NAME>Night-time breathlessness score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.42547467692306784" CI_START="-0.6422391600765575" EFFECT_SIZE="-0.1083822415767448" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="0.32" ORDER="434" SD_1="0.52" SD_2="0.57" SE="0.2723809838909326" STUDY_ID="STD-Stiksa-1982a" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.49189539596956"/>
<CONT_DATA CI_END="0.51829735304804" CI_START="-0.5485884074381003" EFFECT_SIZE="-0.015145527195030166" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.41" ORDER="435" SD_1="0.68" SD_2="0.62" SE="0.272169736000661" STUDY_ID="STD-Stiksa-1982b" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.550117574205586"/>
<CONT_DATA CI_END="0.5068337648062626" CI_START="-0.8018020200260119" EFFECT_SIZE="-0.14748412760987464" ESTIMABLE="YES" MEAN_1="0.37" MEAN_2="0.45" ORDER="436" SD_1="0.51" SD_2="0.55" SE="0.3338417938172912" STUDY_ID="STD-Stiksa-1985" TOTAL_1="18" TOTAL_2="18" WEIGHT="24.957987029824842"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3230433583958507" CI_END="0.4047162300767594" CI_START="-0.24927137139054" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.07772242934310968" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.05" NO="5" P_CHI2="0.8508481070403269" P_Q="1.0" P_Z="0.6413160873612127" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="0.46585948101057695">
<NAME>Sleeping difficulty due to asthma score</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.49558217317972963" CI_START="-0.5713904229010229" EFFECT_SIZE="-0.03790412486064663" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="0.28" ORDER="437" SD_1="0.52" SD_2="0.52" SE="0.2721918883451166" STUDY_ID="STD-Stiksa-1982a" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.569247754985376"/>
<CONT_DATA CI_END="0.7137262106933155" CI_START="-0.35544875739507326" EFFECT_SIZE="0.17913872664912117" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="0.23" ORDER="438" SD_1="0.62" SD_2="0.47" SE="0.2727537282628417" STUDY_ID="STD-Stiksa-1982b" TOTAL_1="27" TOTAL_2="27" WEIGHT="37.41463088995106"/>
<CONT_DATA CI_END="0.7534670766585295" CI_START="-0.554086603477462" EFFECT_SIZE="0.09969023659053378" ESTIMABLE="YES" MEAN_1="0.38" MEAN_2="0.33" ORDER="439" SD_1="0.51" SD_2="0.47" SE="0.33356574162836866" STUDY_ID="STD-Stiksa-1985" TOTAL_1="18" TOTAL_2="18" WEIGHT="25.016121355063564"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0660324282511497" CI_END="0.9569378771947905" CI_START="-0.697101279704907" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.12991829874494176" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.06" NO="6" P_CHI2="0.5868323865494716" P_Q="1.0" P_Z="0.7581622370754472" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="99.99999999999999" Z="0.30789499197840636">
<NAME>Rescue beta2 agonist use (puffs/d)</NAME>
<GROUP_LABEL_1>BDP</GROUP_LABEL_1>
<GROUP_LABEL_2>BUD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours BDP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BUD</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.483993911636958" CI_START="-1.683993911636957" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="8.7" ORDER="440" SD_1="5.7" SD_2="3.8" SE="1.3183884663285508" STUDY_ID="STD-Stiksa-1982a" TOTAL_1="27" TOTAL_2="27" WEIGHT="10.243505614147956"/>
<CONT_DATA CI_END="3.429324794795279" CI_START="-1.4293247947952792" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="9.8" MEAN_2="8.8" ORDER="441" SD_1="5.2" SD_2="3.8" SE="1.2394742015452749" STUDY_ID="STD-Stiksa-1982b" TOTAL_1="27" TOTAL_2="27" WEIGHT="11.589385691223807"/>
<CONT_DATA CI_END="0.8354137873703549" CI_START="-1.0354137873703542" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="8.4" ORDER="442" SD_1="0.7" SD_2="1.9" SE="0.47726070210921173" STUDY_ID="STD-Stiksa-1985" TOTAL_1="18" TOTAL_2="18" WEIGHT="78.16710869462823"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2014-12-08 13:24:40 +0000" MODIFIED_BY="Emma J Welsh">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2014-12-08 13:24:40 +0000" MODIFIED_BY="Emma J Welsh" NO="1">
<TITLE MODIFIED="2014-12-08 12:03:10 +0000" MODIFIED_BY="[Empty name]">Data entry error</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2014-12-08 12:04:47 +0000" MODIFIED_BY="[Empty name]">
<P>In table 1.2 the numbers extracted from Willey 1982 do not seem to match the original paper. I believe the numbers should be BDP 2.00 (0.80) and BUD 2.10 (0.80).</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2014-12-08 13:24:40 +0000" MODIFIED_BY="Emma J Welsh">
<P>Response from Cochrane Airways editorial base: Thank you for bringing this error to our attention. The data has been corrected in analyses 1.2.1, 1.3.1, 2.2.2, 2.3.2, 3.2.1, 3.3.1, 4.2.2 and 4.3.1 and the relevant text in the results section updated to reflect this change. The impact on the results of the analyses over all is negligible.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2014-12-08 12:05:12 +0000" MODIFIED_BY="[Empty name]">
<P>Stephanie Weinreich</P>
<P>Academic Medical Center, Amsterdam, The Netherlands</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>